CN117337302A - Methods of treating psoriatic arthritis patients with inadequate response to TNF therapy with anti-IL 23 specific antibodies - Google Patents
Methods of treating psoriatic arthritis patients with inadequate response to TNF therapy with anti-IL 23 specific antibodies Download PDFInfo
- Publication number
- CN117337302A CN117337302A CN202280034037.9A CN202280034037A CN117337302A CN 117337302 A CN117337302 A CN 117337302A CN 202280034037 A CN202280034037 A CN 202280034037A CN 117337302 A CN117337302 A CN 117337302A
- Authority
- CN
- China
- Prior art keywords
- antibody
- week
- treatment
- seq
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 251
- 201000001263 Psoriatic Arthritis Diseases 0.000 title claims abstract description 135
- 208000036824 Psoriatic arthropathy Diseases 0.000 title claims abstract description 135
- 230000004044 response Effects 0.000 title claims abstract description 107
- 238000002560 therapeutic procedure Methods 0.000 title claims abstract description 63
- 102100040247 Tumor necrosis factor Human genes 0.000 title description 18
- 238000011282 treatment Methods 0.000 claims abstract description 215
- 230000006872 improvement Effects 0.000 claims abstract description 171
- 208000000491 Tendinopathy Diseases 0.000 claims abstract description 68
- 206010043255 Tendonitis Diseases 0.000 claims abstract description 66
- 201000004415 tendinitis Diseases 0.000 claims abstract description 66
- 206010064769 Dactylitis Diseases 0.000 claims abstract description 39
- 230000001747 exhibiting effect Effects 0.000 claims abstract 2
- 229940068196 placebo Drugs 0.000 claims description 177
- 239000000902 placebo Substances 0.000 claims description 177
- 230000009266 disease activity Effects 0.000 claims description 135
- 201000004681 Psoriasis Diseases 0.000 claims description 118
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 89
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 81
- 201000010099 disease Diseases 0.000 claims description 81
- 108010074051 C-Reactive Protein Proteins 0.000 claims description 66
- 102100032752 C-reactive protein Human genes 0.000 claims description 66
- 230000036541 health Effects 0.000 claims description 56
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims description 31
- 238000011301 standard therapy Methods 0.000 claims description 24
- 101150033527 TNF gene Proteins 0.000 claims description 18
- 239000005557 antagonist Substances 0.000 claims description 17
- 108010008165 Etanercept Proteins 0.000 claims description 15
- 229960000403 etanercept Drugs 0.000 claims description 14
- 238000005259 measurement Methods 0.000 claims description 14
- 229960002964 adalimumab Drugs 0.000 claims description 13
- 230000009467 reduction Effects 0.000 claims description 13
- 229960000598 infliximab Drugs 0.000 claims description 12
- 229960001743 golimumab Drugs 0.000 claims description 11
- 230000001185 psoriatic effect Effects 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 208000026721 nail disease Diseases 0.000 claims description 8
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 8
- 229940127557 pharmaceutical product Drugs 0.000 claims description 8
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 7
- 229960005395 cetuximab Drugs 0.000 claims description 7
- 238000011835 investigation Methods 0.000 claims description 7
- 230000001684 chronic effect Effects 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 2
- 208000019622 heart disease Diseases 0.000 claims 1
- 108010065637 Interleukin-23 Proteins 0.000 abstract description 64
- 102000013264 Interleukin-23 Human genes 0.000 abstract description 64
- 238000011221 initial treatment Methods 0.000 abstract description 8
- 101000845005 Macrovipera lebetina Disintegrin lebein-2-alpha Proteins 0.000 abstract 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 100
- 241000282414 Homo sapiens Species 0.000 description 86
- 239000000203 mixture Substances 0.000 description 68
- 210000004027 cell Anatomy 0.000 description 66
- 238000004458 analytical method Methods 0.000 description 58
- 230000000694 effects Effects 0.000 description 46
- 210000001503 joint Anatomy 0.000 description 46
- 239000003814 drug Substances 0.000 description 45
- 150000007523 nucleic acids Chemical class 0.000 description 45
- 102000039446 nucleic acids Human genes 0.000 description 42
- 108020004707 nucleic acids Proteins 0.000 description 42
- 230000027455 binding Effects 0.000 description 41
- 206010066901 Treatment failure Diseases 0.000 description 40
- 229940079593 drug Drugs 0.000 description 40
- 108090000623 proteins and genes Proteins 0.000 description 40
- 238000009739 binding Methods 0.000 description 39
- 239000003795 chemical substances by application Substances 0.000 description 38
- -1 rDNA Proteins 0.000 description 38
- 239000000243 solution Substances 0.000 description 36
- 238000009472 formulation Methods 0.000 description 34
- 235000018102 proteins Nutrition 0.000 description 33
- 102000004169 proteins and genes Human genes 0.000 description 33
- 206010003246 arthritis Diseases 0.000 description 32
- 206010023232 Joint swelling Diseases 0.000 description 31
- 239000012634 fragment Substances 0.000 description 31
- 239000003435 antirheumatic agent Substances 0.000 description 29
- 108090000765 processed proteins & peptides Proteins 0.000 description 29
- 230000006870 function Effects 0.000 description 28
- 208000002193 Pain Diseases 0.000 description 26
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 25
- 239000000872 buffer Substances 0.000 description 25
- 229960000485 methotrexate Drugs 0.000 description 25
- 238000007920 subcutaneous administration Methods 0.000 description 25
- 102000040430 polynucleotide Human genes 0.000 description 24
- 108091033319 polynucleotide Proteins 0.000 description 24
- 239000002157 polynucleotide Substances 0.000 description 24
- 239000003755 preservative agent Substances 0.000 description 24
- 239000012071 phase Substances 0.000 description 23
- 239000003085 diluting agent Substances 0.000 description 22
- 238000011156 evaluation Methods 0.000 description 21
- 239000007924 injection Substances 0.000 description 21
- 238000002347 injection Methods 0.000 description 21
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 21
- 230000002411 adverse Effects 0.000 description 20
- 239000000427 antigen Substances 0.000 description 20
- 108091007433 antigens Proteins 0.000 description 20
- 102000036639 antigens Human genes 0.000 description 20
- 230000002335 preservative effect Effects 0.000 description 20
- 208000024891 symptom Diseases 0.000 description 20
- 235000001014 amino acid Nutrition 0.000 description 19
- 230000008859 change Effects 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 18
- 108060003951 Immunoglobulin Proteins 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 17
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 17
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 17
- 229940024606 amino acid Drugs 0.000 description 17
- 206010016256 fatigue Diseases 0.000 description 17
- 102000018358 immunoglobulin Human genes 0.000 description 17
- 108010065805 Interleukin-12 Proteins 0.000 description 16
- 102000013462 Interleukin-12 Human genes 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 16
- 239000000546 pharmaceutical excipient Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 14
- 239000002299 complementary DNA Substances 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 14
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 14
- 229960000681 leflunomide Drugs 0.000 description 14
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 14
- 229960001940 sulfasalazine Drugs 0.000 description 14
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 14
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 13
- 210000004602 germ cell Anatomy 0.000 description 13
- 239000013598 vector Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 230000014509 gene expression Effects 0.000 description 12
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 12
- 229960004171 hydroxychloroquine Drugs 0.000 description 12
- 230000001976 improved effect Effects 0.000 description 12
- 230000001404 mediated effect Effects 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 11
- 238000009396 hybridization Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 239000000523 sample Substances 0.000 description 11
- 210000002966 serum Anatomy 0.000 description 11
- 208000017520 skin disease Diseases 0.000 description 11
- 230000009261 transgenic effect Effects 0.000 description 11
- 206010061218 Inflammation Diseases 0.000 description 10
- 230000009977 dual effect Effects 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 229940124624 oral corticosteroid Drugs 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 9
- 229960001164 apremilast Drugs 0.000 description 9
- IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 description 9
- 230000013595 glycosylation Effects 0.000 description 9
- 238000006206 glycosylation reaction Methods 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 230000001105 regulatory effect Effects 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 230000008961 swelling Effects 0.000 description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000001815 biotherapy Methods 0.000 description 8
- 229960003444 immunosuppressant agent Drugs 0.000 description 8
- 239000003018 immunosuppressive agent Substances 0.000 description 8
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- 241000124008 Mammalia Species 0.000 description 7
- 239000000654 additive Substances 0.000 description 7
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 239000012636 effector Substances 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 108020004999 messenger RNA Proteins 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 239000005022 packaging material Substances 0.000 description 7
- 230000002093 peripheral effect Effects 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 6
- 102100036672 Interleukin-23 receptor Human genes 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 150000001720 carbohydrates Chemical group 0.000 description 6
- 239000003246 corticosteroid Substances 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 210000004962 mammalian cell Anatomy 0.000 description 6
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 6
- IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 238000010188 recombinant method Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 101710195550 Interleukin-23 receptor Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 206010054094 Tumour necrosis Diseases 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 229960001334 corticosteroids Drugs 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 231100000321 erythema Toxicity 0.000 description 5
- 210000003811 finger Anatomy 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000009267 minimal disease activity Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 239000008363 phosphate buffer Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 229960004618 prednisone Drugs 0.000 description 5
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 5
- 229960004540 secukinumab Drugs 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 201000008827 tuberculosis Diseases 0.000 description 5
- LPLLVINFLBSFRP-UHFFFAOYSA-N 2-methylamino-1-phenylpropan-1-one Chemical compound CNC(C)C(=O)C1=CC=CC=C1 LPLLVINFLBSFRP-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 208000017667 Chronic Disease Diseases 0.000 description 4
- 241000132539 Cosmos Species 0.000 description 4
- 235000005956 Cosmos caudatus Nutrition 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 4
- FBGXMKUWQFPHFB-JBDRJPRFSA-N Ile-Ser-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N FBGXMKUWQFPHFB-JBDRJPRFSA-N 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- 241000880493 Leptailurus serval Species 0.000 description 4
- XOWMDXHFSBCAKQ-SRVKXCTJSA-N Leu-Ser-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC(C)C XOWMDXHFSBCAKQ-SRVKXCTJSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 102000057297 Pepsin A Human genes 0.000 description 4
- 108090000284 Pepsin A Proteins 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 201000002661 Spondylitis Diseases 0.000 description 4
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 239000004599 antimicrobial Substances 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 4
- 229960000106 biosimilars Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 230000001861 immunosuppressant effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002452 interceptive effect Effects 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 229940111202 pepsin Drugs 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 230000002685 pulmonary effect Effects 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 210000002435 tendon Anatomy 0.000 description 4
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 4
- 238000011269 treatment regimen Methods 0.000 description 4
- ALYUMNAHLSSTOU-CIRGZYLNSA-N (6r,7r)-7-[[(2r)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(e)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 ALYUMNAHLSSTOU-CIRGZYLNSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 201000004569 Blindness Diseases 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 229930186147 Cephalosporin Natural products 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 206010010144 Completed suicide Diseases 0.000 description 3
- 108091035707 Consensus sequence Proteins 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- XCLCVBYNGXEVDU-WHFBIAKZSA-N Gly-Asn-Ser Chemical compound NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O XCLCVBYNGXEVDU-WHFBIAKZSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- 101000690301 Homo sapiens Aldo-keto reductase family 1 member C4 Proteins 0.000 description 3
- 101001116548 Homo sapiens Protein CBFA2T1 Proteins 0.000 description 3
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 3
- LBRCLQMZAHRTLV-ZKWXMUAHSA-N Ile-Gly-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LBRCLQMZAHRTLV-ZKWXMUAHSA-N 0.000 description 3
- 108050003558 Interleukin-17 Proteins 0.000 description 3
- 102000013691 Interleukin-17 Human genes 0.000 description 3
- 108010076561 Interleukin-23 Subunit p19 Proteins 0.000 description 3
- 102100036705 Interleukin-23 subunit alpha Human genes 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- FUKDBQGFSJUXGX-RWMBFGLXSA-N Lys-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)N)C(=O)O FUKDBQGFSJUXGX-RWMBFGLXSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 244000061176 Nicotiana tabacum Species 0.000 description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 206010036030 Polyarthritis Diseases 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 208000009921 Rheumatoid Nodule Diseases 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- WLJPJRGQRNCIQS-ZLUOBGJFSA-N Ser-Ser-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O WLJPJRGQRNCIQS-ZLUOBGJFSA-N 0.000 description 3
- 239000004288 Sodium dehydroacetate Substances 0.000 description 3
- 208000007156 Spondylarthritis Diseases 0.000 description 3
- 210000000447 Th1 cell Anatomy 0.000 description 3
- JEDIEMIJYSRUBB-FOHZUACHSA-N Thr-Asp-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O JEDIEMIJYSRUBB-FOHZUACHSA-N 0.000 description 3
- DJDSEDOKJTZBAR-ZDLURKLDSA-N Thr-Gly-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O DJDSEDOKJTZBAR-ZDLURKLDSA-N 0.000 description 3
- 210000001361 achilles tendon Anatomy 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 239000003263 anabolic agent Substances 0.000 description 3
- 229940035676 analgesics Drugs 0.000 description 3
- 239000000730 antalgic agent Substances 0.000 description 3
- 230000002924 anti-infective effect Effects 0.000 description 3
- 229960005475 antiinfective agent Drugs 0.000 description 3
- 239000003430 antimalarial agent Substances 0.000 description 3
- 230000002917 arthritic effect Effects 0.000 description 3
- 229960002170 azathioprine Drugs 0.000 description 3
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 3
- 229960004669 basiliximab Drugs 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- 229960001950 benzethonium chloride Drugs 0.000 description 3
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 239000000090 biomarker Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 229940124587 cephalosporin Drugs 0.000 description 3
- 150000001780 cephalosporins Chemical class 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229960002242 chlorocresol Drugs 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- 229960002806 daclizumab Drugs 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 229960002885 histidine Drugs 0.000 description 3
- 102000054751 human RUNX1T1 Human genes 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000004068 intracellular signaling Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 108010057821 leucylproline Proteins 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000008176 lyophilized powder Substances 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000003340 mental effect Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 239000000346 nonvolatile oil Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 230000003863 physical function Effects 0.000 description 3
- 208000030428 polyarticular arthritis Diseases 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 229940079839 sodium dehydroacetate Drugs 0.000 description 3
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 3
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- 229940033663 thimerosal Drugs 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- ZAVJTSLIGAGALR-UHFFFAOYSA-N 2-(2,2,2-trifluoroacetyl)cyclooctan-1-one Chemical compound FC(F)(F)C(=O)C1CCCCCCC1=O ZAVJTSLIGAGALR-UHFFFAOYSA-N 0.000 description 2
- 108050001326 26S Proteasome regulatory subunit 6A Proteins 0.000 description 2
- 102100029510 26S proteasome regulatory subunit 6A Human genes 0.000 description 2
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- DWINFPQUSSHSFS-UVBJJODRSA-N Ala-Arg-Trp Chemical compound N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=CC=CC=C12)C(=O)O DWINFPQUSSHSFS-UVBJJODRSA-N 0.000 description 2
- BTRULDJUUVGRNE-DCAQKATOSA-N Ala-Pro-Lys Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(O)=O BTRULDJUUVGRNE-DCAQKATOSA-N 0.000 description 2
- 108090000669 Annexin A4 Proteins 0.000 description 2
- 102100034612 Annexin A4 Human genes 0.000 description 2
- 101100227726 Arabidopsis thaliana FRL3 gene Proteins 0.000 description 2
- QLSRIZIDQXDQHK-RCWTZXSCSA-N Arg-Val-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QLSRIZIDQXDQHK-RCWTZXSCSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical class OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- MYTHOBCLNIOFBL-SRVKXCTJSA-N Asn-Ser-Tyr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MYTHOBCLNIOFBL-SRVKXCTJSA-N 0.000 description 2
- VAWNQIGQPUOPQW-ACZMJKKPSA-N Asp-Glu-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O VAWNQIGQPUOPQW-ACZMJKKPSA-N 0.000 description 2
- FAUPLTGRUBTXNU-FXQIFTODSA-N Asp-Pro-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O FAUPLTGRUBTXNU-FXQIFTODSA-N 0.000 description 2
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 2
- ALMIMUZAWTUNIO-BZSNNMDCSA-N Asp-Tyr-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ALMIMUZAWTUNIO-BZSNNMDCSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010075254 C-Peptide Proteins 0.000 description 2
- 101100120609 Caenorhabditis elegans frh-1 gene Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 238000000959 Cochran–Mantel–Haenszel (CMH) test Methods 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- FNQZHYMKRUVOBN-UHFFFAOYSA-N Cys Ala Ser Trp Chemical compound C1=CC=C2C(CC(NC(=O)C(CO)NC(=O)C(NC(=O)C(N)CS)C)C(O)=O)=CNC2=C1 FNQZHYMKRUVOBN-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 101150023991 FMNL1 gene Proteins 0.000 description 2
- 101150005226 FRL1 gene Proteins 0.000 description 2
- 101150065691 FRL2 gene Proteins 0.000 description 2
- 102100028930 Formin-like protein 1 Human genes 0.000 description 2
- 102100032789 Formin-like protein 3 Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- KVXVVDFOZNYYKZ-DCAQKATOSA-N Gln-Gln-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O KVXVVDFOZNYYKZ-DCAQKATOSA-N 0.000 description 2
- CLPQUWHBWXFJOX-BQBZGAKWSA-N Gln-Gly-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O CLPQUWHBWXFJOX-BQBZGAKWSA-N 0.000 description 2
- JXFLPKSDLDEOQK-JHEQGTHGSA-N Gln-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O JXFLPKSDLDEOQK-JHEQGTHGSA-N 0.000 description 2
- LVRKAFPPFJRIOF-GARJFASQSA-N Gln-Met-Pro Chemical compound CSCC[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N LVRKAFPPFJRIOF-GARJFASQSA-N 0.000 description 2
- RWQCWSGOOOEGPB-FXQIFTODSA-N Gln-Ser-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O RWQCWSGOOOEGPB-FXQIFTODSA-N 0.000 description 2
- OTQSTOXRUBVWAP-NRPADANISA-N Gln-Ser-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O OTQSTOXRUBVWAP-NRPADANISA-N 0.000 description 2
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 2
- ZYRXTRTUCAVNBQ-GVXVVHGQSA-N Glu-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZYRXTRTUCAVNBQ-GVXVVHGQSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 2
- AAHSHTLISQUZJL-QSFUFRPTSA-N Gly-Ile-Ile Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AAHSHTLISQUZJL-QSFUFRPTSA-N 0.000 description 2
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 2
- HAOUOFNNJJLVNS-BQBZGAKWSA-N Gly-Pro-Ser Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O HAOUOFNNJJLVNS-BQBZGAKWSA-N 0.000 description 2
- DNAZKGFYFRGZIH-QWRGUYRKSA-N Gly-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CC=C(O)C=C1 DNAZKGFYFRGZIH-QWRGUYRKSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- FOCSWPCHUDVNLP-PMVMPFDFSA-N His-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CC4=CN=CN4)N FOCSWPCHUDVNLP-PMVMPFDFSA-N 0.000 description 2
- YBKKLDBBPFIXBQ-MBLNEYKQSA-N Ile-Thr-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)O)N YBKKLDBBPFIXBQ-MBLNEYKQSA-N 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102100030703 Interleukin-22 Human genes 0.000 description 2
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 2
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 2
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 2
- YSKSXVKQLLBVEX-SZMVWBNQSA-N Leu-Gln-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 YSKSXVKQLLBVEX-SZMVWBNQSA-N 0.000 description 2
- FEHQLKKBVJHSEC-SZMVWBNQSA-N Leu-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(C)C)C(O)=O)=CNC2=C1 FEHQLKKBVJHSEC-SZMVWBNQSA-N 0.000 description 2
- NRFGTHFONZYFNY-MGHWNKPDSA-N Leu-Ile-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 NRFGTHFONZYFNY-MGHWNKPDSA-N 0.000 description 2
- LCNASHSOFMRYFO-WDCWCFNPSA-N Leu-Thr-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O LCNASHSOFMRYFO-WDCWCFNPSA-N 0.000 description 2
- MVJRBCJCRYGCKV-GVXVVHGQSA-N Leu-Val-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O MVJRBCJCRYGCKV-GVXVVHGQSA-N 0.000 description 2
- 241000531897 Loma Species 0.000 description 2
- UWKNTTJNVSYXPC-CIUDSAMLSA-N Lys-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN UWKNTTJNVSYXPC-CIUDSAMLSA-N 0.000 description 2
- FHIAJWBDZVHLAH-YUMQZZPRSA-N Lys-Gly-Ser Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O FHIAJWBDZVHLAH-YUMQZZPRSA-N 0.000 description 2
- OIQSIMFSVLLWBX-VOAKCMCISA-N Lys-Leu-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OIQSIMFSVLLWBX-VOAKCMCISA-N 0.000 description 2
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 2
- SBQDRNOLGSYHQA-YUMQZZPRSA-N Lys-Ser-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SBQDRNOLGSYHQA-YUMQZZPRSA-N 0.000 description 2
- JOSAKOKSPXROGQ-BJDJZHNGSA-N Lys-Ser-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JOSAKOKSPXROGQ-BJDJZHNGSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- GHQFLTYXGUETFD-UFYCRDLUSA-N Met-Tyr-Tyr Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N GHQFLTYXGUETFD-UFYCRDLUSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 2
- 108010079364 N-glycylalanine Proteins 0.000 description 2
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 2
- 206010028703 Nail psoriasis Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 230000004989 O-glycosylation Effects 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- 108010067902 Peptide Library Proteins 0.000 description 2
- YMIZSYUAZJSOFL-SRVKXCTJSA-N Phe-Ser-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O YMIZSYUAZJSOFL-SRVKXCTJSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- JARJPEMLQAWNBR-GUBZILKMSA-N Pro-Asp-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JARJPEMLQAWNBR-GUBZILKMSA-N 0.000 description 2
- AFXCXDQNRXTSBD-FJXKBIBVSA-N Pro-Gly-Thr Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O AFXCXDQNRXTSBD-FJXKBIBVSA-N 0.000 description 2
- AWQGDZBKQTYNMN-IHRRRGAJSA-N Pro-Phe-Asp Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC(=O)O)C(=O)O AWQGDZBKQTYNMN-IHRRRGAJSA-N 0.000 description 2
- FDMKYQQYJKYCLV-GUBZILKMSA-N Pro-Pro-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 FDMKYQQYJKYCLV-GUBZILKMSA-N 0.000 description 2
- MKGIILKDUGDRRO-FXQIFTODSA-N Pro-Ser-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 MKGIILKDUGDRRO-FXQIFTODSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 102000002067 Protein Subunits Human genes 0.000 description 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- LVVBAKCGXXUHFO-ZLUOBGJFSA-N Ser-Ala-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O LVVBAKCGXXUHFO-ZLUOBGJFSA-N 0.000 description 2
- UQFYNFTYDHUIMI-WHFBIAKZSA-N Ser-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CO UQFYNFTYDHUIMI-WHFBIAKZSA-N 0.000 description 2
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 2
- XXXAXOWMBOKTRN-XPUUQOCRSA-N Ser-Gly-Val Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXXAXOWMBOKTRN-XPUUQOCRSA-N 0.000 description 2
- FUMGHWDRRFCKEP-CIUDSAMLSA-N Ser-Leu-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O FUMGHWDRRFCKEP-CIUDSAMLSA-N 0.000 description 2
- UBRMZSHOOIVJPW-SRVKXCTJSA-N Ser-Leu-Lys Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O UBRMZSHOOIVJPW-SRVKXCTJSA-N 0.000 description 2
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 2
- BMKNXTJLHFIAAH-CIUDSAMLSA-N Ser-Ser-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O BMKNXTJLHFIAAH-CIUDSAMLSA-N 0.000 description 2
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 206010065604 Suicidal behaviour Diseases 0.000 description 2
- 208000023835 Tendon disease Diseases 0.000 description 2
- 208000002240 Tennis Elbow Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- UNURFMVMXLENAZ-KJEVXHAQSA-N Thr-Arg-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O UNURFMVMXLENAZ-KJEVXHAQSA-N 0.000 description 2
- FWTFAZKJORVTIR-VZFHVOOUSA-N Thr-Ser-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O FWTFAZKJORVTIR-VZFHVOOUSA-N 0.000 description 2
- SGAOHNPSEPVAFP-ZDLURKLDSA-N Thr-Ser-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SGAOHNPSEPVAFP-ZDLURKLDSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 108700019146 Transgenes Proteins 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- KIMOCKLJBXHFIN-YLVFBTJISA-N Trp-Ile-Gly Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(O)=O)=CNC2=C1 KIMOCKLJBXHFIN-YLVFBTJISA-N 0.000 description 2
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- UABYBEBXFFNCIR-YDHLFZDLSA-N Tyr-Asp-Val Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UABYBEBXFFNCIR-YDHLFZDLSA-N 0.000 description 2
- QVYFTFIBKCDHIE-ACRUOGEOSA-N Tyr-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCCN)C(=O)O)N)O QVYFTFIBKCDHIE-ACRUOGEOSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- CKTMJBPRVQWPHU-JSGCOSHPSA-N Val-Phe-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)NCC(=O)O)N CKTMJBPRVQWPHU-JSGCOSHPSA-N 0.000 description 2
- UGFMVXRXULGLNO-XPUUQOCRSA-N Val-Ser-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O UGFMVXRXULGLNO-XPUUQOCRSA-N 0.000 description 2
- WUFHZIRMAZZWRS-OSUNSFLBSA-N Val-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)N WUFHZIRMAZZWRS-OSUNSFLBSA-N 0.000 description 2
- QHSSPPHOHJSTML-HOCLYGCPSA-N Val-Trp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)NCC(=O)O)N QHSSPPHOHJSTML-HOCLYGCPSA-N 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 108010081404 acein-2 Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 229940126575 aminoglycoside Drugs 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 230000000078 anti-malarial effect Effects 0.000 description 2
- 230000009830 antibody antigen interaction Effects 0.000 description 2
- 239000003793 antidiarrheal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 108010008355 arginyl-glutamine Proteins 0.000 description 2
- 108010092854 aspartyllysine Proteins 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 2
- 229960005207 auranofin Drugs 0.000 description 2
- 210000003403 autonomic nervous system Anatomy 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 229960005354 betamethasone sodium phosphate Drugs 0.000 description 2
- PLCQGRYPOISRTQ-LWCNAHDDSA-L betamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-LWCNAHDDSA-L 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 229960003735 brodalumab Drugs 0.000 description 2
- 230000001364 causal effect Effects 0.000 description 2
- 229960002580 cefprozil Drugs 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229960003115 certolizumab pegol Drugs 0.000 description 2
- 239000002975 chemoattractant Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000009850 completed effect Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 2
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000010437 erythropoiesis Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000011985 exploratory data analysis Methods 0.000 description 2
- 229940124307 fluoroquinolone Drugs 0.000 description 2
- 101150029401 fmnl3 gene Proteins 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 102000035122 glycosylated proteins Human genes 0.000 description 2
- 108091005608 glycosylated proteins Proteins 0.000 description 2
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 108010089804 glycyl-threonine Proteins 0.000 description 2
- 108010010147 glycylglutamine Proteins 0.000 description 2
- 108010084389 glycyltryptophan Proteins 0.000 description 2
- 210000004247 hand Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229940125697 hormonal agent Drugs 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960001067 hydrocortisone acetate Drugs 0.000 description 2
- 229960002927 hydroxychloroquine sulfate Drugs 0.000 description 2
- 230000008076 immune mechanism Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 108010034529 leucyl-lysine Proteins 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 description 2
- 235000009973 maize Nutrition 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 210000000811 metacarpophalangeal joint Anatomy 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- MINDHVHHQZYEEK-HBBNESRFSA-N mupirocin Chemical compound C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-HBBNESRFSA-N 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000004417 patella Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 238000001050 pharmacotherapy Methods 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- 108010070409 phenylalanyl-glycyl-glycine Proteins 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 229940012957 plasmin Drugs 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920001610 polycaprolactone Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 229940071643 prefilled syringe Drugs 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 108010031719 prolyl-serine Proteins 0.000 description 2
- 108010029020 prolylglycine Proteins 0.000 description 2
- 229940076372 protein antagonist Drugs 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 208000013515 tendinosis Diseases 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 229940040944 tetracyclines Drugs 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 229960002117 triamcinolone acetonide Drugs 0.000 description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 108010044292 tryptophyltyrosine Proteins 0.000 description 2
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 108010051110 tyrosyl-lysine Proteins 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- IESDGNYHXIOKRW-YXMSTPNBSA-N (2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-YXMSTPNBSA-N 0.000 description 1
- DIBLBAURNYJYBF-XLXZRNDBSA-N (2s)-2-[[(2s)-2-[[2-[[(2s)-6-amino-2-[[(2s)-2-amino-3-methylbutanoyl]amino]hexanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@H](NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 DIBLBAURNYJYBF-XLXZRNDBSA-N 0.000 description 1
- QZNNVYOVQUKYSC-JEDNCBNOSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CN=CN1 QZNNVYOVQUKYSC-JEDNCBNOSA-N 0.000 description 1
- KYBXNPIASYUWLN-WUCPZUCCSA-N (2s)-5-hydroxypyrrolidine-2-carboxylic acid Chemical compound OC1CC[C@@H](C(O)=O)N1 KYBXNPIASYUWLN-WUCPZUCCSA-N 0.000 description 1
- OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 description 1
- BQIMPGFMMOZASS-CLZZGJSISA-N (6r,7r)-7-amino-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S1CC(CO)=C(C(O)=O)N2C(=O)[C@@H](N)[C@H]21 BQIMPGFMMOZASS-CLZZGJSISA-N 0.000 description 1
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
- VAIZVCMDJPBJCM-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-one;trihydrate Chemical compound O.O.O.FC(F)(F)C(=O)C(F)(F)F.FC(F)(F)C(=O)C(F)(F)F VAIZVCMDJPBJCM-UHFFFAOYSA-N 0.000 description 1
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 1
- QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- DREIJXJRTLTGJC-JQCLMNFQSA-N 4-[[(1r,3s)-5-hydroxy-2-adamantyl]amino]-1h-pyrrolo[2,3-b]pyridine-5-carboxamide Chemical compound C([C@H]1CC(O)(C2)C3)C2C[C@H]3C1NC1=C2C=CNC2=NC=C1C(=O)N DREIJXJRTLTGJC-JQCLMNFQSA-N 0.000 description 1
- LZMWDICWIUVBER-UHFFFAOYSA-N 4-amino-2-(2-hydroxyethylamino)-4-oxobutanoic acid Chemical compound NC(=O)CC(C(O)=O)NCCO LZMWDICWIUVBER-UHFFFAOYSA-N 0.000 description 1
- QTQGHKVYLQBJLO-UHFFFAOYSA-N 4-methylbenzenesulfonate;(4-methyl-1-oxo-1-phenylmethoxypentan-2-yl)azanium Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC(C)CC(N)C(=O)OCC1=CC=CC=C1 QTQGHKVYLQBJLO-UHFFFAOYSA-N 0.000 description 1
- SODWJACROGQSMM-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalen-1-amine Chemical compound C1CCCC2=C1C=CC=C2N SODWJACROGQSMM-UHFFFAOYSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- CXRCVCURMBFFOL-FXQIFTODSA-N Ala-Ala-Pro Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O CXRCVCURMBFFOL-FXQIFTODSA-N 0.000 description 1
- XQGIRPGAVLFKBJ-CIUDSAMLSA-N Ala-Asn-Lys Chemical compound N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)O XQGIRPGAVLFKBJ-CIUDSAMLSA-N 0.000 description 1
- MNZHHDPWDWQJCQ-YUMQZZPRSA-N Ala-Leu-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O MNZHHDPWDWQJCQ-YUMQZZPRSA-N 0.000 description 1
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 1
- IORKCNUBHNIMKY-CIUDSAMLSA-N Ala-Pro-Glu Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O IORKCNUBHNIMKY-CIUDSAMLSA-N 0.000 description 1
- WQLDNOCHHRISMS-NAKRPEOUSA-N Ala-Pro-Ile Chemical compound [H]N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WQLDNOCHHRISMS-NAKRPEOUSA-N 0.000 description 1
- XWFWAXPOLRTDFZ-FXQIFTODSA-N Ala-Pro-Ser Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O XWFWAXPOLRTDFZ-FXQIFTODSA-N 0.000 description 1
- FFZJHQODAYHGPO-KZVJFYERSA-N Ala-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N FFZJHQODAYHGPO-KZVJFYERSA-N 0.000 description 1
- UCDOXFBTMLKASE-HERUPUMHSA-N Ala-Ser-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)N UCDOXFBTMLKASE-HERUPUMHSA-N 0.000 description 1
- IOFVWPYSRSCWHI-JXUBOQSCSA-N Ala-Thr-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C)N IOFVWPYSRSCWHI-JXUBOQSCSA-N 0.000 description 1
- OMSKGWFGWCQFBD-KZVJFYERSA-N Ala-Val-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OMSKGWFGWCQFBD-KZVJFYERSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 101100297694 Arabidopsis thaliana PIP2-7 gene Proteins 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- QHUOOCKNNURZSL-IHRRRGAJSA-N Arg-Tyr-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O QHUOOCKNNURZSL-IHRRRGAJSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- LGCVSPFCFXWUEY-IHPCNDPISA-N Asn-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N LGCVSPFCFXWUEY-IHPCNDPISA-N 0.000 description 1
- CGYKCTPUGXFPMG-IHPCNDPISA-N Asn-Tyr-Trp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O CGYKCTPUGXFPMG-IHPCNDPISA-N 0.000 description 1
- PDECQIHABNQRHN-GUBZILKMSA-N Asp-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O PDECQIHABNQRHN-GUBZILKMSA-N 0.000 description 1
- SNDBKTFJWVEVPO-WHFBIAKZSA-N Asp-Gly-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SNDBKTFJWVEVPO-WHFBIAKZSA-N 0.000 description 1
- NVFSJIXJZCDICF-SRVKXCTJSA-N Asp-Lys-Lys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)O)N NVFSJIXJZCDICF-SRVKXCTJSA-N 0.000 description 1
- DPNWSMBUYCLEDG-CIUDSAMLSA-N Asp-Lys-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O DPNWSMBUYCLEDG-CIUDSAMLSA-N 0.000 description 1
- DONWIPDSZZJHHK-HJGDQZAQSA-N Asp-Lys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)N)O DONWIPDSZZJHHK-HJGDQZAQSA-N 0.000 description 1
- SQIARYGNVQWOSB-BZSNNMDCSA-N Asp-Tyr-Phe Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O SQIARYGNVQWOSB-BZSNNMDCSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100023702 C-C motif chemokine 13 Human genes 0.000 description 1
- 102100032366 C-C motif chemokine 7 Human genes 0.000 description 1
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- NCFTXMQPRQZFMZ-WERGMSTESA-M Cefoperazone sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C([O-])=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 NCFTXMQPRQZFMZ-WERGMSTESA-M 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- KEJCWVGMRLCZQQ-YJBYXUATSA-N Cefuroxime axetil Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OC(C)OC(C)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 KEJCWVGMRLCZQQ-YJBYXUATSA-N 0.000 description 1
- URDOHUPGIOGTKV-JTBFTWTJSA-M Cefuroxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 URDOHUPGIOGTKV-JTBFTWTJSA-M 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108020004998 Chloroplast DNA Proteins 0.000 description 1
- 108020005133 Chloroplast RNA Proteins 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- ZXCAQANTQWBICD-DCAQKATOSA-N Cys-Lys-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N ZXCAQANTQWBICD-DCAQKATOSA-N 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Chemical class OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 101000802894 Dendroaspis angusticeps Fasciculin-2 Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 201000011275 Epicondylitis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010015278 Erythrodermic psoriasis Diseases 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- DHNWZLGBTPUTQQ-QEJZJMRPSA-N Gln-Asp-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N DHNWZLGBTPUTQQ-QEJZJMRPSA-N 0.000 description 1
- MFORDNZDKAVNSR-SRVKXCTJSA-N Gln-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CCC(N)=O MFORDNZDKAVNSR-SRVKXCTJSA-N 0.000 description 1
- XKPACHRGOWQHFH-IRIUXVKKSA-N Gln-Thr-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XKPACHRGOWQHFH-IRIUXVKKSA-N 0.000 description 1
- BETSEXMYBWCDAE-SZMVWBNQSA-N Gln-Trp-Lys Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)N)N BETSEXMYBWCDAE-SZMVWBNQSA-N 0.000 description 1
- FITIQFSXXBKFFM-NRPADANISA-N Gln-Val-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O FITIQFSXXBKFFM-NRPADANISA-N 0.000 description 1
- HNAUFGBKJLTWQE-IFFSRLJSSA-N Gln-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCC(=O)N)N)O HNAUFGBKJLTWQE-IFFSRLJSSA-N 0.000 description 1
- GLWXKFRTOHKGIT-ACZMJKKPSA-N Glu-Asn-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O GLWXKFRTOHKGIT-ACZMJKKPSA-N 0.000 description 1
- CKOFNWCLWRYUHK-XHNCKOQMSA-N Glu-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)N)C(=O)O CKOFNWCLWRYUHK-XHNCKOQMSA-N 0.000 description 1
- KVBPDJIFRQUQFY-ACZMJKKPSA-N Glu-Cys-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O KVBPDJIFRQUQFY-ACZMJKKPSA-N 0.000 description 1
- HNVFSTLPVJWIDV-CIUDSAMLSA-N Glu-Glu-Gln Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HNVFSTLPVJWIDV-CIUDSAMLSA-N 0.000 description 1
- DNPCBMNFQVTHMA-DCAQKATOSA-N Glu-Leu-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O DNPCBMNFQVTHMA-DCAQKATOSA-N 0.000 description 1
- QDMVXRNLOPTPIE-WDCWCFNPSA-N Glu-Lys-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QDMVXRNLOPTPIE-WDCWCFNPSA-N 0.000 description 1
- BPCLDCNZBUYGOD-BPUTZDHNSA-N Glu-Trp-Glu Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CNC2=C1 BPCLDCNZBUYGOD-BPUTZDHNSA-N 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- VSVZIEVNUYDAFR-YUMQZZPRSA-N Gly-Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN VSVZIEVNUYDAFR-YUMQZZPRSA-N 0.000 description 1
- GRIRDMVMJJDZKV-RCOVLWMOSA-N Gly-Asn-Val Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O GRIRDMVMJJDZKV-RCOVLWMOSA-N 0.000 description 1
- PABFFPWEJMEVEC-JGVFFNPUSA-N Gly-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)CN)C(=O)O PABFFPWEJMEVEC-JGVFFNPUSA-N 0.000 description 1
- FFJQHWKSGAWSTJ-BFHQHQDPSA-N Gly-Thr-Ala Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O FFJQHWKSGAWSTJ-BFHQHQDPSA-N 0.000 description 1
- GNNJKUYDWFIBTK-QWRGUYRKSA-N Gly-Tyr-Asp Chemical compound [H]NCC(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O GNNJKUYDWFIBTK-QWRGUYRKSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 241000989913 Gunnera petaloidea Species 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- ZPVJJPAIUZLSNE-DCAQKATOSA-N His-Arg-Ser Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(O)=O ZPVJJPAIUZLSNE-DCAQKATOSA-N 0.000 description 1
- MAABHGXCIBEYQR-XVYDVKMFSA-N His-Asn-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC1=CN=CN1)N MAABHGXCIBEYQR-XVYDVKMFSA-N 0.000 description 1
- WMKXFMUJRCEGRP-SRVKXCTJSA-N His-Asn-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N WMKXFMUJRCEGRP-SRVKXCTJSA-N 0.000 description 1
- HIAHVKLTHNOENC-HGNGGELXSA-N His-Glu-Ala Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O HIAHVKLTHNOENC-HGNGGELXSA-N 0.000 description 1
- AKEDPWJFQULLPE-IUCAKERBSA-N His-Glu-Gly Chemical compound N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O AKEDPWJFQULLPE-IUCAKERBSA-N 0.000 description 1
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 1
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 description 1
- 101100382872 Homo sapiens CCL13 gene Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- MKWSZEHGHSLNPF-NAKRPEOUSA-N Ile-Ala-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)O)N MKWSZEHGHSLNPF-NAKRPEOUSA-N 0.000 description 1
- FADXGVVLSPPEQY-GHCJXIJMSA-N Ile-Cys-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(=O)N)C(=O)O)N FADXGVVLSPPEQY-GHCJXIJMSA-N 0.000 description 1
- PWDSHAAAFXISLE-SXTJYALSSA-N Ile-Ile-Asp Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(O)=O PWDSHAAAFXISLE-SXTJYALSSA-N 0.000 description 1
- JHNJNTMTZHEDLJ-NAKRPEOUSA-N Ile-Ser-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O JHNJNTMTZHEDLJ-NAKRPEOUSA-N 0.000 description 1
- JZNVOBUNTWNZPW-GHCJXIJMSA-N Ile-Ser-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)O)N JZNVOBUNTWNZPW-GHCJXIJMSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000004560 Interleukin-12 Receptors Human genes 0.000 description 1
- 108010017515 Interleukin-12 Receptors Proteins 0.000 description 1
- 102000014154 Interleukin-12 Subunit p35 Human genes 0.000 description 1
- 108010011301 Interleukin-12 Subunit p35 Proteins 0.000 description 1
- 102100020790 Interleukin-12 receptor subunit beta-1 Human genes 0.000 description 1
- 101710103841 Interleukin-12 receptor subunit beta-1 Proteins 0.000 description 1
- 102100020792 Interleukin-12 receptor subunit beta-2 Human genes 0.000 description 1
- 101710103840 Interleukin-12 receptor subunit beta-2 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- 208000022120 Jeavons syndrome Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 239000005572 Lenacil Substances 0.000 description 1
- 241000270322 Lepidosauria Species 0.000 description 1
- OIARJGNVARWKFP-YUMQZZPRSA-N Leu-Asn-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O OIARJGNVARWKFP-YUMQZZPRSA-N 0.000 description 1
- PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 1
- HYMLKESRWLZDBR-WEDXCCLWSA-N Leu-Gly-Thr Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O HYMLKESRWLZDBR-WEDXCCLWSA-N 0.000 description 1
- YOKVEHGYYQEQOP-QWRGUYRKSA-N Leu-Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O YOKVEHGYYQEQOP-QWRGUYRKSA-N 0.000 description 1
- UHNQRAFSEBGZFZ-YESZJQIVSA-N Leu-Phe-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N UHNQRAFSEBGZFZ-YESZJQIVSA-N 0.000 description 1
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 1
- LINKCQUOMUDLKN-KATARQTJSA-N Leu-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)N)O LINKCQUOMUDLKN-KATARQTJSA-N 0.000 description 1
- AIQWYVFNBNNOLU-RHYQMDGZSA-N Leu-Thr-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O AIQWYVFNBNNOLU-RHYQMDGZSA-N 0.000 description 1
- YQFZRHYZLARWDY-IHRRRGAJSA-N Leu-Val-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCCN YQFZRHYZLARWDY-IHRRRGAJSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- MPGHETGWWWUHPY-CIUDSAMLSA-N Lys-Ala-Asp Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN MPGHETGWWWUHPY-CIUDSAMLSA-N 0.000 description 1
- XFIHDSBIPWEYJJ-YUMQZZPRSA-N Lys-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCCCN XFIHDSBIPWEYJJ-YUMQZZPRSA-N 0.000 description 1
- ODUQLUADRKMHOZ-JYJNAYRXSA-N Lys-Glu-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N)O ODUQLUADRKMHOZ-JYJNAYRXSA-N 0.000 description 1
- XNKDCYABMBBEKN-IUCAKERBSA-N Lys-Gly-Gln Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O XNKDCYABMBBEKN-IUCAKERBSA-N 0.000 description 1
- LECIJRIRMVOFMH-ULQDDVLXSA-N Lys-Pro-Phe Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 LECIJRIRMVOFMH-ULQDDVLXSA-N 0.000 description 1
- YTJFXEDRUOQGSP-DCAQKATOSA-N Lys-Pro-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O YTJFXEDRUOQGSP-DCAQKATOSA-N 0.000 description 1
- CTJUSALVKAWFFU-CIUDSAMLSA-N Lys-Ser-Cys Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N CTJUSALVKAWFFU-CIUDSAMLSA-N 0.000 description 1
- IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 description 1
- VHTOGMKQXXJOHG-RHYQMDGZSA-N Lys-Thr-Val Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O VHTOGMKQXXJOHG-RHYQMDGZSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710091437 Major capsid protein 2 Proteins 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100382870 Mus musculus Ccl12 gene Proteins 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- OLUNPKFOFGZHRT-YGCVIUNWSA-N Naftifine hydrochloride Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OLUNPKFOFGZHRT-YGCVIUNWSA-N 0.000 description 1
- JKWKMORAXJQQSR-MOPIKTETSA-N Nandrolone Decanoate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCCCCC)[C@@]1(C)CC2 JKWKMORAXJQQSR-MOPIKTETSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101150037263 PIP2 gene Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 description 1
- 102000043299 Parathyroid hormone-related Human genes 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- MSHZERMPZKCODG-ACRUOGEOSA-N Phe-Leu-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 MSHZERMPZKCODG-ACRUOGEOSA-N 0.000 description 1
- JDMKQHSHKJHAHR-UHFFFAOYSA-N Phe-Phe-Leu-Tyr Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)CC1=CC=CC=C1 JDMKQHSHKJHAHR-UHFFFAOYSA-N 0.000 description 1
- JLLJTMHNXQTMCK-UBHSHLNASA-N Phe-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 JLLJTMHNXQTMCK-UBHSHLNASA-N 0.000 description 1
- IIEOLPMQYRBZCN-SRVKXCTJSA-N Phe-Ser-Cys Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O IIEOLPMQYRBZCN-SRVKXCTJSA-N 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 1
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 1
- IHCXPSYCHXFXKT-DCAQKATOSA-N Pro-Arg-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O IHCXPSYCHXFXKT-DCAQKATOSA-N 0.000 description 1
- TUYWCHPXKQTISF-LPEHRKFASA-N Pro-Cys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N2CCC[C@@H]2C(=O)O TUYWCHPXKQTISF-LPEHRKFASA-N 0.000 description 1
- UAYHMOIGIQZLFR-NHCYSSNCSA-N Pro-Gln-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O UAYHMOIGIQZLFR-NHCYSSNCSA-N 0.000 description 1
- LGSANCBHSMDFDY-GARJFASQSA-N Pro-Glu-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)O)C(=O)N2CCC[C@@H]2C(=O)O LGSANCBHSMDFDY-GARJFASQSA-N 0.000 description 1
- VPEVBAUSTBWQHN-NHCYSSNCSA-N Pro-Glu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O VPEVBAUSTBWQHN-NHCYSSNCSA-N 0.000 description 1
- UIMCLYYSUCIUJM-UWVGGRQHSA-N Pro-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 UIMCLYYSUCIUJM-UWVGGRQHSA-N 0.000 description 1
- ZLXKLMHAMDENIO-DCAQKATOSA-N Pro-Lys-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLXKLMHAMDENIO-DCAQKATOSA-N 0.000 description 1
- PCWLNNZTBJTZRN-AVGNSLFASA-N Pro-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 PCWLNNZTBJTZRN-AVGNSLFASA-N 0.000 description 1
- GOMUXSCOIWIJFP-GUBZILKMSA-N Pro-Ser-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GOMUXSCOIWIJFP-GUBZILKMSA-N 0.000 description 1
- OWQXAJQZLWHPBH-FXQIFTODSA-N Pro-Ser-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(O)=O OWQXAJQZLWHPBH-FXQIFTODSA-N 0.000 description 1
- GMJDSFYVTAMIBF-FXQIFTODSA-N Pro-Ser-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GMJDSFYVTAMIBF-FXQIFTODSA-N 0.000 description 1
- QKDIHFHGHBYTKB-IHRRRGAJSA-N Pro-Ser-Phe Chemical compound N([C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C(=O)[C@@H]1CCCN1 QKDIHFHGHBYTKB-IHRRRGAJSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- VQXSOUPNOZTNAI-UHFFFAOYSA-N Pyrethrin I Natural products CC(=CC1CC1C(=O)OC2CC(=O)C(=C2C)CC=C/C=C)C VQXSOUPNOZTNAI-UHFFFAOYSA-N 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 101000908657 Rattus norvegicus Deoxyuridine 5'-triphosphate nucleotidohydrolase Proteins 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 102000005886 STAT4 Transcription Factor Human genes 0.000 description 1
- 108010019992 STAT4 Transcription Factor Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101100456541 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MEC3 gene Proteins 0.000 description 1
- 101100262439 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UBA2 gene Proteins 0.000 description 1
- 101100483663 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) UFD1 gene Proteins 0.000 description 1
- 101100129590 Schizosaccharomyces pombe (strain 972 / ATCC 24843) mcp5 gene Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- OOKCGAYXSNJBGQ-ZLUOBGJFSA-N Ser-Asn-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O OOKCGAYXSNJBGQ-ZLUOBGJFSA-N 0.000 description 1
- VGNYHOBZJKWRGI-CIUDSAMLSA-N Ser-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO VGNYHOBZJKWRGI-CIUDSAMLSA-N 0.000 description 1
- GZFAWAQTEYDKII-YUMQZZPRSA-N Ser-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO GZFAWAQTEYDKII-YUMQZZPRSA-N 0.000 description 1
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 1
- GZSZPKSBVAOGIE-CIUDSAMLSA-N Ser-Lys-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O GZSZPKSBVAOGIE-CIUDSAMLSA-N 0.000 description 1
- BYCVMHKULKRVPV-GUBZILKMSA-N Ser-Lys-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O BYCVMHKULKRVPV-GUBZILKMSA-N 0.000 description 1
- FPCGZYMRFFIYIH-CIUDSAMLSA-N Ser-Lys-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O FPCGZYMRFFIYIH-CIUDSAMLSA-N 0.000 description 1
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 description 1
- CUXJENOFJXOSOZ-BIIVOSGPSA-N Ser-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CO)N)C(=O)O CUXJENOFJXOSOZ-BIIVOSGPSA-N 0.000 description 1
- OLKICIBQRVSQMA-SRVKXCTJSA-N Ser-Ser-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OLKICIBQRVSQMA-SRVKXCTJSA-N 0.000 description 1
- VGQVAVQWKJLIRM-FXQIFTODSA-N Ser-Ser-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O VGQVAVQWKJLIRM-FXQIFTODSA-N 0.000 description 1
- PCJLFYBAQZQOFE-KATARQTJSA-N Ser-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N)O PCJLFYBAQZQOFE-KATARQTJSA-N 0.000 description 1
- BDMWLJLPPUCLNV-XGEHTFHBSA-N Ser-Thr-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BDMWLJLPPUCLNV-XGEHTFHBSA-N 0.000 description 1
- AXKJPUBALUNJEO-UBHSHLNASA-N Ser-Trp-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(O)=O AXKJPUBALUNJEO-UBHSHLNASA-N 0.000 description 1
- OQSQCUWQOIHECT-YJRXYDGGSA-N Ser-Tyr-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OQSQCUWQOIHECT-YJRXYDGGSA-N 0.000 description 1
- RCOUFINCYASMDN-GUBZILKMSA-N Ser-Val-Met Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCSC)C(O)=O RCOUFINCYASMDN-GUBZILKMSA-N 0.000 description 1
- SIEBDTCABMZCLF-XGEHTFHBSA-N Ser-Val-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SIEBDTCABMZCLF-XGEHTFHBSA-N 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 206010072005 Spinal pain Diseases 0.000 description 1
- 208000006045 Spondylarthropathies Diseases 0.000 description 1
- 101100289792 Squirrel monkey polyomavirus large T gene Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010042458 Suicidal ideation Diseases 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 101150104425 T4 gene Proteins 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 210000000068 Th17 cell Anatomy 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- KWQBJOUOSNJDRR-XAVMHZPKSA-N Thr-Cys-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N1CCC[C@@H]1C(=O)O)N)O KWQBJOUOSNJDRR-XAVMHZPKSA-N 0.000 description 1
- DSLHSTIUAPKERR-XGEHTFHBSA-N Thr-Cys-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O DSLHSTIUAPKERR-XGEHTFHBSA-N 0.000 description 1
- FIFDDJFLNVAVMS-RHYQMDGZSA-N Thr-Leu-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(O)=O FIFDDJFLNVAVMS-RHYQMDGZSA-N 0.000 description 1
- BDGBHYCAZJPLHX-HJGDQZAQSA-N Thr-Lys-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O BDGBHYCAZJPLHX-HJGDQZAQSA-N 0.000 description 1
- DXPURPNJDFCKKO-RHYQMDGZSA-N Thr-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O DXPURPNJDFCKKO-RHYQMDGZSA-N 0.000 description 1
- XKWABWFMQXMUMT-HJGDQZAQSA-N Thr-Pro-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O XKWABWFMQXMUMT-HJGDQZAQSA-N 0.000 description 1
- MROIJTGJGIDEEJ-RCWTZXSCSA-N Thr-Pro-Pro Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 MROIJTGJGIDEEJ-RCWTZXSCSA-N 0.000 description 1
- ZESGVALRVJIVLZ-VFCFLDTKSA-N Thr-Thr-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@@H]1C(=O)O)N)O ZESGVALRVJIVLZ-VFCFLDTKSA-N 0.000 description 1
- BEZTUFWTPVOROW-KJEVXHAQSA-N Thr-Tyr-Arg Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N)O BEZTUFWTPVOROW-KJEVXHAQSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- 241001351429 Tosale Species 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- XGMPVBXKDAHORN-RBWIMXSLSA-N Triamcinolone diacetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](OC(C)=O)[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O XGMPVBXKDAHORN-RBWIMXSLSA-N 0.000 description 1
- DQDXHYIEITXNJY-BPUTZDHNSA-N Trp-Gln-Gln Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N DQDXHYIEITXNJY-BPUTZDHNSA-N 0.000 description 1
- GDPDVIBHJDFRFD-RNXOBYDBSA-N Trp-Tyr-Tyr Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O GDPDVIBHJDFRFD-RNXOBYDBSA-N 0.000 description 1
- VCXWRWYFJLXITF-AUTRQRHGSA-N Tyr-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 VCXWRWYFJLXITF-AUTRQRHGSA-N 0.000 description 1
- SCCKSNREWHMKOJ-SRVKXCTJSA-N Tyr-Asn-Ser Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O SCCKSNREWHMKOJ-SRVKXCTJSA-N 0.000 description 1
- SINRIKQYQJRGDQ-MEYUZBJRSA-N Tyr-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 SINRIKQYQJRGDQ-MEYUZBJRSA-N 0.000 description 1
- SZEIFUXUTBBQFQ-STQMWFEESA-N Tyr-Pro-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O SZEIFUXUTBBQFQ-STQMWFEESA-N 0.000 description 1
- KWKJGBHDYJOVCR-SRVKXCTJSA-N Tyr-Ser-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N)O KWKJGBHDYJOVCR-SRVKXCTJSA-N 0.000 description 1
- MQGGXGKQSVEQHR-KKUMJFAQSA-N Tyr-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 MQGGXGKQSVEQHR-KKUMJFAQSA-N 0.000 description 1
- NHOVZGFNTGMYMI-KKUMJFAQSA-N Tyr-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NHOVZGFNTGMYMI-KKUMJFAQSA-N 0.000 description 1
- RIVVDNTUSRVTQT-IRIUXVKKSA-N Tyr-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O RIVVDNTUSRVTQT-IRIUXVKKSA-N 0.000 description 1
- PWKMJDQXKCENMF-MEYUZBJRSA-N Tyr-Thr-Leu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O PWKMJDQXKCENMF-MEYUZBJRSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- ZLFHAAGHGQBQQN-GUBZILKMSA-N Val-Ala-Pro Natural products CC(C)[C@H](N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O ZLFHAAGHGQBQQN-GUBZILKMSA-N 0.000 description 1
- VJOWWOGRNXRQMF-UVBJJODRSA-N Val-Ala-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](C)NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 VJOWWOGRNXRQMF-UVBJJODRSA-N 0.000 description 1
- GNWUWQAVVJQREM-NHCYSSNCSA-N Val-Asn-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N GNWUWQAVVJQREM-NHCYSSNCSA-N 0.000 description 1
- QHDXUYOYTPWCSK-RCOVLWMOSA-N Val-Asp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N QHDXUYOYTPWCSK-RCOVLWMOSA-N 0.000 description 1
- LHADRQBREKTRLR-DCAQKATOSA-N Val-Cys-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](C(C)C)N LHADRQBREKTRLR-DCAQKATOSA-N 0.000 description 1
- WDIGUPHXPBMODF-UMNHJUIQSA-N Val-Glu-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N1CCC[C@@H]1C(=O)O)N WDIGUPHXPBMODF-UMNHJUIQSA-N 0.000 description 1
- XWYUBUYQMOUFRQ-IFFSRLJSSA-N Val-Glu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C(C)C)N)O XWYUBUYQMOUFRQ-IFFSRLJSSA-N 0.000 description 1
- UEHRGZCNLSWGHK-DLOVCJGASA-N Val-Glu-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O UEHRGZCNLSWGHK-DLOVCJGASA-N 0.000 description 1
- ZIGZPYJXIWLQFC-QTKMDUPCSA-N Val-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](C(C)C)N)O ZIGZPYJXIWLQFC-QTKMDUPCSA-N 0.000 description 1
- HGJRMXOWUWVUOA-GVXVVHGQSA-N Val-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](C(C)C)N HGJRMXOWUWVUOA-GVXVVHGQSA-N 0.000 description 1
- UMPVMAYCLYMYGA-ONGXEEELSA-N Val-Leu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O UMPVMAYCLYMYGA-ONGXEEELSA-N 0.000 description 1
- XTDDIVQWDXMRJL-IHRRRGAJSA-N Val-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N XTDDIVQWDXMRJL-IHRRRGAJSA-N 0.000 description 1
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 1
- HPANGHISDXDUQY-ULQDDVLXSA-N Val-Lys-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N HPANGHISDXDUQY-ULQDDVLXSA-N 0.000 description 1
- VCIYTVOBLZHFSC-XHSDSOJGSA-N Val-Phe-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N VCIYTVOBLZHFSC-XHSDSOJGSA-N 0.000 description 1
- KRAHMIJVUPUOTQ-DCAQKATOSA-N Val-Ser-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N KRAHMIJVUPUOTQ-DCAQKATOSA-N 0.000 description 1
- ZLNYBMWGPOKSLW-LSJOCFKGSA-N Val-Val-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLNYBMWGPOKSLW-LSJOCFKGSA-N 0.000 description 1
- LLJLBRRXKZTTRD-GUBZILKMSA-N Val-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N LLJLBRRXKZTTRD-GUBZILKMSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 description 1
- FPVRUILUEYSIMD-RPRRAYFGSA-N [(8s,9r,10s,11s,13s,14s,16r,17r)-9-fluoro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(OC(C)=O)[C@@]1(C)C[C@@H]2O FPVRUILUEYSIMD-RPRRAYFGSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000002682 anti-psoriatic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125708 antidiabetic agent Drugs 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000000228 antimanic agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 1
- 239000011668 ascorbic acid Chemical class 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 108010093581 aspartyl-proline Proteins 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960002255 azelaic acid Drugs 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229940125388 beta agonist Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229960004648 betamethasone acetate Drugs 0.000 description 1
- AKUJBENLRBOFTD-QZIXMDIESA-N betamethasone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(C)=O)(O)[C@@]1(C)C[C@@H]2O AKUJBENLRBOFTD-QZIXMDIESA-N 0.000 description 1
- 229960001102 betamethasone dipropionate Drugs 0.000 description 1
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 1
- 229960004311 betamethasone valerate Drugs 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 229940126587 biotherapeutics Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical class O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960002120 butoconazole nitrate Drugs 0.000 description 1
- ZHPWRQIPPNZNML-UHFFFAOYSA-N butoconazole nitrate Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1CCC(SC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 ZHPWRQIPPNZNML-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960004841 cefadroxil Drugs 0.000 description 1
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 1
- 229960003408 cefazolin sodium Drugs 0.000 description 1
- FLKYBGKDCCEQQM-WYUVZMMLSA-M cefazolin sodium Chemical compound [Na+].S1C(C)=NN=C1SCC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 FLKYBGKDCCEQQM-WYUVZMMLSA-M 0.000 description 1
- 229960003719 cefdinir Drugs 0.000 description 1
- RTXOFQZKPXMALH-GHXIOONMSA-N cefdinir Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 description 1
- 229960000927 cefepime hydrochloride Drugs 0.000 description 1
- LRAJHPGSGBRUJN-OMIVUECESA-N cefepime hydrochloride Chemical compound O.Cl.[Cl-].S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 LRAJHPGSGBRUJN-OMIVUECESA-N 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- SNBUBQHDYVFSQF-HIFRSBDPSA-N cefmetazole Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSCC#N)OC)CC=1CSC1=NN=NN1C SNBUBQHDYVFSQF-HIFRSBDPSA-N 0.000 description 1
- 229960002676 cefmetazole sodium Drugs 0.000 description 1
- 229960002417 cefoperazone sodium Drugs 0.000 description 1
- 229960002727 cefotaxime sodium Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- ZQQALMSFFARWPK-ZTQQJVKJSA-L cefotetan disodium Chemical compound [Na+].[Na+].N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C([O-])=O)=O)C(=O)C1SC(=C(C(N)=O)C([O-])=O)S1 ZQQALMSFFARWPK-ZTQQJVKJSA-L 0.000 description 1
- 229960004445 cefotetan disodium Drugs 0.000 description 1
- 229960003016 cefoxitin sodium Drugs 0.000 description 1
- 229960004797 cefpodoxime proxetil Drugs 0.000 description 1
- LTINZAODLRIQIX-FBXRGJNPSA-N cefpodoxime proxetil Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(=O)OC(C)OC(=O)OC(C)C)C(=O)C(=N/OC)\C1=CSC(N)=N1 LTINZAODLRIQIX-FBXRGJNPSA-N 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 229960004086 ceftibuten Drugs 0.000 description 1
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 description 1
- 229960000636 ceftizoxime sodium Drugs 0.000 description 1
- ADLFUPFRVXCDMO-LIGXYSTNSA-M ceftizoxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=CCS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 ADLFUPFRVXCDMO-LIGXYSTNSA-M 0.000 description 1
- 229960000479 ceftriaxone sodium Drugs 0.000 description 1
- 229960002620 cefuroxime axetil Drugs 0.000 description 1
- 229960000534 cefuroxime sodium Drugs 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000013507 chronic prostatitis Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229960002291 clindamycin phosphate Drugs 0.000 description 1
- 229960004703 clobetasol propionate Drugs 0.000 description 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 229940124301 concurrent medication Drugs 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- BMCQMVFGOVHVNG-TUFAYURCSA-N cortisol 17-butyrate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O BMCQMVFGOVHVNG-TUFAYURCSA-N 0.000 description 1
- FZCHYNWYXKICIO-FZNHGJLXSA-N cortisol 17-valerate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O FZCHYNWYXKICIO-FZNHGJLXSA-N 0.000 description 1
- BGSOJVFOEQLVMH-VWUMJDOOSA-N cortisol phosphate Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 BGSOJVFOEQLVMH-VWUMJDOOSA-N 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 description 1
- 229960003338 crotamiton Drugs 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 201000000255 cycloplegia Diseases 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- POZRVZJJTULAOH-LHZXLZLDSA-N danazol Chemical compound C1[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=CC2=C1C=NO2 POZRVZJJTULAOH-LHZXLZLDSA-N 0.000 description 1
- 229960000766 danazol Drugs 0.000 description 1
- 238000013481 data capture Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- 229960002593 desoximetasone Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003657 dexamethasone acetate Drugs 0.000 description 1
- 229940096516 dextrates Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 229960004154 diflorasone Drugs 0.000 description 1
- WXURHACBFYSXBI-XHIJKXOTSA-N diflorasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-XHIJKXOTSA-N 0.000 description 1
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
- FDRNWTJTHBSPMW-GNXCPKRQSA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-GNXCPKRQSA-L 0.000 description 1
- VZFDRQUWHOVFCA-UHFFFAOYSA-L disodium;2-sulfanylbutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(S)C([O-])=O VZFDRQUWHOVFCA-UHFFFAOYSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 108010067396 dornase alfa Proteins 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 229960003645 econazole nitrate Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229940073621 enbrel Drugs 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000000913 erythropoietic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000002834 estrogen receptor modulator Substances 0.000 description 1
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960003336 fluorocortisol acetate Drugs 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- JLYXXMFPNIAWKQ-GNIYUCBRSA-N gamma-hexachlorocyclohexane Chemical compound Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl JLYXXMFPNIAWKQ-GNIYUCBRSA-N 0.000 description 1
- JLYXXMFPNIAWKQ-UHFFFAOYSA-N gamma-hexachlorocyclohexane Natural products ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl JLYXXMFPNIAWKQ-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000023368 generalized pustular psoriasis Diseases 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000000174 gluconic acid Chemical class 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- 108010013768 glutamyl-aspartyl-proline Proteins 0.000 description 1
- 108010000434 glycyl-alanyl-leucine Proteins 0.000 description 1
- 108010027668 glycyl-alanyl-valine Proteins 0.000 description 1
- 108010050475 glycyl-leucyl-tyrosine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 229940015045 gold sodium thiomalate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000000527 greater trochanter Anatomy 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960002383 halcinonide Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000002372 hematologic agent Substances 0.000 description 1
- 229940124562 hematologic agent Drugs 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 150000004687 hexahydrates Chemical class 0.000 description 1
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 1
- 229960003446 histidine monohydrochloride Drugs 0.000 description 1
- 230000008889 homeostatic pathway Effects 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229960001524 hydrocortisone butyrate Drugs 0.000 description 1
- 229960004204 hydrocortisone sodium phosphate Drugs 0.000 description 1
- 229960001401 hydrocortisone sodium succinate Drugs 0.000 description 1
- 229960000631 hydrocortisone valerate Drugs 0.000 description 1
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
- OWLCGJBUTJXNOF-HDNKIUSMSA-N hydron;2-morpholin-4-ylethyl (e)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1h-2-benzofuran-5-yl)-4-methylhex-4-enoate;chloride Chemical compound Cl.COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 OWLCGJBUTJXNOF-HDNKIUSMSA-N 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011502 immune monitoring Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000024949 interleukin-17 production Effects 0.000 description 1
- 108010074108 interleukin-21 Proteins 0.000 description 1
- 108010074109 interleukin-22 Proteins 0.000 description 1
- 230000003704 interleukin-23 production Effects 0.000 description 1
- 108040001844 interleukin-23 receptor activity proteins Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 208000018934 joint symptom Diseases 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- ZTMKADLOSYKWCA-UHFFFAOYSA-N lenacil Chemical compound O=C1NC=2CCCC=2C(=O)N1C1CCCCC1 ZTMKADLOSYKWCA-UHFFFAOYSA-N 0.000 description 1
- 229950007278 lenercept Drugs 0.000 description 1
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 229960002809 lindane Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 108010025153 lysyl-alanyl-alanine Proteins 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 1
- 101150018062 mcp4 gene Proteins 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000002705 metabolomic analysis Methods 0.000 description 1
- 230000001431 metabolomic effect Effects 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960001293 methylprednisolone acetate Drugs 0.000 description 1
- PLBHSZGDDKCEHR-LFYFAGGJSA-N methylprednisolone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(C)=O)CC[C@H]21 PLBHSZGDDKCEHR-LFYFAGGJSA-N 0.000 description 1
- 229960000334 methylprednisolone sodium succinate Drugs 0.000 description 1
- 229960001566 methyltestosterone Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960005040 miconazole nitrate Drugs 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 108091064355 mitochondrial RNA Proteins 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- 229960003128 mupirocin Drugs 0.000 description 1
- 229930187697 mupirocin Natural products 0.000 description 1
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical compound O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 229940087560 mycophenolate mofetil hydrochloride Drugs 0.000 description 1
- 239000002637 mydriatic agent Substances 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 229960003979 naftifine hydrochloride Drugs 0.000 description 1
- 229960001935 nandrolone decanoate Drugs 0.000 description 1
- 229960001133 nandrolone phenpropionate Drugs 0.000 description 1
- UBWXUGDQUBIEIZ-QNTYDACNSA-N nandrolone phenpropionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@H]4CCC(=O)C=C4CC3)CC[C@@]21C)C(=O)CCC1=CC=CC=C1 UBWXUGDQUBIEIZ-QNTYDACNSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229940053050 neomycin sulfate Drugs 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000000842 neuromuscular blocking agent Substances 0.000 description 1
- IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
- 229960001907 nitrofurazone Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 101800000857 p40 protein Proteins 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940090048 pen injector Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 108010024654 phenylalanyl-prolyl-alanine Proteins 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229940116406 poloxamer 184 Drugs 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- 229960002800 prednisolone acetate Drugs 0.000 description 1
- JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 description 1
- 229960002943 prednisolone sodium phosphate Drugs 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 108010070643 prolylglutamic acid Proteins 0.000 description 1
- 108010090894 prolylleucine Proteins 0.000 description 1
- 108010053725 prolylvaline Proteins 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000009430 psychological distress Effects 0.000 description 1
- 229940107568 pulmozyme Drugs 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 201000010914 pustulosis of palm and sole Diseases 0.000 description 1
- 208000011797 pustulosis palmaris et plantaris Diseases 0.000 description 1
- HYJYGLGUBUDSLJ-UHFFFAOYSA-N pyrethrin Natural products CCC(=O)OC1CC(=C)C2CC3OC3(C)C2C2OC(=O)C(=C)C12 HYJYGLGUBUDSLJ-UHFFFAOYSA-N 0.000 description 1
- VJFUPGQZSXIULQ-XIGJTORUSA-N pyrethrin II Chemical compound CC1(C)[C@H](/C=C(\C)C(=O)OC)[C@H]1C(=O)O[C@@H]1C(C)=C(C\C=C/C=C)C(=O)C1 VJFUPGQZSXIULQ-XIGJTORUSA-N 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 229940121896 radiopharmaceutical Drugs 0.000 description 1
- 230000002799 radiopharmaceutical effect Effects 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000000407 respiratory system agent Substances 0.000 description 1
- 229940125704 respiratory tract agent Drugs 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 208000002203 sacroiliac arthritis Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229940063122 sandimmune Drugs 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 210000002832 shoulder Anatomy 0.000 description 1
- 229960003600 silver sulfadiazine Drugs 0.000 description 1
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- 229940064707 sympathomimetics Drugs 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 239000011975 tartaric acid Chemical class 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
- 229960000699 terbinafine hydrochloride Drugs 0.000 description 1
- 229960000580 terconazole Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- HPFVBGJFAYZEBE-ZLQWOROUSA-N testosterone cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(CCC(=O)C=C4CC3)C)CC[C@@]21C)C(=O)CCC1CCCC1 HPFVBGJFAYZEBE-ZLQWOROUSA-N 0.000 description 1
- VOCBWIIFXDYGNZ-IXKNJLPQSA-N testosterone enanthate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC2 VOCBWIIFXDYGNZ-IXKNJLPQSA-N 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 150000004044 tetrasaccharides Chemical class 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 229960004214 tioconazole Drugs 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 239000003859 topical antiinfective agent Substances 0.000 description 1
- 229940125379 topical corticosteroid Drugs 0.000 description 1
- 210000005010 torso Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960004320 triamcinolone diacetate Drugs 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 108010080629 tryptophan-leucine Proteins 0.000 description 1
- 239000000814 tuberculostatic agent Substances 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 108010052774 valyl-lysyl-glycyl-phenylalanyl-tyrosine Proteins 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000009528 vital sign measurement Methods 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 108010027345 wheylin-1 peptide Proteins 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
A method of treating psoriatic arthritis in a patient exhibiting an inadequate response to treatment with anti-TNF therapy by administering an IL-23 specific antibody, e.g., gu Saiku mab, in a clinically proven safe and clinically proven effective amount, and which patient achieves significant ACR20/50/70, IGA, HAQ-DI, CRP, SF-36PCS/MCS, MDA, VLDA, tendinitis, dactylitis and LEI/dactylitis improvement as measured at 16, 24 and 48 weeks after initial treatment.
Description
Electronically submitted reference sequence listing
The present application contains a sequence listing submitted electronically via EFS-Web as an ASCII formatted sequence listing, with a file name of "JBIT 6473 WOCCT 1SEQLIST. Txt", a creation date of 2022, 3, 4 and a size of 9KB. This sequence listing submitted via EFS-Web is part of this specification and is incorporated by reference herein in its entirety.
Technical Field
The present invention relates to methods of treating psoriatic arthritis using antibodies that bind to human IL-23 protein. In particular, the invention relates to methods of administering an anti-IL-23 specific antibody (e.g., antilincomab) that is safe and effective for patients with psoriatic arthritis.
Background
Interleukin (IL) -12 is a secreted heterodimeric cytokine consisting of 2 disulfide-linked glycosylated protein subunits, designated p35 and p40 according to their approximate molecular weights. IL-12 is produced primarily by antigen presenting cells and drives cell-mediated immunity by binding to double-stranded receptor complexes expressed on the surface of T cells or Natural Killer (NK) cells. The IL-12 receptor beta-1 (IL-12Rbeta 1) chain binds to the p40 subunit of IL-12, thereby providing the primary interaction between IL-12 and its receptor. However, it is the IL-12p35 linkage of the second receptor chain IL-12Rβ2 that confers intracellular signaling (e.g., STAT4 phosphorylation) and activation of receptor-bearing cells. IL-12 signaling concurrent with antigen presentation is thought to cause T-cell differentiation to the T helper 1 (Th 1) phenotype, characterized by the production of interferon gamma (IFNγ). Th1 cells are believed to promote immunity to some intracellular pathogens, produce complement fixing antibody isoforms, and aid in tumor immune monitoring. Thus, IL-12 is considered an important component of host defensive immune mechanisms.
It was found that the p40 protein subunit of IL-12 can also be associated with a separate protein subunit designated p19 to form the novel cytokine IL-23.IL-23 also signals through double-stranded receptor complexes. Since the p40 subunit is shared between IL-12 and IL-23, the IL-12Rβ1 chain is also shared between IL-12 and IL-23. However, IL-23p19 ligation of IL-23R, the second component of the IL-23 receptor complex, confers IL-23-specific intracellular signaling (e.g., STAT3 phosphorylation) and subsequent IL-17 production by T cells. Recent studies have demonstrated that the biological function of IL-23 differs from that of IL-12, despite the structural similarity between these two cytokines.
Dysregulation of IL-12 and Th1 cell populations has been associated with many immune-mediated diseases, because neutralization of IL-12 with antibodies is effective in treating animal models of psoriasis, multiple Sclerosis (MS), rheumatoid arthritis, inflammatory bowel disease, insulin-dependent (type 1) diabetes, and uveitis. However, since these studies target the common p40 subunit, both IL-12 and IL-23 are neutralized in vivo. Thus, it is not clear whether IL-12 or IL-23 mediates disease, or whether inhibition of both cytokines is required to achieve disease suppression. Studies have confirmed that IL-23 inhibition may provide an equivalent benefit to the anti-IL-12 p40 strategy by neutralization of specific antibodies to IL-23p19 deficient mice or IL-23. Thus, there is increasing evidence that IL-23 has a specific role in immune-mediated diseases. Thus, neutralizing IL-23 without inhibiting the IL-12 pathway may provide an effective therapy for immune-mediated diseases with limited impact on important host defense immune mechanisms. This would represent a significant improvement over current treatment options.
Psoriasis is a common chronic immune-mediated skin disease with significant complications such as psoriatic arthritis (PsA), depression, cardiovascular disease, hypertension, obesity, diabetes, metabolic syndrome and Crohn's disease. Plaque psoriasis is the most common form of the disease and appears as a well-defined erythema lesion with white silver scale on top. Plaque is itchy, painful, often devastating and disabling to the patient, and a substantial proportion of psoriatic patients have plaque on the hands, nails, face, feet, and genitals. Thus, psoriasis has significant negative effects on health-related quality of life (HRQoL), including imposing physical and psychological burden beyond the symptoms of physical skin and interfering with daily activities. For example, psoriasis has a negative impact on family, spouse, social and work relationships and is associated with a higher incidence of depression and an increased propensity for suicide.
Psoriatic arthritis (PsA) is a multi-system disease characterized by joint inflammation and psoriasis, with a variety of clinical and radiological manifestations including dactylitis, tendinitis, sacroiliac arthritis, and/or joint deformity. The functional impairment, reduced quality of life and increased utilization of healthcare resources associated with poorly controlled PSAs present a significant economic burden. Despite the availability of biological agents (e.g., tumor necrosis factor [ TNF ] alpha inhibitors, you-tec-mab, secukinumab) and other agents (e.g., apremilast), there is a significant unmet need for new PsA therapies that can provide high levels of efficacy and safety in the treatment of heterogeneous disease components.
Histological characterization of psoriasis lesions showed thickened epidermis resulting from abnormal keratinocyte proliferation and differentiation, dermal infiltration and co-localization of cd3+ T lymphocytes and dendritic cells. Although the etiology of psoriasis is not well defined, genetic and protein analysis has shown that IL-12, IL-23 and downstream molecules thereof are overexpressed in psoriasis lesions, and some may be associated with the severity of psoriasis disease. Some therapies for the treatment of psoriasis regulate the levels of IL-12 and IL-23, which presumably contribute to their efficacy. Th1 and Th17 cells can produce effector cytokines that induce the production of vasodilators, chemoattractants, and expression of adhesion molecules on endothelial cells, which in turn promote monocyte and neutrophil recruitment, T cell infiltration, neovascularization, and keratinocyte activation and proliferation. Activated keratinocytes can produce chemoattractant factors that promote neutrophil, monocyte, T cell and dendritic cell trafficking, thereby establishing a cycle of inflammation and keratinocyte hyperproliferation.
Elucidation of the pathogenesis of psoriasis has led to effective biotherapeutics targeting tumor necrosis factor-alpha (TNF-alpha), interleukin (IL) -12 and IL-23, and recently, individually targeting IL-17 as well as IL-23 (including archaebankizumab). Gusaikumab (also known as CNTO 1959, in order toSold) is a fully human IgG1 lambda monoclonal antibody that binds to the p19 subunit of IL-23 and inhibits intracellular and downstream signaling of IL-23, which is required for terminal differentiation of T helper cells (Th 17). The current use of gulcomab is approved in the united states, the european union, and other countries of the world for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis. In addition, the gulku mab is being evaluated for several other immune-mediated disorders, including generalized pustular psoriasis, erythrodermic psoriasis, palmoplantar pustulosis, hidradenitis suppurativa, crohn's disease, and ulcerative colitis.
Disclosure of Invention
The present invention relates to the treatment of psoriatic arthritis (PsA). In particular, the invention relates to a clinically proven safe and effective method of treating PsA by administering an anti-IL-23 specific antibody to a subject.
In one general aspect, the invention relates to a method of treating psoriatic arthritis (PsA) in a subject in need thereof who is non-responder, hyporesponsive (refractory) and/or intolerant to anti-tnfα therapy, such as an anti-tnfα antibody, comprising subcutaneously administering to the subject an effective amount of an anti-IL-23 antibody (also referred to as an IL-23p19 antibody), such as Gu Saiku mab, wherein the anti-IL-23 antibody is administered once every 4 weeks (q 4 w). Preferably, the subject achieves at least a 20% improvement in the american college of rheumatology core set disease index (ACR 20) after treatment without clinically significant adverse events.
In embodiments, the anti-tnfα therapy is selected from the group consisting of etanercept, adalimumab, golimumab or cetuximab therapy, infliximab, or biological analogs of these molecules.
In certain embodiments, an anti-IL-23 antibody comprises a heavy chain variable region comprising the complementarity determining region heavy chain 1 (CDRH 1) amino acid sequence of SEQ ID NO. 1, CDRH2 of SEQ ID NO. 2, and CDRH3 of SEQ ID NO. 3; and the light chain variable region comprises the complementarity determining region light chain 1 (CDRL 1) amino acid sequence of SEQ ID NO. 4, CDRL2 of SEQ ID NO. 5 and CDRL3 of SEQ ID NO. 6.
In certain embodiments, an anti-IL-23 antibody comprises a heavy chain variable region of the amino acid sequence of SEQ ID NO. 7 and a light chain variable region of the amino acid sequence of SEQ ID NO. 8.
In certain embodiments, an anti-IL-23 antibody comprises the heavy chain amino acid sequence of SEQ ID NO. 9 and the light chain amino acid sequence of SEQ ID NO. 10.
In certain embodiments, the anti-IL-23 antibody is administered at a total dose of 25mg to 200mg, preferably about 50mg to about 150mg, more preferably about 100mg per administration.
In certain embodiments, the subject is a responder to treatment with an anti-IL-23 antibody and is identified as having a statistically significant improvement in disease activity, wherein disease activity is determined by one or more criteria selected from the group consisting of: 20% improvement in the american college core set disease index (ACR 20), 50% improvement in the american college core set disease index (ACR 50), 70% improvement in the american college core set disease index (ACR 70), health assessment questionnaire disability index (HAQ-DI), overall assessment by researchers (IGA), disease activity score 28 (DAS 28) C-reactive protein (CRP), resolution of tendinitis, resolution of dactylitis, litz tendinitis index (LEI), dactylitis assessment score, brief health investigation of psychological and physiological component summary (MCS and PCS) (SF-36), realization of Minimum Disease Activity (MDA), and realization of Very Low Disease Activity (VLDA).
In another general aspect, the invention relates to a method of treating psoriatic arthritis in a subject in need thereof, the method comprising subcutaneously administering an anti-IL-23 antibody to the subject, wherein the anti-IL-23 antibody is administered at an initial dose, a dose 4 weeks later, and a dosing interval once every 8 weeks later (q 8 w), and wherein the subject has at least one psoriatic plaque having a diameter of ≡2cm or a recorded history of nail changes or plaque psoriasis consistent with psoriasis. Preferably, the subject achieves at least a 20% improvement in the american college of rheumatology core set disease index (ACR 20) after treatment without clinically significant adverse events.
In certain embodiments, the subject has an inadequate response to standard therapy for PsA. Optionally, during treatment according to embodiments of the invention, standard therapy is also administered to the subject.
The details of one or more embodiments of the invention are set forth in the description below. Other features and advantages will be apparent from the following detailed description and the appended claims.
Drawings
The foregoing summary, as well as the following detailed description of the invention, will be better understood when read in conjunction with the appended drawings. It should be understood that the invention is not limited to the precise embodiments shown in the drawings.
Fig. 1A-1D show key secondary results of COSMOS by week 48. Primary analysis by week 24 and post hoc NRI analysis of HAQ-DI scores at week 48 (fig. 1A), ACR50 response (fig. 1B), SF-36PCS scores (fig. 1C), and PASI100 response (fig. 1D). After 24 weeks, analysis was performed using NRI, including the inclusion of EE patients into non-responders (see patient and method). Results for placebo → the antiku mab group at week 48 were reported for patients that did not enter EE and crossed Gu Saiku mab at week 24. ACR50, improvement of greater than or equal to 50% of American society of rheumatology response criteria; CI, confidence interval; GUS, gusaiku monoclonal antibody; HAQ-DI, health assessment questionnaire-disability index; LS, least squares; PASI100, 100% improvement in psoriasis area and severity index; PBO, placebo; Q8W, once every 8 weeks; SF-36PCS, physiological components of 36 concise health surveys are summarized.
Detailed Description
As used herein, methods of treating psoriatic arthritis include administering isolated, recombinant and/or synthetic anti-IL-23 specific human antibodies as well as diagnostic and therapeutic compositions, methods and devices.
As used herein, "anti-IL-23 specific antibody," "anti-IL-23 antibody," "antibody portion," or "antibody fragment" and/or "antibody variant" and the like include any protein or peptide comprising: the molecule comprises at least a portion of an immunoglobulin molecule, such as, but not limited to, at least one Complementarity Determining Region (CDR) of a heavy or light chain or a ligand binding portion thereof, a heavy or light chain variable region, a heavy or light chain constant region, a framework region, or any portion thereof, or at least a portion of an IL-23 receptor or binding protein that may be incorporated into an antibody of the invention. Such antibodies optionally further affect specific ligands, such as, but not limited to, such antibodies modulate, decrease, increase, antagonize, agonize, alleviate, mitigate, block, inhibit, eliminate, and/or interfere with at least one IL-23 activity or binding, or IL-23 receptor activity or binding, in vitro, in situ, and/or in vivo. As one non-limiting example, a suitable anti-IL-23 antibody, designated portion or variant of the invention may bind to at least one IL-23 molecule, or designated portion, variant or domain thereof. Suitable anti-IL-23 antibodies, designated portions or variants may also optionally affect at least one of IL-23 activity or function, such as, but not limited to, RNA, DNA or protein synthesis, IL-23 release, IL-23 receptor signaling, membrane IL-23 cleavage, IL-23 activity, IL-23 production and/or synthesis.
The term "antibody" is also intended to encompass antibodies, digested fragments, specific portions and variants thereof, including antibody mimics or antibody portions comprising the structure and/or function of a mimetic antibody or specific fragment or portion thereof, including single chain antibodies and fragments thereof. Functional fragments include antigen-binding fragments that bind to mammalian IL-23. For example, the invention encompasses antibody fragments capable of binding to IL-23 or a portion thereof, including but not limited to Fab fragments (e.g., obtained by papain digestion), fab 'fragments (e.g., obtained by pepsin digestion and partial reduction), and F (ab') 2 Fragments (e.g., obtained by pepsin digestion), facb fragments (e.g., obtained by plasmin digestion), pFc fragments (e.g., obtained by pepsin or plasmin digestion), fd fragments (e.g., obtained by pepsin digestion, partial reduction, and reaggregation), fv, or scFv fragments (e.g., obtained by molecular biology techniques) (see, e.g., colligan, immunology, supra).
Such fragments may be produced by enzymatic cleavage, synthetic or recombinant techniques, as known in the art and/or as described herein. Antibodies can also be produced in a variety of truncated forms using antibody genes in which one or more stop codons have been introduced upstream of the natural stop site. For example, the code F (ab') 2 The combinatorial genes of the heavy chain portion are designed to include a C encoding a heavy chain H 1 domain and/or hinge region. The individual portions of the antibodies may be chemically linked together by conventional techniques, or may be prepared as a continuous protein using genetic engineering techniques.
As used herein, the term "human antibody" refers to an antibody that: wherein substantially each part of the protein (e.g. CDR, framework, C L 、C H Domain (e.g. C H 1、C H 2、C H 3) Hinge (V) L 、V H ) Is substantially non-immunogenic in humans, with only small sequence changes or alterations. A "human antibody" may also be an antibody derived from or closely matching human germline immunoglobulin sequences. Human antibodies may include amino acid residues not encoded by germline immunoglobulin sequences (e.g., mutations introduced in vitro by random mutagenesis or site-specific mutagenesis, or mutations introduced in vivo by somatic mutation). Typically, this means that human antibodies are substantially non-immune in humans. Human antibodies have been classified into groups based on their amino acid sequence similarity. Thus, using a sequence similarity search, antibodies with similar linear sequences can be selected as templates to produce human antibodies. Similarly, antibodies designating genus primate (monkey, baboon, chimpanzee, etc.), rodent (mouse, rat, rabbit, guinea pig, hamster, etc.), and other mammals represent specific antibodies of these species, subgenera, genus, subfamily, family. Furthermore, chimeric antibodies may include any combination of the above antibodies. Such changes or alterations optionally and preferably maintain or reduce immunogenicity in humans or other species relative to unmodified antibodies. Thus, human antibodies are different from chimeric or humanized antibodies.
It should be noted that human antibodies may be produced by non-human animals or prokaryotic or eukaryotic cells capable of expressing functionally rearranged human immunoglobulin (e.g., heavy and/or light chain) genes. Furthermore, when the human antibody is a single chain antibody, it may comprise a linking peptide that is not present in the native human antibody. For example, fv may comprise a connecting peptide, such as two to about eight glycine or other amino acid residues, connecting the heavy and light chain variable regions. Such connecting peptides are considered to be of human origin.
Bispecific antibodies, xenogenous specific antibodies, xenogenous conjugated antibodies or similar antibodies, which are monoclonal antibodies, preferably human antibodies or humanized antibodies, having binding specificities for at least two different antigens, may also be used. In this case, one of the binding specificities is for at least one IL-23 protein and the other is for any other antigen. Methods for preparing bispecific antibodies are known in the art. Typically, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy chain-light chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, nature 305:537 (1983)). Due to the random distribution of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a mixture of potentially 10 different antibody molecules, only one of which has the correct bispecific structure. Purification of the correct molecule (usually by affinity chromatography steps) is quite cumbersome and the yield of the product is low. Similar procedures are disclosed in, for example, the following documents: WO 93/08829, U.S. Pat. Nos. 6210668, 6193967, 6132992, 6106833, 6060285, 6037453, 6010902, 5989530, 5959084, 5959083, 5932448, 5833985, 5821333, 5807706, 5643759, 5601819, 5582996, 5496549, 4676980, WO 91/00360, WO 92/00373, EP 03089, traunecker et al, EMBO J.10:3655 (1991), suresh et al, methods in Enzymology121:210 (1986), each of which is incorporated herein by reference in its entirety.
anti-IL-23 specific antibodies (also referred to as IL-23 specific antibodies) (or anti-IL-23 antibodies) useful in the methods and compositions of the invention may optionally have the following characteristics: binds with high affinity to IL-23 and optionally and preferably has low toxicity. In particular, antibodies, specific fragments or variants of the invention (wherein the individual components, such as the variable, constant and framework regions, are individually and/or collectively optionally and preferably have low immunogenicity) may be used in the invention. Antibodies useful in the present invention are optionally characterized in that they can be used for long periods of time in the treatment of patients, measurably alleviating symptoms and have low and/or acceptable toxicity. Low or acceptable immunogenicity and/or high affinity, as well as other suitable properties, may help achieve therapeutic results. "Low immunogenicity" is defined herein as eliciting a significant HAHA, HACA or HAMA response in less than about 75%, or preferably less than about 50% of the treated patients, and/or eliciting a low titer (less than about 300, preferably less than about 100, as measured by a double antigen enzyme immunoassay) in the treated patients (Elliott et al, lancet 344:1125-1127 (1994), which is incorporated herein by reference in its entirety). "hypoimmunogenicity" may also be defined as the occurrence of titratable levels of antibody against IL-23 in patients treated with anti-IL-23 antibody during the treatment period occurring in less than 25% of patients treated with recommended doses of the recommended course of therapy, preferably in less than 10% of patients treated with recommended doses of the recommended course of therapy.
As used herein, the terms "clinically proven effective" and "clinically proven effective" in the context of a dose, dose regimen, treatment or method refer to the clinically proven effectiveness of a particular dose, dose or treatment regimen. Efficacy may be measured based on changes in the course of the disease in response to agents of the invention based on clinical trials performed (e.g., phase 3 clinical trials and earlier clinical trials). For example, an anti-IL-23 antibody of the invention (e.g., anti-IL-23 antibody, antilinku mab) is administered to a patient in an amount and for a time sufficient to induce an improvement, preferably a sustained improvement, in at least one indicator reflecting the severity of the disease being treated. Various indicators reflecting the degree of disease, disorder or condition in a subject can be evaluated to determine whether the amount and time of treatment is sufficient. Such indicators include, for example, clinically recognized indicators of disease severity, symptoms, or manifestations of the condition under consideration. The extent of improvement is typically determined by a physician, who can make this determination based on the sign, symptom, biopsy, or other test result, and can also make this determination using a questionnaire administered to the subject, such as a quality of life questionnaire developed for a given disease. For example, the anti-IL-23 antibodies of the invention may be administered to effect an improvement in a psoriatic arthritis-related condition in a patient. Improvement may be indicated by an improvement in the disease activity index, by an improvement in clinical symptoms, or by any other measure of disease activity.
In one embodiment, preliminary criteria for rheumatoid arthritis improvement of the American College of Rheumatology (ACR) may be used to determine the efficacy of psoriatic arthritis treatment in a subject. ACR criteria measures improvement in tenderness or swollen joint counts and improvement in three of the following five parameters: acute phase reactants (such as settling velocity); patient assessment; a physician evaluates; pain scale; disability/function questionnaires. ACR criteria are expressed as ACR 20 (20% improvement in tended or swollen joint count and 20% improvement in three of the other five criteria), ACR 50 (50% improvement in tended or swollen joint count and 50% improvement in three of the other five criteria), and ACR 70 (70% improvement in tended or swollen joint count and 70% improvement in three of the other five criteria) (see Felson D T et al, archritis Rheum 1995; 38:727-35).
In another embodiment, the efficacy of treatment of psoriatic arthritis in a subject is determined by a Psoriasis Area and Severity Index (PASI), which is a disease index used to assess the severity/extent of skin disease, e.g., pasi75=75% improvement, pasi90=90% improvement and pasi100=substantially clear plaque. Metrics of efficacy may also include one or more of health assessment questionnaire disability index (HAQ-DI), tendinitis/dactylitis improvement in patients with baseline tendinitis/dactylitis, changes in SF-36 psychological and physiological component summary (MCS and PCS) scores, and achievement of Minimum Disease Activity (MDA) standard scores.
The term "clinically proven safe" when it relates to a dose, dosage regimen, treatment, or method of treatment with an anti-IL-23 antibody of the invention (e.g., anti-IL-23 antibody antique-ku-mab) refers to a relatively low or reduced frequency, and/or low or reduced severity, of adverse events (known as AE or TEAE) occurring during treatment from a clinical trial performed (e.g., phase 2 clinical trial and earlier clinical trial) as compared to a standard of care or another comparator. An adverse event is an adverse medical event that occurs in a patient administered a drug. In particular, when referring to a dose, dosage regimen or treatment with an anti-IL-23 antibody of the invention, "clinically proven safe" refers to a relatively low or reduced frequency, and/or a low or reduced severity of adverse events associated with administration of the anti-IL-23 antibody if considered to be due, likely or very likely to be due to use of the antibody.
As used herein, unless otherwise indicated, the term "clinically validated" (used alone or in modifying the terms "safe" and/or "effective") may mean that a clinical trial has proven to be effective, wherein the clinical trial has met approval standards of the united states food and drug administration, EMEA, or corresponding national regulatory authorities. For example, a clinical study may be a full sample size, randomized, double blind study for clinically confirming the efficacy of a drug.
Practicality of use
The isolated nucleic acids of the invention may be used to produce at least one anti-IL-23 antibody or designated variant thereof, which may be used to measure or affect cells, tissues, organs or animals (including mammals and humans) to diagnose, monitor, regulate, treat, alleviate, help prevent the occurrence of or alleviate symptoms of psoriasis.
Such methods may include administering to a cell, tissue, organ, animal or patient in need of such modulation, treatment, alleviation, prevention or reduction of a symptom, effect or mechanism an effective amount of a composition or pharmaceutical composition comprising at least one anti-IL-23 antibody. The effective amount may comprise an amount of about 0.001mg/kg to 500mg/kg per single administration (e.g., bolus), multiple administrations, or continuous administration, or achieve a serum concentration of 0.01 μg/ml to 5000 μg/ml per single administration, multiple administrations, or continuous administration, or any effective range or value thereof, using known methods as described herein or known in the relevant art.
Citation(s)
All publications or patents cited herein, whether or not specifically indicated, are incorporated herein by reference in their entirety as they show the state of the art upon which this invention pertains and/or provide a description and practice of the invention. Publication refers to any scientific publication or patent publication, or any other information that may be obtained in any media format, including all record formats, electronic formats, or print formats. The following references are incorporated by reference herein in their entirety: ausubel et al, editions, "Current Protocols in Molecular Biology", john Wiley & Sons, inc., NY, NY (1987-2001); sambrook et al, "Molecular Cloning: A Laboratory Manual", 2 nd edition, cold Spring Harbor, NY (1989); harlow and Lane, "anti-bodies, a Laboratory Manual", cold Spring Harbor, NY (1989); colligan et al, "Current Protocols in Immunology", john Wiley & Sons, inc., NY (1994-2001); colligan et al, "Current Protocols in Protein Science", john Wiley & Sons, NY, NY (1997-2001).
Antibody-production and production useful in the present invention
The at least one anti-IL-23 antibody used in the methods of the invention may optionally be prepared by a cell line, a mixed cell line, immortalized cells, or clonal populations of immortalized cells, as is well known in the art. See, e.g., ausubel et al, editions, "Current Protocols in Molecular Biology", john Wiley & Sons, inc., NY, NY (1987-2001); sambrook et al, "Molecular Cloning: A Laboratory Manual", 2 nd edition, cold Spring Harbor, NY (1989); harlow and Lane, "anti-bodies, a Laboratory Manual", cold Spring Harbor, NY (1989); colligan et al, "Current Protocols in Immunology", john Wiley & Sons, inc., NY (1994-2001); colligan et al, "Current Protocols in Protein Science", john Wiley & Sons, NY, NY (1997-2001), each of which is incorporated herein by reference in its entirety.
Human antibodies specific for human IL-23 protein or fragments thereof, such as isolated IL-23 protein and/or portions thereof (including synthetic molecules such as synthetic peptides), may be produced against suitable immunogenic antigens. Other specific or generic mammalian antibodies can be similarly produced. The preparation of the immunogenic antigen and the generation of monoclonal antibodies may be performed using any suitable technique.
In one mode, the hybridoma is produced by fusing a suitable immortal cell line (e.g., a myeloma cell line such as, but not limited to, sp2/0-AG14, NSO, NS1, NS2, AE-1, L.5, L243, P3X63Ag8.653, sp2 SA3, sp2 MAI, sp2 SS1, sp2 SA5, U937, MLA 144, ACT IV, MOLT4, DA-1, JURKAT, WEHI, K-562, COS, RAJI, NIH 3T3, HL-60, MLA 144, NAMALWA, NEURO A, etc., or heteromyeloma, fusion products thereof, or any cell or fusion cell derived therefrom, or any other suitable cell line known in the art) (see, e.g., www.atcc.org, www.lifetech.com., etc.), such as, but not limited to, isolated or cloned spleen, peripheral blood, lymph, tonsil or other cells containing immune or B cells, or any other cell expressing a heavy or light chain constant or variable or framework or CDR sequence, as an endogenous or heterologous nucleic acid, such as recombinant or endogenous, viral, bacterial, algal, prokaryotic, amphibian, insect, reptile, fish, mammal, rodent, horse, sheep, goat, sheep, primate, eukaryotic, genomic DNA, cDNA, rDNA, mitochondrial DNA or RNA, chloroplast DNA or RNA, hnRNA, mRNA, tRNA, single-stranded, double-stranded or triple-stranded, hybrid, or the like, or any combination thereof. See, e.g., ausubel, supra, and Colligan, immunology, supra, chapter 2, incorporated by reference in its entirety.
Antibody-producing cells may also be obtained from peripheral blood, or preferably spleen or lymph nodes, of a human or other suitable animal that has been immunized with the antigen of interest. Any other suitable host cell may also be used to express a heterologous or endogenous nucleic acid encoding an antibody, specific fragment or variant thereof of the invention. The fused cells (hybridomas) or recombinant cells can be isolated using selective culture conditions or other suitable known methods, and cloned by limiting dilution or cell sorting or other known methods. Cells producing antibodies of the desired specificity may be selected by a suitable assay (e.g., ELISA).
Other suitable methods of producing or isolating antibodies with the requisite specificity may be used, including, but not limited to, methods of selecting recombinant antibodies from peptide or protein libraries (e.g., without limitation, phage, ribosomes, oligonucleotides, RNA, cDNA, etc. display libraries; for example, available from Cambridge antibody Technologies, cambridge shire, UK; morphoSys, martinsreid/Planegg, DE; biovation, aberdeen, scotland, UK, bioInvent, lund, sweden, dyax, enzon, affymax/Biosite, xoma, berkeley, CA, ixsys. See, e.g., EP368,684, PCT/GB91/01134, PCT/GB92/01755, PCT/GB92/002240, PCT/GB92/00883, PCT/GB93/00605, U.S. 08/350260 (5/12/94), PCT/GB94/01422, PCT/GB94/02662, PCT/GB97/01835, (CAT/MRC), WO90/14443, WO90/14424, WO90/14430, PCT/US94/1234, WO92/18619, WO96/07754, (Scrilpps), WO96/13583, WO97/08320 (MohoSys), WO95/16027 (Invent), WO 88/0690/WO 90/069, PCT/GB94/01422, PCT/GB94/02662, PCT/GB97/01835, (PCT/MRC), WO90/14424, WO90/14430, WO 94/1234, WO92/18619 (WO 92/MV32), WO 92/7492/3803, WO 92/FIG. 9 (WO 92/FIG. 9, WO 92/FIG. F.F.F, WO 92/F, WO 92/F.F.F, WO 92/F.F, WO 92/F.F.K.K.K.K, WO 92/F.K, WO 92/K, WO 97/XK 3, WO 35 (F, WO 3, WO 35, each incorporated herein by reference in its entirety)) or dependent on immunization of transgenic animals (e.g., SCID mice, nguyen et al, microbiol. Immunol.41:901-907 (1997); sandhu et al, crit.Rev.Biotechnol.16:95-118 (1996); eren et al, immunol.93:154-161 (1998), each of which is incorporated herein by reference in its entirety and related patents and applications), are capable of producing a complete set of human antibodies, as known in the art and/or as described herein. Such techniques include, but are not limited to, ribosome display (Hanes et al, proc. Natl. Acad. Sci. USA,94:4937-4942 (month 5 1997); hanes et al, proc. Natl. Acad. Sci. USA,95:14130-14135 (month 11 1998)); single Cell antibody production techniques (e.g., selected lymphocyte antibody methods ("SLAM") (U.S. Pat. No. 5,627,052, wen et al, J.Immunol.17:887-892 (1987)), babcook et al, proc.Natl. Acad. Sci. USA 93:7843-7848 (1996)), gel droplets and flow cytometry (Powell et al, biotechnol.8:333-337 (1990), one Cell Systems, cambridge, MA; gray et al, J.Imm. Meth.182:155-163 (1995)), kenny et al, bio/Technol.13:787-790 (1995)), B Cell selection (Steenbaks et al, molecular biol. Reports 19:125-134 (1994)), progress et al, biotech, vol 5, "Borrek 35, amerson, 1988).
Methods for engineering or humanizing non-human or human antibodies may also be used, and are well known in the art. Generally, humanized or engineered antibodies have one or more amino acid residues from a non-human source such as, but not limited to, mice, rats, rabbits, non-human primates, or other mammals. They are typically taken from the "input" variable, constant, or other domains of a known human sequence. These non-human amino acid residues are substituted with residues commonly referred to as "import" residues, which are typically taken from "import" varying, constant or other domains of known human sequences.
Known human Ig sequences are disclosed, for example www.ncbi.nlm.nih.gov/entrez/query. Fcgi; www.ncbi.nih.gov/igblast; www.atcc.org/phase/hdb. www.mrc-cpe.cam.ac.uk/ALIGNMENTS.php; www.kabatdatabase.com/top. ftp.ncbi.nih.gov/repositisource/kabat; www.sciquest.com; www.abcam.com; www.antibodyresource.com/onlinecomp. www.public.iastate.edu/-pedro/research tools. www.whfreeman.com/immunology/CH05/kuby05. Htm; www.hhmi.org/grads/options/1996/vlab; www.path.cam.ac.uk/-mrc/mikeimages.html; mcb.harvard.edu/BioLink/immunology.html; www.immunologylink.com; pathbox.wust.edu/-hcenter/index.html; www.appliedbiosystems.com; www.nal.usda.gov/awic/pubs/anti; www.m.ehime-u.ac.jp/-yasuhito/elisa.html; www.biodesign.com; www.cancerresearchuk.org; www.biotech.ufl.edu; www.isac-net. Org; baserv.uci.kun.nl/-jraats/links 1. Html; www.recab.uni-hd.de/imuno.bme.nwu.edu; www.mrc-cpe.cam.ac.uk; www.ibt.unam.mx/vir/V_micro.html; http:// www.bioinf.org.uk/abs; anti. www.unizh.ch; www.cryst.bbk.ac.uk/-ubcg 07s; www.nimr.mrc.ac.uk/CC/ccaawg/ccaawg.html; www.path.cam.ac.uk/-mrc/humation/TAHHP.html; www.ibt.unam.mx/vir/structure/stat_aid. www.biosci.missouri.edu/smithgp/index. Html; www.jerini.de; kabat et al, "Sequences of Proteins of Immunological Interest", U.S. Dept. Health (1983), each of which is incorporated herein by reference in its entirety.
Such input sequences may be used to reduce immunogenicity or to reduce, enhance or modify binding, affinity, binding rate, dissociation rate, avidity, specificity, half-life, or any other suitable feature, as known in the art. Generally, CDR residues are directly and substantially mostly involved in influencing antigen binding. Thus, non-human CDR sequences or portions or all of human CDR sequences are retained, while non-human sequences of the variable and constant regions may be replaced with human amino acids or other amino acids.
Antibodies may also optionally be humanized or human antibodies designed to retain high affinity for antigen and other advantageous biological properties. To achieve this goal, humanized (or human) antibodies can also optionally be prepared by analysis of the parent sequence and various conceptual humanized products using three-dimensional models of the parent and humanized sequences. Three-dimensional immunoglobulin models are generally available and familiar to those skilled in the art. Computer programs are available that illustrate and display the possible three-dimensional conformational structures of selected candidate immunoglobulin sequences. These displayed assays allow for analysis of the likely role of the residues in the functional functioning of the candidate immunoglobulin sequence, i.e., analysis of residues that affect the ability of the candidate immunoglobulin to bind to its antigen. In this way, framework (FR) residues can be selected and combined from consensus and input sequences to enable desired antibody characteristics, such as increased affinity for the target antigen.
In addition, the human IL-23 specific antibodies used in the methods of the invention may include a human germline light chain framework. In particular embodiments, the sequence of the light chain germline sequence is selected from the group consisting of human VK including, but not limited to, A1, a10, a11, a14, a17, a18, a19, A2, a20, a23, a26, a27, A3, a30, A5, A7, B2, B3, L1, L10, L11, L12, L14, L15, L16, L18, L19, L2, L20, L22, L23, L24, L25, L4/18a, L5, L6, L8, L9, O1, O11, O12, O14, O18, O2, O4, and O8. In certain embodiments, the light chain human germline framework is selected from the group consisting of: v1-11, V1-13, V1-16, V1-17, V1-18, V1-19, V1-2, V1-20, V1-22, V1-3, V1-4, V1-5, V1-7, V1-9, V2-1, V2-11, V2-13, V2-14, V2-15, V2-17, V2-19, V2-6, V2-7, V2-8, V3-2, V3-3, V3-4, V4-1, V4-2, V4-3, V4-4, V4-6, V5-1, V5-2, V5-4, and V5-6.
In other embodiments, the human IL-23 specific antibodies used in the methods of the invention may include a human germline heavy chain framework. In particular embodiments, the heavy chain human germline framework is selected from the group consisting of VH1-18, VH1-2, VH1-24, VH1-3, VH1-45, VH1-46, VH1-58, VH1-69, VH1-8, VH2-26, VH2-5, VH2-70, VH3-11, VH3-13, VH3-15, VH3-16, VH3-20, VH3-21, VH3-23, VH3-30, VH3-33, VH3-35, VH3-38, VH3-43, VH3-48, VH3-49, VH3-53, VH3-64, VH3-66, VH3-7, VH3-72, VH3-73, VH3-74, VH3-9, VH4-28, VH4-31, VH4-34, VH4-39, VH4-4, VH4-59, VH4-61, VH5-51, VH6-1 and VH7-81.
In particular embodiments, the light chain variable region and/or the heavy chain variable region comprises a framework region or at least a portion of a framework region (e.g., comprising 2 or 3 sub-regions, such as FR2 and FR 3). In certain embodiments, at least FRL1, FRL2, FRL3, or FRL4 is fully human. In other embodiments, at least FRH1, FRH2, FRH3, or FRH4 is fully human. In some embodiments, at least FRL1, FRL2, FRL3, or FRL4 is a germline sequence (e.g., human germline) or a human consensus sequence comprising a particular framework (readily available at the source of the known human Ig sequences described above). In other embodiments, at least FRH1, FRH2, FRH3, or FRH4 is a germline sequence (e.g., human germline) or a human consensus sequence comprising a particular framework. In a preferred embodiment, the framework region is a fully human framework region.
Humanization or engineering of the antibodies of the invention may be performed using any known method, such as, but not limited to, those described below, winter (Jones et al, nature 321:522 (1986); riechmann et al, nature 332:323 (1988); verhoeyen et al, science 239:1534 (1988)); sims et al, J.Immunol.151:2296 (1993); chothia and Lesk, J.mol.biol.196:901 (1987); carter et al, proc.Natl.Acad.Sci.U.S. A.89:4285 (1992); presta et al, J.Immunol.151:2623 (1993); U.S. patent: 5723323, 5976862, 5824514, 5817483, 5814476, 5763192, 5723323, 5,766886, 5714352, 6204023, 6180370, 5693762, 5530101, 5585089, 5225539, 4815567; PCT/: US98/16280, US96/18978, US91/09630, US91/05939, US94/01234, GB89/01334, GB91/01134, GB92/01755; WO90/14443, WO90/14424, WO90/14430, EP229246 are each incorporated herein by reference in its entirety, including the references cited therein.
In certain embodiments, the antibody comprises an altered (e.g., mutated) Fc region. For example, in some embodiments, the Fc region has been altered to reduce or enhance the effector function of the antibody. In some embodiments, the Fc region is of a isotype selected from IgM, igA, igG, igE or other isotype. Alternatively or in addition, it may be useful to combine amino acid modifications with one or more other amino acid modifications that alter C1q binding and/or complement-dependent cytotoxicity functions of the Fc region of the IL-23 binding molecule. The specific starting polypeptide of interest may be a polypeptide that binds to C1q and exhibits Complement Dependent Cytotoxicity (CDC). Polypeptides having pre-existing C1q binding activity, optionally also having the ability to mediate CDC, may be modified such that one or both of these activities are enhanced. Amino acid modifications that alter C1q and/or modify its complement dependent cytotoxic function are described, for example, in WO0042072, hereby incorporated by reference.
As disclosed above, one can design the Fc region of the human IL-23 specific antibodies of the invention with altered effector function, e.g., by modifying C1q binding and/or fcγr binding, thereby altering Complement Dependent Cytotoxicity (CDC) activity and/or antibody dependent cell mediated cytotoxicity (ADCC) activity. The "effector function" is responsible for activating or reducing biological activity (e.g., in a subject). Examples of effector functions include, but are not limited to: c1q binding; CDC; fc receptor binding; ADCC; phagocytosis; down-regulation of cell surface receptors (e.g., B cell receptors; BCR), and the like. Such effector function may require the Fc region to be combined with a binding domain (e.g., an antibody variable domain), and may be assessed using a variety of assays (e.g., fc binding assays, ADCC assays, CDC assays, etc.).
For example, one can generate a variant Fc region of a human IL-23 (or anti-IL-23) antibody having improved C1q binding and improved fcyriii binding (e.g., having both improved ADCC activity and improved CDC activity). Alternatively, variant Fc regions with reduced CDC activity and/or reduced ADCC activity may be designed if reduced or eliminated effector function is desired. In other embodiments, only one of these activities may be increased, and optionally, other activities may also be decreased (e.g., to produce an Fc region variant with improved ADCC activity but reduced CDC activity (or vice versa)).
Fc mutations can also be introduced in the design to alter their interactions with neonatal Fc receptors (FcRn) and improve their pharmacokinetic properties. Collections of human Fc variants with improved binding to FcRn have been described (Shields et al, (2001), high resolution mapping of the binding site on human IgG for FcGamma RI, fcGamma RII, fcGamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R, J.biol. Chem. 276:6591-6604).
Another type of amino acid substitution is used to alter the glycosylation pattern of the Fc region of a human IL-23 specific antibody. Glycosylation of the Fc region is typically N-linked or O-linked. N-linked refers to the attachment of the carbohydrate moiety to the side chain of an asparagine residue. O-linked glycosylation refers to the attachment of one of the sugars N-acetylgalactosamine, galactose or xylose to a hydroxy amino acid, most commonly serine or threonine, but 5-hydroxyproline or 5-hydroxylysine may also be used. Recognition sequences for enzymatic attachment of the carbohydrate moiety to the asparagine side chain peptide sequence are asparagine-X-serine and asparagine-X-threonine, where X is any amino acid other than proline. Thus, the presence of any of these peptide sequences in the polypeptide creates a potential glycosylation site.
Glycosylation patterns can be altered, for example, by deleting one or more glycosylation sites found in the polypeptide, and/or adding one or more glycosylation sites not present in the polypeptide. The addition of glycosylation sites to the Fc region of a human IL-23-specific antibody can conveniently be accomplished by altering the amino acid sequence to contain one or more of the tripeptide sequences described above (for N-linked glycosylation sites). An exemplary glycosylation variant has an amino acid substitution of heavy chain residue Asn 297. Alterations (for O-linked glycosylation sites) may also be made by adding or substituting one or more serine or threonine residues to the sequence of the original polypeptide. In addition, one glycosylation site can be removed to change Asn297 to Ala.
In certain embodiments, the human IL-23 specific antibodies of the invention are expressed in cells that express β (1, 4) -N-acetylglucosamine transferase III (GnT III), such that GnT III adds GlcNAc to the human IL-23 antibody. Methods of producing antibodies in this manner are provided in WO/9954342, WO/03011878, patent publication 20030003097A1 and Umana et al, nature Biotechnology,17:176-180, 1999, month 2; all of these documents are specifically incorporated by reference herein in their entirety.
anti-IL-23 antibodies can also optionally be produced by immunization of transgenic animals (e.g., mice, rats, hamsters, non-human primates, etc.) capable of producing a complete set of human antibodies, as described herein and/or as known in the art. Cells that produce human anti-IL-23 antibodies can be isolated and immortalized from such animals using suitable methods, such as those described herein.
A whole set of human antibodies that can be produced in conjunction with human antigen can be produced by known methods (e.g., but not limited to, U.S. Pat. Nos. 5,770,428, 5,569,825, 5,545,806, 5,625,126, 5,625,825, 5,633,425, 5,661,016 and 5,789,650, issued to Lonberg et al; jakobovits et al, WO 98/50433; jakobovits et al, WO 98/24893; lonberg et al, WO 98/24884; lonberg et al, WO 97/13852; lonberg et al, WO 94/25585; kucherlinate et al, WO 96/34096; kucherlinate et al, EP 0463 151B1;Kucherlapate et al, EP 0710 719A1;Surani et al, and patents 5,545,807, bruggen et al, WO 90/04036; brugge 0438 474B1;Lonberg et al, EP 0814 259A2;Lonberg et al, GB 2A, lonberg et al, WO 98/249; lonberg et al, 1994; men et al, 1994-7, 1997-1997) and (1997-25, 1997-35; men's, 1997-25, 1996; men's, 1997-25, 1995-7) and (1997-7) by means of the methods of, such as described in U.S. Pat. No. 6, WO 97-25, 1995, WO 96/34096, WO 94, 1996, and 1996, and F.7, 1997, respectively. Generally, these mice comprise at least one transgene comprising DNA from at least one human immunoglobulin locus that has undergone a functional rearrangement or that may undergo a functional rearrangement. Endogenous immunoglobulin loci in such mice can be disrupted or deleted to eliminate the ability of the animal to produce antibodies encoded by the endogenous genes.
Screening for antibodies that specifically bind to similar proteins or fragments can be conveniently accomplished using peptide display libraries. This method involves screening a large collection of peptides for individual members having a desired function or structure. Antibody screening of peptide display libraries is well known in the art. The peptide sequences displayed may be 3 to 5000 or more amino acids in length, often 5 to 100 amino acids in length, and typically about 8 to 25 amino acids in length. In addition to the direct chemical synthesis methods used to generate peptide libraries, several recombinant DNA methods have been described. One type involves displaying peptide sequences on the surface of phage or cells. Each phage or cell contains a nucleotide sequence encoding a specific displayed peptide sequence. Such methods are described in PCT patent publications 91/17271, 91/18980, 91/19818 and 93/08278.
Other systems for generating peptide libraries have aspects of both in vitro chemical synthesis methods and recombinant methods. See PCT patent publications 92/05258, 92/14843 and 96/19256. See also U.S. patent nos. 5,658,754 and 5,643,768. Peptide display libraries, vectors and screening kits are commercially available from suppliers such as Invitrogen (Carlsbad, calif.) and Cambridge antibody Technologies (Cambridge shire, UK). See, for example, U.S. patent nos. 4704692, 4939666, 4946778, 5260203, 5455030, 5518889, 5534621, 5656730, 5763733, 5767260, 5856456, assigned to Enzon;5223409, 5403484, 5571698, 5837500, assigned to Dyax,5427908, 5580717, assigned to Affymax;5885793, assigned to Cambridge antibody Technologies;5750373, assigned to Genentech,5618920, 5595898, 5576195, 5698435, 5693493, 5698417, assigned to Xoma, colligan, supra; ausubel, supra; or Sambrook, supra, each of the above patents and publications are incorporated by reference herein in their entirety.
The use of at least one anti-IL 23 antibody encoding nucleic acid to provide transgenic animals or mammals, such as goats, cows, horses, sheep, rabbits, etc., may also produce antibodies for use in the methods of the invention, which transgenic animals or mammals are capable of producing such antibodies in their milk. Such animals may be provided using known methods. See, for example, but not limited to, U.S. patent 5,827,690;5,849,992;4,873,316;5,849,992;5,994,616;5,565,362;5,304,489, etc., each of which is incorporated by reference herein in its entirety.
Antibodies useful in the methods of the invention may also be prepared using at least one anti-IL 23 antibody encoding nucleic acid to provide transgenic plants and cultured plant cells (such as, but not limited to, tobacco and maize) that produce such antibodies, specific parts or variants thereof in plant parts thereof or cells cultured from plant parts. As a non-limiting example, transgenic tobacco leaves expressing recombinant proteins have been successfully used to provide large amounts of recombinant proteins, for example using inducible promoters. See, e.g., cramer et al, curr. Top. Microbol. Immunol.240:95-118 (1999), and references cited therein. Likewise, transgenic maize has also been used to express mammalian proteins on a commercial production scale, with biological activities equivalent to those produced in other recombinant systems or purified from natural sources. See, for example, hood et al, adv. Exp. Med. Biol.464:127-147 (1999), and references cited therein. Antibodies, including antibody fragments, such as single chain antibodies (scFv), can also be produced in large quantities from transgenic plant seeds, including tobacco seeds and potato tubers. See, for example, conrad et al Plant mol. Biol.38:101-109 (1998), and references cited therein. Thus, the antibodies of the invention can also be produced using transgenic plants according to known methods. See, for example, fischer et al, biotechnol. Appl. Biochem.30:99-108 (Oct., 1999); ma et al, trends Biotechnol.13:522-7 (1995); ma et al Plant Physiol.109:341-6 (1995); whitelam et al, biochem. Soc. Trans.22:940-944 (1994); and references cited therein. Each of the above references is incorporated by reference herein in its entirety.
Antibodies used in the methods of the invention can have a wide range of affinities (K D ) Binds human IL-23. In a preferred embodiment, the human mAb optionally binds human IL-23 with high affinity. For example, the human mAb can be equal to or less than about 10 - 7 M, such as but not limited to 0.1-9.9 (or any range or value therein) ×10 -7 、10 -8 、10 -9 、10 -10 、10 -11 、10 -12 、10 -13 Or K of any range or value therein D Binds human IL-23.
The affinity or avidity of an antibody for an antigen can be determined experimentally using any suitable method. (see, e.g., berzofsky et al, "anti-body-Antigen Interactions", in Fundamental Immunology, paul, W.E. editions, raven Press: new York, N.Y. (1984); kuby, janis Immunology, W.H. Freeman and Company: new York, N.Y. (1992); and methods described herein). If measured under different conditions (e.g., salt concentration, pH), the affinity of the particular antibody-antigen interaction measured will be different. Thus, affinity and other antigen binding parameters (e.g., K D 、K a 、K d ) Preferably with standard solutions of antibodies and antigens and standard buffers (e.g., buffers as described herein).
Nucleic acid molecules
Using the information provided herein, e.g., nucleotide sequences encoding at least 70% to 100% of the contiguous amino acids of at least one of the light or heavy chain variable or CDR regions described herein, as well as other sequences disclosed herein, designated fragments, variants, or consensus sequences thereof, or preservation vectors comprising at least one of these sequences, nucleic acid molecules of the invention encoding at least one anti-IL-23 antibody can be obtained using methods described herein or as known in the art.
The nucleic acid molecules of the invention may be in the form of RNA, such as mRNA, hnRNA, tRNA or any other form, or in the form of DNA, including, but not limited to, cDNA and genomic DNA produced by cloning or synthesis, or any combination thereof. The DNA may be triplex, double stranded or single stranded or any combination thereof. Any portion of at least one strand of DNA or RNA may be the coding strand, also referred to as the sense strand, or it may be the non-coding strand, also referred to as the antisense strand.
The isolated nucleic acid molecules used in the methods of the invention may include the following: a nucleic acid molecule comprising an Open Reading Frame (ORF) optionally having one or more introns, for example, but not limited to, at least one designated portion of at least one CDR, such as CDR1, CDR2, and/or CDR3 of at least one heavy or light chain; nucleic acid molecules comprising a variable region for use in an anti-IL-23 antibody; and nucleic acid molecules comprising nucleotide sequences that are significantly different from those described above, but which, due to the degeneracy of the genetic code, still encode at least one anti-IL-23 antibody as described herein and/or as known in the art. Of course, the genetic code is well known in the art. Thus, it should be routinely possible for one of skill in the art to produce such degenerate nucleic acid variants that encode specific anti-IL-23 antibodies for use in the methods of the present invention. See, e.g., ausubel et al, supra, and such nucleic acid variants are included in the invention. Non-limiting examples of isolated nucleic acid molecules include nucleic acids encoding HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2 and LC CDR3, respectively.
As noted herein, nucleic acid molecules comprising nucleic acids encoding anti-IL-23 antibodies may include, but are not limited to, those nucleic acids encoding the amino acid sequences of antibody fragments alone; a coding sequence for the whole antibody or a portion thereof; the coding sequence of the antibody, fragment or portion, and additional sequences, such as the coding sequence of at least one signal leader peptide or fusion peptide with or without the aforementioned additional coding sequences, such as at least one intron, along with additional non-coding sequences, including but not limited to non-coding 5 'sequences and 3' sequences, such as transcribed, non-translated sequences that function in transcription, mRNA processing, including splicing and polyadenylation signals (e.g., ribosome binding and stabilization of mRNA); additional coding sequences that encode additional amino acids, such as those that provide additional functions. Thus, the sequences encoding the antibodies may be fused to a marker sequence, such as a sequence encoding a peptide that may facilitate purification of the fused antibody comprising the antibody fragment or portion.
Polynucleotides that selectively hybridize to polynucleotides as described herein
The methods of the invention use isolated nucleic acids that hybridize under selective hybridization conditions to the polynucleotides disclosed herein. Thus, the polynucleotides of the present embodiments can be used to isolate, detect, and/or quantify nucleic acids comprising such polynucleotides. For example, polynucleotides of the invention may be used to identify, isolate or amplify partial or full length clones in a registered library. In some embodiments, the polynucleotide is an isolated genomic sequence or a cDNA sequence, or is complementary to a cDNA from a human or mammalian nucleic acid library.
Preferably, the cDNA library comprises at least 80% of the full length sequence, preferably at least 85% or 90% of the full length sequence, and more preferably at least 95% of the full length sequence. cDNA libraries can be normalized to increase the expression of rare sequences. Low or medium stringency hybridization conditions are generally, but not exclusively, used for sequences having reduced sequence identity relative to the complementary sequence. Medium and high stringency conditions can optionally be used for sequences of greater identity. Low stringency conditions allow for selective hybridization of sequences having about 70% sequence identity, and can be used to identify orthologous or paralogous sequences.
Optionally, the polynucleotide will encode at least a portion of an antibody. The polynucleotides comprise nucleic acid sequences that can be used for selective hybridization with polynucleotides encoding antibodies of the invention. See, for example, ausubel (supra); colligan (supra), each incorporated by reference herein in its entirety.
Construction of nucleic acids
The isolated nucleic acids can be prepared using (a) recombinant methods, (b) synthetic techniques, (c) purification techniques, and/or (d) combinations thereof, as is well known in the art.
The nucleic acid may conveniently comprise a sequence other than a polynucleotide of the invention. For example, multiple cloning sites comprising one or more endonuclease restriction sites may be inserted into the nucleic acid to aid in the isolation of the polynucleotide. In addition, translatable sequences may be inserted to aid in the isolation of translated polynucleotides of the invention. For example, the hexahistidine tag sequences provide a convenient means for purifying the proteins of the present invention. The nucleic acids of the invention (except for the coding sequences) are optionally vectors, adaptors or linkers for cloning and/or expressing the polynucleotides of the invention.
Additional sequences may be added to such cloning and/or expression sequences to optimize their function in cloning and/or expression to aid in isolation of the polynucleotide or to improve its introduction into a cell. The use of cloning vectors, expression vectors, adaptors and linkers is well known in the art. (see, e.g., ausubel, supra; or Sambrook, supra).
Recombinant methods for constructing nucleic acids
The isolated nucleic acid composition (such as RNA, cDNA, genomic DNA, or any combination thereof) can be obtained from a biological source using a variety of cloning methods known to those of skill in the art. In some embodiments, oligonucleotide probes that selectively hybridize under stringent conditions to polynucleotides of the invention are used to identify a desired sequence in a cDNA or genomic DNA library. Isolation of RNA, and construction of cDNA and genomic libraries are well known to those of ordinary skill in the art. (see, e.g., ausubel, supra; or Sambrook, supra).
Nucleic acid screening and separation methods
cDNA or genomic libraries can be screened using probes based on the sequences of polynucleotides used in the methods of the invention, such as those disclosed herein. Probes can be used to hybridize to genomic DNA or cDNA sequences to isolate homologous genes in the same or different organisms. Those skilled in the art will appreciate that hybridization of various degrees of stringency can be employed in the assay; and the hybridization or washing medium may be stringent. As the conditions for hybridization become more stringent, a higher degree of complementarity must exist between the probe and target to allow duplex formation to occur. The degree of stringency can be controlled by one or more of temperature, ionic strength, pH, and the presence of partially denaturing solvents (such as formamide). For example, the polarity of the reactant solution is varied by manipulating the concentration of formamide, for example, in the range of 0% to 50%, to thereby conveniently vary the stringency of hybridization. The degree of complementarity (sequence identity) required for detectable binding will vary depending upon the stringency of the hybridization medium and/or the wash medium. The degree of complementarity will optimally be 100% or 70% to 100% or any range or value therein. It will be appreciated, however, that minor sequence variations in the probes and primers can be compensated for by reducing the stringency of the hybridization and/or wash medium.
Methods of amplifying RNA or DNA are well known in the art and can be used according to the present invention without undue experimentation based on the teachings and guidance presented herein.
Known DNA or RNA amplification methods include, but are not limited to, polymerase Chain Reaction (PCR) and related amplification methods (see, e.g., U.S. Pat. nos. 4,683,195, 4,683,202, 4,800,159, 4,965,188 to Mullis et al, 4,795,699 and 4,921,794 to Tabor et al, 5,142,033 to inis, 5,122,464 to Wilson et al, 5,091,310 to inis, 5,066,584 to gillenten et al, 4,889,818 to gelfan et al, 4,994,370 to Silver et al, 4,766,067 to biswans, 4,656,134 to Ringold) and RNA-mediated amplification using antisense RNA of a target sequence as a template for double stranded DNA synthesis (U.S. Pat. No. 5,130,238 to Malek et al, trade name NASBA), the entire contents of which are incorporated herein by reference. ( See, e.g., ausubel, supra; or Sambrook, supra. )
For example, the sequences of polynucleotides and related genes used in the methods of the invention can be amplified directly from genomic DNA or cDNA libraries using Polymerase Chain Reaction (PCR) techniques. For example, PCR and other in vitro amplification methods can also be used to clone nucleic acid sequences encoding the proteins to be expressed, prepare nucleic acids for use as probes to detect the presence of a desired mRNA in a sample, for nucleic acid sequencing, or for other purposes. Examples of techniques sufficient to guide the skilled artisan throughout the in vitro amplification method can be found in Berger (supra), sambrook (supra), and Ausubel (supra), and us patent 4,683,202 (1987) to Mullis et al; and Innis et al PCR Protocols A Guide to Methods and Applications, eds., academic Press Inc., san Diego, calif. (1990). Commercially available kits for genomic PCR amplification are known in the art. See, e.g., advantage-GC Genomic PCR Kit (Clontech). In addition, for example, the T4 gene 32 protein (Boehringer Mannheim) can be used to increase the yield of long PCR products.
Synthetic methods for constructing nucleic acids
The isolated nucleic acids used in the methods of the invention may also be prepared by direct chemical synthesis by known methods (see, e.g., ausubel et al, supra). Chemical synthesis typically results in single stranded oligonucleotides that can be converted into double stranded DNA by hybridization to complementary sequences, or by polymerization with a DNA polymerase using the single strand as a template. Those skilled in the art will recognize that while chemical synthesis of DNA may be limited to sequences of about 100 bases or more, longer sequences may be obtained by ligating shorter sequences.
Recombinant expression cassette
The present invention uses recombinant expression cassettes comprising nucleic acids. Nucleic acid sequences, such as cDNA or genomic sequences encoding antibodies used in the methods of the invention, can be used to construct recombinant expression cassettes that can be introduced into at least one desired host cell. A recombinant expression cassette will typically comprise a polynucleotide operably linked to a transcription initiation regulatory sequence that directs transcription of the polynucleotide in a predetermined host cell. Both heterologous and non-heterologous (i.e., endogenous) promoters can be used to direct expression of the nucleic acid.
In some embodiments, an isolated nucleic acid that is a promoter, enhancer, or other element may be introduced at a suitable location (upstream, downstream, or within an intron) of a polynucleotide of the invention in a non-heterologous form so as to up-regulate or down-regulate expression of the polynucleotide. For example, endogenous promoters can be altered in vivo or in vitro by mutation, deletion, and/or substitution.
Vectors and host cells
The invention also relates to vectors comprising the isolated nucleic acid molecules, host cells genetically engineered with the recombinant vectors, and the production of at least one anti-IL-23 antibody by recombinant techniques well known in the art. See, for example, sambrook et al (supra); ausubel et al (supra), each incorporated by reference in its entirety.
The polynucleotide may optionally be linked to a vector comprising a selectable marker for propagation in a host. Generally, plasmid vectors are introduced in a precipitate, such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.
The DNA insert should be operably linked to an appropriate promoter. The expression construct will also contain a transcription start site, a termination site and a ribosome binding site for translation in the transcribed region. The coding portion of the mature transcript expressed by the construct will preferably include a translation initiation at the beginning of the mRNA to be translated and a stop codon (e.g., UAA, UGA or UAG) at the appropriate position at the end of the mRNA, with UAA and UAG being preferred for mammalian or eukaryotic cell expression.
The expression vector will preferably, but optionally, include at least one selectable marker. Such markers include, for example, but are not limited to: suitable culture media and conditions for the above-described host cells are known in the art, and suitable vectors will be apparent to the skilled artisan, the vector constructs being introduced into the host cells by calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, transfection or the like, and the methods described in chapters 1-16, 16-16 and 16. The like are accomplished by the methods of calcium phosphate transfection, DEAE-dextran-mediated transfection, cationic lipid-mediated transfection, electroporation, transfection or the like, and the methods described in chapters 1-16, 16-16 and 16-16, such as chapter 1-16, and the like, for eukaryotic cell cultures, methotrexate (MTX), dihydrofolate reductase (DHFR), U.S. Pat. No. 4,399,216;4,634,665;4,656,134;4,956,288;5,149,636, 5,179, and 7, as well as for E.coli (E.coli) and other bacteria or prokaryotes.
At least one antibody used in the methods of the invention may be expressed in a modified form (such as a fusion protein) and may include not only secretion signals, but also additional heterologous functional regions. For example, regions of additional amino acids (particularly charged amino acids) may be added to the N-terminus of the antibody to improve stability and persistence in the host cell during purification or during subsequent handling and storage. Likewise, peptide moieties may be added to the antibodies of the invention to aid in purification. Such regions may be removed prior to final preparation of the antibody or at least one fragment thereof. Such methods are described in many standard laboratory manuals, such as Sambrook, supra, chapters 17.29-17.42 and chapters 18.1-18.74; ausubel, supra, chapters 16, 17 and 18.
Those skilled in the art will recognize that many expression systems may be used to express nucleic acids encoding proteins for use in the methods of the invention. Alternatively, the nucleic acid may be expressed in a host cell by opening (by manipulation) in a host cell containing endogenous DNA encoding the antibody. Such methods are well known in the art, for example, as described in U.S. Pat. nos. 5,580,734, 5,641,670, 5,733,746, and 5,733,761, which are incorporated herein by reference in their entirety.
Exemplary cell cultures useful for producing antibodies, specific portions or variants thereof are mammalian cells. The mammalian cell system will typically be in the form of a monolayer of cells, but mammalian cell suspensions or bioreactors may also be used. Many suitable host cell lines capable of expressing intact glycosylated proteins have been developed in the art, including COS-1 (e.g., ATCC CRL 1650), COS-7 (e.g., ATCC CRL-1651), HEK293, BHK21 (e.g., ATCC CRL-10), CHO (e.g., ATCC CRL 1610) and BSC-1 (e.g., ATCC CRL-26) cell lines, cos-7 cells, CHO cells, hep G2 cells, P3X63Ag8.653, SP2/0-Ag14, 293 cells, heLa cells, etc., which are readily available from, for example, the American type culture Collection (Manassas, va (www.atcc.org)). Preferred host cells include cells of lymphoid origin, such as myeloma cells and lymphoma cells. Particularly preferred host cells are P3X63Ag8.653 cells (ATCC accession number CRL-1580) and SP2/0-Ag14 cells (ATCC accession number CRL-1851). In a particularly preferred embodiment, the recombinant cell is a P3X63Ab8.653 or SP2/0-Ag14 cell.
Expression vectors for these cells may include one or more of the following expression control sequences, such as but not limited to: an origin of replication; promoters (e.g., late or early SV40 promoter, CMV promoter (U.S. Pat. No. 5,168,062; U.S. Pat. No. 5,385,839), HSV tk promoter, pgk (phosphoglycerate kinase) promoter, EF-1. Alpha. Promoter (U.S. Pat. No. 5,266,491), at least one human immunoglobulin promoter, enhancers and/or processing information sites such as ribosome binding sites, RNA splice sites, polyadenylation sites (e.g., SV40 large-T Ag poly A addition sites), and transcription terminator sequences see, e.g., ausubel et al (supra); sambrook et al (supra); other cells useful in producing nucleic acids or proteins of the invention are also known and/or may be obtained, e.g., from the American type culture Collection cell line and hybridoma catalog (www.atcc.org), or other known sources or commercial sources.
When eukaryotic host cells are used, polyadenylation or transcription termination sequences are typically incorporated into the vector. An example of a termination sequence is a polyadenylation sequence from the bovine growth hormone gene. Sequences for accurate splicing of transcripts may also be included. An example of a splicing sequence is the VP1 intron from SV40 (Sprague et al, J. Virol.45:773-781 (1983)). In addition, the gene sequences that control replication in the host cell may be incorporated into vectors, as known in the art.
Purification of antibodies
anti-IL-23 antibodies can be recovered and purified from recombinant cell cultures by well known methods including, but not limited to, protein a purification, ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxyapatite chromatography, and lectin chromatography. High performance liquid chromatography ("HPLC") may also be used for purification. See, e.g., colligan, current Protocols in Immunology or Current Protocols in Protein Science, john Wiley & Sons, NY, (1997-2001), e.g., chapters 1, 4, 6, 8, 9, 10, each of which is incorporated by reference herein in its entirety.
Antibodies useful in the methods of the invention include naturally purified products, products of chemical synthetic procedures, and products produced by recombinant techniques from eukaryotic hosts including, for example, yeast, higher plant, insect, and mammalian cells. Depending on the host employed in the recombinant production method, the antibody may be glycosylated or may be non-glycosylated, with glycosylated being preferred. Such methods are described in many standard laboratory manuals, such as Sambrook, supra, sections 17.37-17.42; ausubel, supra, chapter 10, chapter 12, chapter 13, chapter 16, chapter 18 and chapter 20; colligan, protein Science, supra, chapters 12-14, all of which are incorporated herein by reference in their entirety.
anti-IL-23 antibodies
anti-IL-23 antibodies (also referred to herein as "anti-IL-23 specific antibodies") useful in methods according to embodiments of the invention include any protein or peptide comprising: the part is divided intoThe sub-comprises at least a portion of an immunoglobulin molecule, such as, but not limited to, at least one Ligand Binding Portion (LBP), such as, but not limited to, a Complementarity Determining Region (CDR) of a heavy or light chain or a ligand binding portion thereof, a heavy or light chain variable region, a framework region (e.g., FR1, FR2, FR3, FR4 or a fragment thereof, and optionally also at least one substitution, insertion or deletion), a heavy or light chain constant region (e.g., comprising at least one C H 1. Hinge 1, hinge 2, hinge 3, hinge 4, C H 2 or C H 3 or fragments thereof, optionally further comprising at least one substitution, insertion or deletion), or they may be incorporated into any portion of the antibody. Antibodies may include or be derived from any mammal, such as, but not limited to, human, mouse, rabbit, rat, rodent, primate, or any combination thereof, and the like.
The isolated antibodies used in the methods of the invention comprise the antibody amino acid sequences disclosed herein encoded by any suitable polynucleotide, or any isolated or prepared antibody. Preferably, the human antibody or antigen-binding fragment binds human IL-23, thereby partially or substantially neutralizing at least one biological activity of the protein. Antibodies, or designated portions or variants thereof, that partially or preferably substantially neutralize at least one biological activity of at least one IL-23 protein or fragment may bind to the protein or fragment, thereby inhibiting activity mediated through binding of IL-23 to IL-23 receptor or through other IL-23 dependent or mediated mechanisms. As used herein, the term "neutralizing antibody" refers to an antibody that can inhibit IL-23 dependent activity by about 20% to 120%, preferably at least about 10%, 20%, 30%, 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 100% or more, depending on the assay. The ability of an anti-IL-23 antibody to inhibit IL-23 dependent activity is preferably assessed by at least one suitable IL-23 protein or receptor assay as described herein and/or as known in the art. The human antibody may be of any type (IgG, igA, igM, igE, igD, etc.) or isotype and may comprise a K or lambda light chain. In one embodiment, the human antibody comprises an IgG heavy chain or a defined fragment, e.g., at least one of isotypes IgG1, igG2, igG3, or IgG4 (e.g., γ1, γ2, γ3, γ4). Antibodies of this type may be prepared as described herein and/or as known in the art by using transgenic mice or other transgenic non-human mammals that contain at least one human light chain (e.g., igG, igA, and IgM) transgene. In another embodiment, the anti-IL-23 human antibody comprises an IgG1 heavy chain and an IgG1 light chain.
The antibodies bind to at least one designated epitope that is specific for at least one IL-23 protein, subunit, fragment, portion, or any combination thereof. The at least one epitope may comprise at least one antibody binding region comprising at least a portion of a protein, the epitope preferably being constituted by at least one extracellular, soluble, hydrophilic, external or cytoplasmic portion of the protein.
Generally, a human antibody or antigen binding fragment will comprise an antigen binding region comprising at least one human complementarity determining region (CDR 1, CDR2, and CDR 3) or a variant of at least one heavy chain variable region and at least one human complementarity determining region (CDR 1, CDR2, and CDR 3) or a variant of at least one light chain variable region. CDR sequences may be derived from human germline sequences or closely match these germline sequences. For example, CDRs from a synthetic library of original non-human CDRs may be used. These CDRs can be formed by incorporating conservative substitutions from the original non-human sequence. In another specific embodiment, an antibody or antigen binding portion or variant may have an antigen binding region comprising at least a portion of at least one light chain CDR (i.e., CDR1, CDR2, and/or CDR 3) having the amino acid sequence of the corresponding CDR1, CDR2, and/or CDR 3.
Such antibodies can be prepared by the following method: the various portions (e.g., CDRs, frameworks) of the antibody are chemically linked together using conventional techniques, using conventional techniques of recombinant DNA technology, or by using any other suitable method to prepare and express the nucleic acid molecule(s) encoding the antibody.
In one embodiment, an anti-IL-23 antibody useful in the invention comprises a heavy chain variable region comprising the complementarity determining region heavy chain 1 (CDRH 1) amino acid sequence of SEQ ID NO. 1, CDRH2 of SEQ ID NO. 2, and CDRH3 of SEQ ID NO. 3; and the light chain variable region comprises the complementarity determining region light chain 1 (CDRL 1) amino acid sequence of SEQ ID NO. 4, CDRL2 of SEQ ID NO. 5 and CDRL3 of SEQ ID NO. 6.
A preferred anti-IL-23 antibody useful in the present invention comprises a heavy chain variable region having the amino acid sequence of SEQ ID NO. 7 and a light chain variable region having the amino acid sequence of SEQ ID NO. 8.
A more preferred anti-IL-23 useful in the present invention is Costuzumab (also known as CNTO1959, toSales).
Other anti-IL-23 antibodies useful in the present invention include, but are not limited to, those having the sequences described in U.S. patent No. 7,935,344 (the entire contents of which are incorporated herein by reference).
Antibody compositions comprising additional therapeutically active ingredients
The composition used in the method of the invention may optionally further comprise an effective amount of at least one compound or protein selected from at least one of the following: anti-infective agents, cardiovascular (CV) system agents, central Nervous System (CNS) agents, autonomic Nervous System (ANS) agents, respiratory tract agents, gastrointestinal (GI) tract agents, hormonal agents, agents for humoral or electrolyte balance, hematologic agents, antineoplastic agents, immunomodulating agents, ophthalmic, otic or nasal agents, topical agents, nutritional agents, statin agents, and the like. Such drugs are well known in the art and include the formulation, indication, administration and administration of each of the drugs given herein (see, e.g., "numbing 2001 Handbook of Drugs", 21 st edition, springrouse corp., springrouse, PA,2001; "Health Professional's Drug Guide 2001", ed., shannon, wilson, stang, pre-Hall, inc, upper Saddle River, NJ; "Pharmcotherapy Handbook", wells et al, editions, appleton & Lange, stamford, CT, each of which is incorporated herein by reference in its entirety).
As an example of a drug that can be combined with an antibody for use in the method of the present invention, the anti-infective drug may be at least one selected from the group consisting of: antimalarial or antiprotozoal agents, antihelminthic agents, antifungal agents, antimalarial agents, antitubercular agents or at least one antimalarial, aminoglycoside, penicillin, cephalosporin, tetracyclines, sulfonamide agents, fluoroquinolones, antivirals, macrolide antiinfectives and other antiinfectives. The hormonal agent may be at least one selected from the group consisting of: corticosteroids, androgens or at least one anabolic steroid, estrogen or at least one progesterone, gonadotrophin, antidiabetic agent or at least one glucagon, thyroid hormone antagonist, pituitary hormone and parathyroid hormone-like agent. The at least one cephalosporin may be at least one selected from the group consisting of: cefaclor, cefadroxil, cefazolin sodium, cefdinir, cefepime hydrochloride, cefixime, cefmetazole sodium, cefnesium sodium, cefoperazone sodium, cefotaxime sodium, cefotetan disodium, cefoxitin sodium, cefpodoxime proxetil, cefprozil, ceftazidime, ceftibuten, ceftizoxime sodium, ceftriaxone sodium, cefuroxime axetil, cefuroxime sodium, cefprozil hydrochloride, cefalexin, cefprozil monohydrate, and chlorocarbon.
The at least one corticosteroid may be at least one selected from the group consisting of: betamethasone acetate or betamethasone sodium phosphate, betamethasone sodium phosphate cortisone acetate, dexamethasone acetate dexamethasone sodium phosphate, fludrocortisone acetate, hydrocortisone acetate, hydrocortisone cyclopentanepropionate, hydrocortisone sodium phosphate hydrocortisone sodium succinate, methylprednisolone acetate, methylprednisolone sodium succinate, prednisolone acetate, prednisolone sodium phosphate, prednisolone tert-butyl ethyl ester, prednisone, triamcinolone acetonide and triamcinolone diacetate. The at least one androgen or anabolic steroid may be at least one selected from the group consisting of: danazol, fluoxytestosterone, methyltestosterone, nandrolone decanoate, nandrolone phenylpropionate, testosterone cyclopentanepropionate, testosterone heptanoate, testosterone propionate, and testosterone transdermal systems.
The at least one immunosuppressant may be at least one selected from the group consisting of: azathioprine, basiliximab, cyclosporine, daclizumab, lymphocyte immunoglobulins, moruzumab-CD 3, mycophenolate mofetil hydrochloride, sirolimus and tacrolimus.
The at least one topical anti-infective agent may be at least one selected from the group consisting of: acyclovir, amphotericin B, azelaic acid cream, bacitracin, butoconazole nitrate, clindamycin phosphate, clotrimazole, econazole nitrate, erythromycin, gentamicin sulfate, ketoconazole, sulfamilone acetate, metronidazole (topical), miconazole nitrate, mupirocin, naftifine hydrochloride, neomycin sulfate, nitrofurazone, nystatin, silver sulfadiazine, terbinafine hydrochloride, terconazole, tetracycline hydrochloride, tioconazole, and tolnaftate. The at least one scabicide or pediculicide may be at least one selected from the group consisting of: crotamiton, lindane, plodin and pyrethrin. The at least one topical corticosteroid may be at least one selected from the group consisting of: betamethasone dipropionate, betamethasone valerate, clobetasol propionate, desonide, desoxymethasone, dexamethasone sodium phosphate, diflorasone acetate, fluocinolone acetonide, fludrolide, fluticasone propionate, halcinonide, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone valerate, mometasone furoate and triamcinolone acetonide. (see, e.g., nursing 2001 Drug Handbook, pages 1098-1136.)
The anti-IL-23 antibody composition may further comprise any suitable and effective amount of at least one of a composition or pharmaceutical composition comprising at least one anti-IL-23 antibody in contact with or administered to a cell, tissue, organ, animal or patient in need of modulation, treatment or therapy of such, the composition or pharmaceutical composition optionally further comprising at least one agent selected from the group consisting of: at least one TNF antagonist (such as, but not limited to, TNF chemical or protein antagonists, TNF monoclonal or polyclonal antibodies or fragments, soluble TNF receptors (such as p55, p70 or p 85) or fragments thereof, fusion polypeptides, or small molecule TNF antagonists (such as TNF binding protein I or II (TBP-1 or TBP-II)), nereimomab (nereimomab), infliximab, etanercept (etanercept), CDP-571, CDP-870, alfimomab (afelimab), lennaproxipp (lenercept), etc.), antirheumatic agents (such as methotrexate, auranofin, thioglucogold, azathioprine, etanercept), sodium thiomalate, hydroxychloroquine sulfate, leflunomide (leflunomide), sulfasalazine), immunoinhibitors, immunoglobulins (such as basiliximab, cyclosporin, daclizumab), cytokine antagonists or cytokine antagonists. Non-limiting examples of such cytokines include, but are not limited to, any of IL-1 through IL-23, and the like. (e.g., IL-1, IL-2, etc.). Suitable dosages are well known in the art. See, e.g., wells et al, edit, "Pharmacotherapy Handbook", 2 nd edition, appleton and Lange, stamford, CT (2000); "PDR Pharmacopoeia, tarascon Pocket Pharmacopoeia 2000", deluxe, eds., tarascon Publishing, loma Linda, calif. (2000), each of these references is incorporated herein by reference in its entirety.
The anti-IL-23 antibody compounds, compositions, or combinations used in the methods of the invention may further comprise at least one of any suitable adjuvants, such as, but not limited to, diluents, binders, stabilizers, buffers, salts, lipophilic solvents, preservatives, adjuvants, and the like. Pharmaceutically acceptable adjuvants are preferred. Non-limiting examples and methods of preparing such sterile solutions are well known in the art, such as, but not limited to, gennaro editions, remington's Pharmaceutical Sciences, 18 th edition, mack Publishing co. (Easton, PA) 1990. Pharmaceutically acceptable carriers suitable for the mode of administration, solubility, and/or stability of the anti-IL-23 antibody, fragment, or variant compositions can be selected in a conventional manner, as is well known in the art or as described herein.
Pharmaceutical excipients and additives for use in the compositions of the present invention include, but are not limited to: proteins, peptides, amino acids, lipids and carbohydrates (e.g., sugars, including monosaccharides, disaccharides, trisaccharides, tetrasaccharides and oligosaccharides; derivatized sugars such as sugar alcohols, aldonic acids, esterified sugars, etc., and polysaccharides or sugar polymers), pharmaceutical excipients and additives may be present alone or in combination, with 1-99.99% by weight or volume. Exemplary protein excipients include serum albumin, such as Human Serum Albumin (HSA), recombinant human albumin (rHA), gelatin, casein, and the like. Representative amino acid/antibody components that may also function in terms of buffering capacity include alanine, glycine, arginine, betaine, histidine, glutamic acid, aspartic acid, cysteine, lysine, leucine, isoleucine, valine, methionine, phenylalanine, aspartame, and the like. One preferred amino acid is glycine.
Carbohydrate excipients suitable for use in the present invention include, for example, monosaccharides such as fructose, maltose, galactose, glucose, D-mannose, sorbose, and the like; disaccharides such as lactose, sucrose, trehalose, cellobiose, and the like; polysaccharides such as raffinose, melezitose, maltodextrins, glucans, starches, and the like; and sugar alcohols such as mannitol, xylitol, maltitol, lactitol, xylitol, sorbitol (glucitol), inositol and the like. Preferred carbohydrate excipients for use in the present invention are mannitol, trehalose and raffinose.
The anti-IL-23 antibody composition may further comprise a buffer or pH adjuster; typically, the buffer is a salt prepared from an organic acid or base. Representative buffers include organic acid salts such as salts of citric acid, ascorbic acid, gluconic acid, carbonic acid, tartaric acid, succinic acid, acetic acid, or phthalic acid; tris (hydroxymethyl) aminomethane hydrochloride or phosphate buffers. Preferred buffers for use in the compositions of the present invention are organic acid salts, such as citrate.
In addition, the anti-IL-23 antibody composition may include polymeric excipients/additives such as polyvinylpyrrolidone, polysucrose (polymeric sugar), dextrates (e.g., cyclodextrins such as 2-hydroxypropyl- β -cyclodextrin), polyethylene glycol, flavoring agents, antimicrobial agents, sweeteners, antioxidants, antistatic agents, surfactants (e.g., polysorbates such as "TWEEN 20" and "TWEEN 80"), lipids (e.g., phospholipids, fatty acids), steroids (e.g., cholesterol), and chelators (e.g., EDTA).
These and additional known pharmaceutical excipients and/or additives suitable for use in the anti-IL-23 antibodies, portions or variant compositions according to the invention are known in the art, for example, as listed in the following documents: "Remington: the Science & Practice of Pharmacy", 19 th edition, williams & Williams, (1995), and "Physician's Desk Reference", 52 th edition, medical Economics, montvale, NJ (1998), the disclosures of which are incorporated herein by Reference in their entirety. Preferred carrier or excipient materials are carbohydrates (e.g., sugar and alditols) and buffers (e.g., citrate) or polymeric reagents. An exemplary carrier molecule is mucopolysaccharide hyaluronic acid, which may be used for intra-articular delivery.
Formulations
As indicated above, the present invention provides stable formulations suitable for pharmaceutical or veterinary use, preferably comprising phosphate buffer with saline or selected salts, as well as preservative solutions and formulations comprising preservatives, and multi-purpose preservative formulations comprising at least one anti-IL-23 antibody in a pharmaceutically acceptable formulation. The preservative formulation comprises at least one known preservative or is optionally selected from the group consisting of: at least one of phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, phenylmercuric nitrite, phenoxyethanol, formaldehyde, chlorobutanol, magnesium chloride (e.g., hexahydrate), alkyl benzoates (methyl, ethyl, propyl, butyl, and the like), benzalkonium chloride, benzethonium chloride, sodium dehydroacetate, and thimerosal, or mixtures thereof, dissolved in an aqueous diluent. Any suitable concentration or mixture as known in the art may be used, for example 0.001% to 5% or any range or value therein, such as but not limited to: 0.001, 0.003, 0.005, 0.009, 0.01, 0.02, 0.03, 0.05, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.3, 4.5, 4.6, 4.7, 4.8, 4.9 or any range or value therein. Non-limiting examples include: preservative-free, 0.1% to 2% m-cresol (e.g., 0.2%, 0.3%, 0.4%, 0.5%, 0.9%, 1.0%), 0.1% to 3% benzyl alcohol (e.g., 0.5%, 0.9%, 1.1%, 1.5%, 1.9%, 2.0%, 2.5%), 0.001% to 0.5% merthiolate (e.g., 0.005%, 0.01%), 0.001% to 2.0% phenol (e.g., 0.05%, 0.25%, 0.28%, 0.5%, 0.9%, 1.0%), 0.0005% to 1.0% alkyl p-hydroxybenzoate (e.g., 0.00075%, 0.0009%, 0.001%, 0.002%, 0.005%, 0.0075%, 0.009%, 0.01%, 0.02%, 0.05%, 0.075%, 0.09%, 0.1%, 0.2%, 0.3%, 0.5%, 0.75%, 0.9%, 1%, and the like.
As noted above, the methods of the invention use an article comprising a packaging material and at least one vial comprising a solution (optionally dissolved in an aqueous diluent) of at least one anti-IL-23 specific antibody and a defined buffer and/or preservative, wherein the packaging material comprises a label indicating that such a solution can be stored for a period of 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 9 hours, 12 hours, 18 hours, 20 hours, 24 hours, 30 hours, 36 hours, 40 hours, 48 hours, 54 hours, 60 hours, 66 hours, 72 hours or more. The invention also uses an article of manufacture comprising a packaging material, a first vial comprising a lyophilized anti-IL-23 specific antibody, and a second vial comprising an aqueous diluent of a defined buffer or preservative, wherein the packaging material comprises a label that directs a patient to reconstitute the anti-IL-23 specific antibody in the aqueous diluent to form a solution that can be stored for a period of 24 hours or more.
The anti-IL-23 specific antibodies used according to the invention may be prepared by recombinant means, including from mammalian cells or transgenic preparations, or may be purified from other biological sources, as described herein or as known in the art.
The range of anti-IL-23 specific antibodies includes the amount produced upon reconstitution, if in a wet/dry system, from about 1.0 μg/ml to about 1000mg/ml, although lower and higher concentrations are also possible and depending on the intended delivery vehicle, for example, the solution formulation will be different from transdermal patches, pulmonary, transmucosal, or osmotic or micropump methods.
Preferably, the aqueous diluent further optionally comprises a pharmaceutically acceptable preservative. Preferred preservatives include those selected from the group consisting of: phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, alkyl p-hydroxybenzoates (methyl, ethyl, propyl, butyl, etc.), benzalkonium chloride, benzethonium chloride, sodium dehydroacetate and thimerosal or mixtures thereof. The concentration of preservative used in the formulation is that which is sufficient to produce an antimicrobial effect. This concentration depends on the preservative selected and is readily determined by the skilled artisan.
Other excipients such as isotonic agents, buffers, antioxidants and preservative enhancers may optionally and preferably be added to the diluent. Isotonic agents, such as glycerol, are often used in known concentrations. A physiologically tolerated buffer is preferably added to provide improved pH control. The formulation may cover a wide pH range, such as from about pH 4 to about pH 10, with a preferred range being from about pH 5 to about pH 9, and a most preferred range being from about 6.0 to about 8.0. Preferably the formulation of the present invention has a pH of between about 6.8 and about 7.8. Preferred buffers include phosphate buffers, most preferably sodium phosphate, especially Phosphate Buffered Saline (PBS).
Other additives such as pharmaceutically acceptable solubilizers, such as Tween 20 (polyoxyethylene (20) sorbitan monolaurate), tween 40 (polyoxyethylene (20) sorbitan monopalmitate), tween 80 (polyoxyethylene (20) sorbitan monooleate), pluronic F68 (polyoxyethylene polyoxypropylene block copolymer) and PEG (polyethylene glycol) or nonionic surfactants such as polysorbate 20 or 80 or poloxamer 184 or 188,Polyols, other block copolymers, and chelates such as EDTA and EGTA may optionally be added to the formulation or composition to reduce aggregation. These additives are particularly useful if pumps or plastic containers are used to apply the formulation. The presence of a pharmaceutically acceptable surfactant reduces the tendency of the protein to aggregate.
The formulation may be prepared by a method comprising mixing at least one anti-IL-23 specific antibody and a preservative in an aqueous diluent, the preservative selected from the group consisting of: phenol, m-cresol, p-cresol, o-cresol, chlorocresol, benzyl alcohol, alkyl p-hydroxybenzoates (methyl, ethyl, propyl, butyl, etc.), benzalkonium chloride, benzethonium chloride, sodium dehydroacetate and thimerosal or mixtures thereof. The at least one anti-IL-23 specific antibody and preservative are mixed in an aqueous diluent using conventional dissolution and mixing procedures. To prepare a suitable formulation, for example, a measured amount of at least one anti-IL-23 specific antibody in a buffer is combined with a desired preservative in the buffer in an amount sufficient to provide the desired concentration of protein and preservative. Variations of this method will be recognized by those of ordinary skill in the art. For example, the order of addition of the ingredients, whether additional additives are used, the temperature and pH at which the formulation is prepared, are all factors that can be optimized for the concentration and mode of administration used.
These formulations may be provided to the patient as clear solutions or as dual vials comprising a vial of lyophilized anti-IL-23 specific antibody reconstituted with a second vial containing water, preservative and/or excipient, preferably phosphate buffer and/or saline and selected salts in an aqueous diluent. A single solution vial or dual vials requiring reconstitution may be reused multiple times and may meet a single or multiple cycles of patient treatment and thus may provide a more convenient treatment regimen than currently available.
The articles of the present invention may be used for applications ranging from immediate to twenty-four hours or more. Thus, the claimed article of the invention provides significant advantages to the patient. The formulations of the present invention may optionally be safely stored at a temperature of about 2 ℃ to about 40 ℃ and retain the biological activity of the protein for a long period of time, allowing the packaging label indicator solution to be maintained and/or used for a period of 6, 12, 18, 24, 36, 48, 72 or 96 hours or more. Such labels may include use periods of up to 1-12 months, half a year, and/or two years if a preservative diluent is used.
Solutions of anti-IL-23 specific antibodies may be prepared by a method comprising mixing at least one antibody in an aqueous diluent. Mixing is performed using conventional dissolution and mixing procedures. To prepare a suitable diluent, for example, a measured amount of at least one antibody in water or buffer is combined in an amount sufficient to provide the protein and optionally a preservative or buffer to the desired concentration. Variations of this method will be recognized by those of ordinary skill in the art. For example, the order of addition of the ingredients, whether additional additives are used, the temperature and pH at which the formulation is prepared, are all factors that can be optimized for the concentration and mode of administration used.
The claimed product may be provided to a patient as a clear solution or as dual vials comprising a vial of lyophilized at least one anti-IL-23 specific antibody reconstituted with a second vial containing an aqueous diluent. A single solution vial or dual vials requiring reconstitution may be reused multiple times and may meet a single or multiple cycles of patient treatment and thus provide a more convenient treatment regimen than currently available.
The claimed product may be indirectly provided to a patient by providing a clarified solution or a dual vial to a pharmacy, clinic, or other such facility or unit, the dual vial comprising a vial of lyophilized at least one anti-IL-23 specific antibody reconstituted with a second vial containing an aqueous diluent. In this case the clear solution may be up to one liter or even more in volume, thereby providing a large reservoir from which smaller portions of at least one antibody solution may be withdrawn one or more times for transfer into smaller vials and provided to their customers and/or patients through a pharmacy or clinic.
Recognized devices including single vial systems include pen injector devices for delivering solutions, such as BD Pens, BD And Genotronorm/>Humatro /> Roferon/> J-tip Needle-Free /> for example, devices including a dual vial system as recognized by Becton Dickensen (Franklin Lakes, N.J., www.bectondickenson.com), disetronic (Burgdorf, switzerland, www.disetronic.com; bioject, portland, oregon (www.bioject.com)), national Medical Products, weston Medical (Peterborough, UK, www.weston-medium.com), medi-select Corp (Minneapolis, MN, www.mediject.com), and the like include pen-type injector systems for reconstitution of lyophilized drug in a cartridge for delivery of the reconstituted solution, such as >Examples of other suitable devices include prefilled syringes, auto-syringes, needleless syringes, and needleless IV infusers.
These products may include packaging materials. The packaging material provides conditions under which the product may be used, in addition to information required by regulatory authorities. For a dual vial, wet/dry product, the packaging material of the present invention provides instructions to the patient: where applicable, at least one anti-IL-23 antibody is reconstituted in an aqueous diluent to form a solution, and the solution is used for a period of 2 hours to 24 hours or more. For single vials, solution products, pre-filled syringes or auto-syringes, the label indicates that such solutions can be used for 2 hours to 24 hours or more. The product can be used for human medicine products.
The formulation used in the method of the invention may be prepared by the following method: the method comprises mixing an anti-IL-23 antibody with a selected buffer, preferably a phosphate buffer containing saline or a selected salt. anti-IL-23 antibodies and buffers were mixed in aqueous diluent using conventional solubilization and mixing procedures. For example, to prepare a suitable formulation, a measured amount of at least one antibody in water or buffer is mixed with the desired buffer in an amount of water sufficient to provide the protein and buffer to the desired concentration. Variations of this method will be recognized by those of ordinary skill in the art. For example, the order of addition of the ingredients, whether additional additives are used, the temperature and pH at which the formulation is prepared, are all factors that can be optimized for the concentration and mode of administration used.
The methods of the present invention provide pharmaceutical compositions comprising various formulations useful and acceptable for administration to a human or animal patient. Such pharmaceutical compositions are prepared using "standard state" water as a diluent and conventional methods well known to those of ordinary skill in the art. For example, the buffer components (such as histidine and histidine monohydrochloride hydrate) may be provided first, followed by the addition of appropriate non-final volumes of water diluent, sucrose, and polysorbate 80 in the "standard state". The isolated antibody may then be added. Finally, the volume of the pharmaceutical composition is adjusted to the desired final volume under "standard state" conditions using water as diluent. Those skilled in the art will recognize many other methods suitable for preparing pharmaceutical compositions.
These pharmaceutical compositions may be aqueous solutions or suspensions, which in the "standard state" contain each component of a specified mass per unit volume of water or have a specified pH. As used herein, the term "standard state" refers to a temperature of 25 ℃ +/-2 ℃ and a pressure of 1 atmosphere. The term "standard state" is not used in the art to refer to a single art-recognized temperature or pressure, but rather is a reference state that is designated to describe a temperature and pressure of a solution or suspension having a particular composition under the reference "standard state" conditions. This is because the volume of the solution is partially a function of temperature and pressure. Those skilled in the art will recognize that pharmaceutical compositions comparable to those disclosed herein may be produced at other temperatures and pressures. It should be determined whether such pharmaceutical compositions are identical to those disclosed herein under the above-identified "standard state" conditions (e.g., 25 c +/-2 c and 1 atmosphere pressure).
Importantly, such pharmaceutical compositions can contain a component mass of "about" a certain value (e.g., "about 0.53mg L-histidine") or a pH value of about a certain value per unit volume of the pharmaceutical composition. An isolated antibody present in a pharmaceutical composition is "about" a given value if it is capable of binding a peptide chain at the same time as the isolated antibody is present in the pharmaceutical composition or after the isolated antibody is removed from the pharmaceutical composition (e.g., by dilution). In other words, when the binding activity of an isolated antibody is maintained and detectable after the isolated antibody is placed in a pharmaceutical composition, a value such as a component mass value or pH value is "about" the given value.
Competition binding assays were performed to determine if IL-23 specific mabs bind to similar or different epitopes and/or compete with each other. Abs were individually coated on ELISA plates. The competing mAbs were added followed by biotinylated hrIL-23. For positive controls, the same mAb can be used to coat as a competitive mAb ("self-competitive"). IL-23 binding was detected using streptavidin. These results demonstrate whether mAbs recognize similar or partially overlapping epitopes on IL-23.
One aspect of the methods of the invention is to administer to a patient a pharmaceutical composition comprising:
in one embodiment of the pharmaceutical composition, the concentration of the isolated antibody is about 77mg to about 104mg per milliliter of the pharmaceutical composition. In another embodiment of the pharmaceutical composition, the pH is from about 5.5 to about 6.5.
The stable or preserved formulation may be provided to the patient in the form of a clear solution or in dual vials comprising a vial of lyophilized at least one anti-IL-23 antibody reconstituted with a second vial containing a preservative or buffer and excipients in an aqueous diluent. A single solution vial or dual vials requiring reconstitution may be reused multiple times and may meet a single or multiple cycles of patient treatment and thus provide a more convenient treatment regimen than currently available.
Other formulations or methods of stabilizing an anti-IL-23 antibody may produce solutions other than a clear solution of a lyophilized powder comprising the antibody. Formulations comprising suspensions of particles, which are anti-IL-23 antibody-containing compositions having variable size structures and each referred to as microspheres, microparticles, nanoparticles, nanospheres or liposomes, are included in non-clear solutions. Such relatively uniform, substantially spherical particulate formulations containing the active agent may be formed by contacting an aqueous phase containing the active agent and polymer with a non-aqueous phase and then evaporating the non-aqueous phase to cause the particles to coalesce from the aqueous phase, as taught in U.S. patent 4,589,330. Porous microparticles may be prepared using a first phase comprising the active agent and polymer dispersed in a continuous solvent and removing the solvent from suspension by freeze drying or dilution-extraction-precipitation, as taught in us patent 4,818,542. Preferred polymers for such preparation are natural or synthetic copolymers or polymers selected from the group consisting of: gelatin agar, starch, arabinogalactan, albumin, collagen, polyglycolic acid, polylactic acid, glycolide-L (-) lactide, poly (epsilon-caprolactone), poly (epsilon-caprolactone-CO-lactic acid), poly (epsilon-caprolactone-CO-glycolic acid), poly (beta-hydroxybutyric acid), polyethylene oxide, polyethylene, poly (alkyl 2-cyanoacrylate), poly (hydroxyethyl methacrylate), polyamides, poly (amino acids), poly (2-hydroxyethyl DL-asparagine), poly (ester urea), poly (L-phenylalanine/ethylene glycol/1, 6-diisocyanatohexane) and poly (methyl methacrylate). Particularly preferred polymers are polyesters such as polyglycolic acid, polylactic acid, glycolide-L (-) lactide, poly (epsilon-caprolactone), poly (epsilon-caprolactone-CO-lactic acid) and poly (epsilon-caprolactone-CO-glycolic acid). Solvents that may be used to dissolve the polymer and/or active include: water, hexafluoroisopropanol, dichloromethane, tetrahydrofuran, hexane, benzene or hexafluoroacetone sesquihydrate. The method of dispersing the active-containing phase with the second phase may include applying pressure to force the first phase through an orifice in the nozzle to effect droplet formation.
Dry powder formulations may be produced by methods other than lyophilization, such as solvent extraction by spray drying or by evaporation, or by precipitation of a crystalline composition, followed by one or more steps to remove aqueous or non-aqueous solvents. The preparation of spray-dried antibody preparations is taught in us patent 6,019,968. The antibody-based dry powder composition may be prepared by spray drying a solution or slurry of the antibody and optional excipients in a solvent under conditions that provide an inhalable dry powder. The solvent may include polar compounds such as water and ethanol, which may be easily dried. The stability of the antibody may be enhanced by performing the spray drying procedure in the absence of oxygen, such as under a nitrogen blanket or by using nitrogen as a drying gas. Another relatively dry formulation is a dispersion of a plurality of perforated microstructures dispersed in a suspending medium that typically contains a hydrofluoroalkane propellant, as taught in WO 9916419. The stabilized dispersion may be administered to the patient's lungs using a metered dose inhaler. The equipment that can be used in the commercial preparation of spray-dried medicaments is manufactured by Buchi ltd.
anti-IL-23 antibodies in a stable or preserved formulation or solution described herein may be administered to a patient according to the invention via a variety of delivery methods, including SC or IM injections; transdermal, pulmonary, transmucosal, implant, osmotic pump, cartridge, micropump, or other means known to those skilled in the art.
Therapeutic application
In one general aspect, the present application provides methods for modulating or treating psoriatic arthritis in a cell, tissue, organ, animal or patient as known in the art or as described herein using at least one IL-23 antibody of the invention, e.g., administering a therapeutically effective amount of an IL-23 specific antibody to the cell, tissue, organ, animal or patient, or contacting the cell, tissue, organ, animal or patient with the therapeutically effective amount of an IL-23 specific antibody.
Any of the methods of the invention can comprise administering an effective amount of a composition or pharmaceutical composition comprising an anti-IL-23 antibody to a cell, tissue, organ, animal or patient in need of such modulation, treatment or therapy. Such methods may optionally further comprise co-administration or combination therapy for treating such diseases or disorders, wherein administering the at least one anti-IL-23 antibody, designated portion or variant thereof further comprises administering before, concurrently with, and/or after at least one agent selected from the group consisting of: at least one TNF antagonist (such as but not limited to a TNF chemical antagonist or protein antagonist, a TNF monoclonal or polyclonal antibody or fragment, a soluble TNF receptor (such as p55, p70 or p 85) or fragment thereof, a fusion polypeptide, or a small molecule TNF antagonist such as TNF binding protein I or II (TBP-1 or TBP-II), nemumomab, infliximab, etanercept (Enbrel) TM ) Adalimumab (Humira) TM ) CDP-571, CDP-870, african monoclonal antibody, lenacil, etc.), antirheumatic drugs (e.g., methotrexate, auranofin, thioglucogold, azathioprine, gold sodium thiomalate, hydroxychloroquine sulfate, leflunomide, sulfasalazine), muscle relaxants, anesthetics (narcotic), non-steroidal anti-inflammatory drugs (NSAIDs), analgesics, anesthetics (anestic), sedatives, local anesthetics, neuromuscular blocking agents, antimicrobial agents (e.g., aminoglycosides, antifungals, antiparasitics, antiviral, carbapenems, cephalosporins, fluoroquinolones, macrolides, penicillins, sulfanilotics, tetracyclines, other antimicrobial agents), antipsoriatic agents, corticosteroids, anabolic steroids, diabetes-related agents, minerals, nutraceuticals, thyroid agents, vitamins, calcium-related hormones, antidiarrheals, anti-diarrhea agents, antiulcer agents, light-weight agents, anticoagulants, erythropoietics (e.g., erythropoiesis), erythropoiesis (e.g., leujin-CSF), leujogin, fog-sand, g., G-sandImmune inoculants, immunoglobulins, immunosuppressants (e.g., basiliximab, cyclosporine, daclizumab), growth hormone, hormone replacement drugs, estrogen receptor modulators, mydriatic agents, ciliary muscle paralysis agents, alkylating agents, antimetabolites, mitotic inhibitors, radiopharmaceuticals, antidepressants, antimanic agents, antipsychotics, anxiolytics, hypnotics, sympathomimetics, stimulants, donepezil, tacrine, asthma drugs, beta agonists, inhaled steroids, leukotriene inhibitors, methylxanthines, cromolyn, epinephrine or the like, alfa-enzymes (Pulmozyme), cytokines or cytokine antagonists. Suitable dosages are well known in the art. See, e.g., wells et al, edit, "Pharmacotherapy Handbook", 2 nd edition, appleton and Lange, stamford, CT (2000); "PDR Pharmacopoeia, tarascon Pocket Pharmacopoeia 2000", luxury version, tarascon Publishing, loma Linda, CA (2000); "Nursing 2001Handbook of Drugs, 21 st edition", springrouse corp., springrouse, PA,2001; "Health Professional's Drug Guide 2001", shannon, wilson, stang et al, prentice-Hall, inc, upper Saddle River, NJ, each of which is incorporated herein by reference in its entirety.
Medical treatment
Typically, the treatment of psoriatic arthritis is accomplished by administering an effective amount or dose of an anti-IL-23 antibody composition, which, depending on the specific activity of the active agent contained in the composition, amounts to a range of at least about 0.01 mg to 500mg of anti-IL-23 antibody per kilogram of patient on average per dose, preferably at least about 0.1 mg to 100 mg of antibody per kilogram of patient per single or multiple administrations. Alternatively, the effective serum concentration may comprise a serum concentration of 0.1 to 5000 μg/ml per single or multiple administrations. Suitable dosages are known to the medical practitioner and will of course depend on the particular disease state, the specific activity of the composition to be administered, and the particular patient undergoing treatment. In some cases, in order to achieve a desired therapeutic amount, it may be necessary to provide repeated administrations, i.e., repeated individual administrations of a particular monitored or metered dose, wherein individual administrations may be repeated until a desired daily dose or effect is achieved.
Preferred dosages may optionally include 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 96, 99, 95, 99 and/or 100, or a serum concentration in the range or range of any of values, or the following, or the values, are used to achieve a serum concentration of any of the following or serum concentration: 0.1, 0.5, 0.9, 1.0, 1.1, 1.2, 1.5, 1.9, 2.0, 2.5, 2.9, 3.0, 3.5, 3.9, 4.0, 4.5, 4.9, 5.0, 5.5, 5.9, 6.0, 6.5, 6.9, 7.0, 7.5, 7.9, 8.0, 8.5, 8.9, 9.0, 9.5, 9.9, 10, 10.5, 10.9, 11, 11.5 11.9, 20, 12.5, 12.9, 13.0, 13.5, 13.9, 14.0, 14.5, 4.9, 5.0, 5.5, 5.9, 6.0, 6.5, 6.9, 7.0, 7.5, 7.9, 8.0, 8.5, 8.9, 9.0, 9.5, 9.9, 10, 10.5, 10.9, 11, 11.5, 11.9, 12, 12.5, 12.9 13.0, 13.5, 13.9, 14, 14.5, 15, 15.5, 15.9, 16, 16.5, 16.9, 17, 17.5, 17.9, 18, 18.5, 18.9, 19, 19.5, 19.9, 20, 20.5, 20.9, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 96, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500 and/or 5000 μg/ml serum concentration per single or multiple administration, or any range, value, or fraction thereof.
Alternatively, the dosage administered may vary depending upon known factors, such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; age, health, and weight of the recipient; the nature and extent of the symptoms, the nature of the concurrent treatment, the frequency of treatment, and the desired effect. Typically the dosage of the active ingredient may be about 0.1 to 100mg/kg body weight. Typically, each administration or administration in a slow release form of from 0.1mg/kg to 50 mg/kg, preferably from 0.1mg/kg to 10 mg/kg, is effective to achieve the desired result.
As one non-limiting example, the treatment of the human or animal may be on at least one of days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40, or alternatively or in addition, on at least one of weeks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, or 52, or alternatively or in addition, at least one of years 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20, or any combination thereof, is provided as one or regular administration of at least one antibody of the invention of 0.1mg/kg to 100mg/kg, such as 0.5, 0.9, 1.0, 1.1, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 45, 50, 60, 70, 80, 90, or 100mg/kg, using a single, infusion, or repeated administration.
Dosage forms (compositions) suitable for internal administration typically contain from about 0.001 mg to about 500 mg of active ingredient per unit or container. In these pharmaceutical compositions, the active ingredient will generally be present in an amount of about 0.5% to 99.999% by weight, based on the total weight of the composition.
For parenteral administration, the antibodies may be formulated as solutions, suspensions, emulsions, granules, powders or lyophilized powders, which are provided in association with or separately from a pharmaceutically acceptable parenteral medium. Examples of such media are water, saline, ringer's solution, dextrose solution, and 1% to 10% human serum albumin. Liposomes and non-aqueous media such as fixed oils can also be used. The medium or lyophilized powder may contain additives that maintain isotonicity (e.g., sodium chloride, mannitol) and chemical stability (e.g., buffers and preservatives). The formulation may be sterilized by known or suitable techniques.
Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, a.osol's latest version (standard reference text in this field).
Alternative application
Many modes of known and developed are useful for administering pharmaceutically effective amounts of anti-IL-23 antibodies according to the present invention. Although pulmonary administration is used in the following description, other modes of administration may be used in accordance with the present invention with appropriate results. The IL-23 specific antibodies of the invention can be delivered in a carrier as a solution, emulsion, colloid, or suspension or as a dry powder using any of a variety of devices and methods suitable for administration by inhalation or other means described herein or known in the art.
Parenteral formulations and administration
Formulations for parenteral administration may contain sterile water or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes and the like as conventional excipients. Aqueous or oily suspensions for injection may be prepared according to known methods by using suitable emulsifying or wetting agents and suspending agents. The injectable medicament may be a nontoxic, non-orally administrable diluent such as an aqueous solution in a solvent, a sterile injectable solution or a suspension. As a usable medium or solvent, water, ringer's solution, isotonic saline, or the like is allowed to be used; as the common solvent or suspension solvent, sterile fixed oils may be employed. For these purposes, any type of non-volatile oils and fatty acids may be used, including natural or synthetic or semi-synthetic fatty oils or fatty acids; natural or synthetic or semisynthetic mono-or diglycerides or triglycerides. Parenteral administration is known in the art and includes, but is not limited to, injection in conventional form, pneumatic needle-free injection devices as described in U.S. patent 5,851,198, and laser perforator devices as described in U.S. patent 5,839,446, which are incorporated herein by reference in their entirety.
Alternative delivery
The invention also relates to the administration of an anti-IL-23 antibody by: parenteral, subcutaneous, intramuscular, intravenous, intra-articular, intrabronchial, intra-abdominal, intracapsular, intracartilaginous, intracavity, cerebellar, intracerebroventricular, intracolonic, endocervical, intragastric, intrahepatic, intramyocardial, intraosseous, intrapelvic, intracardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, intralesional, bolus injection, vaginal, rectal, buccal, sublingual, intranasal, or transdermal modes. anti-IL-23 antibody compositions may be prepared for parenteral (subcutaneous, intramuscular or intravenous) or any other administration, particularly in the form of liquid solutions or suspensions; for vaginal or rectal administration, particularly semi-solid forms such as, but not limited to, creams and suppositories; for oral or sublingual administration, such as but not limited to tablet or capsule form; or intranasally, such as but not limited to in the form of a powder, nasal drops or aerosol or some pharmaceutical agent; or transdermal, such as but not limited to, gels, ointments, emulsions, suspensions, or patch delivery systems containing chemical enhancers such as dimethyl sulfoxide to alter the skin structure or increase the drug concentration in transdermal patches (Junginger et al, "Drug Permeation Enhancement", hsieh, d.s. editors, pages 59-90, (Marcel Dekker, inc. New York 1994, incorporated herein by reference in its entirety), or oxidizing agents that enable the application of protein and peptide-containing formulations to the skin (WO 98/53847), or the application of electric fields to create transient transport pathways such as electroporation, or to increase the mobility of charged drugs through the skin such as iontophoresis, or the application of ultrasound such as transdermally absorbed ultrasound (us patents 4,309,989 and 4,767,402) (the publications and patents described above are incorporated herein by reference in their entirety).
Having generally described the invention, the same will be more readily understood by reference to the following examples, which are given by way of illustration only and are not intended to be limiting. Further details of the invention are illustrated by the following non-limiting examples. The disclosures of all references in the specification are expressly incorporated herein by reference.
Description of the embodiments
Embodiment 1 is a method of treating psoriatic arthritis (PsA) in a subject in need thereof, wherein the subject exhibits inadequate therapeutic response to treatment with an anti-TNF therapy, such as an anti-tnfα antibody, or other therapy, the method comprising subcutaneously administering to the subject a pharmaceutical composition comprising a safe and effective amount of an anti-IL-23 antibody and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is administered once every 4 four weeks (4 w).
Embodiment 1a is the method of embodiment 1, wherein the anti-IL-23 antibody comprises a heavy chain variable region comprising the complementarity determining region heavy chain 1 (CDRH 1) amino acid sequence of SEQ ID No. 1, CDRH2 of SEQ ID No. 2, and CDRH3 of SEQ ID No. 3; and the light chain variable region comprises the complementarity determining region light chain 1 (CDRL 1) amino acid sequence of SEQ ID NO. 4, CDRL2 of SEQ ID NO. 5 and CDRL3 of SEQ ID NO. 6.
Embodiment 1b is the method according to embodiment 1, wherein the antibody comprises a heavy chain variable region of the amino acid sequence of SEQ ID NO. 7 and a light chain variable region of the amino acid sequence of SEQ ID NO. 8.
Embodiment 2 is the method of any one of embodiments 1 to 1c, wherein the antibody is administered at a total dose of 25mg to 200mg per administration, such as 25mg, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg, and 200mg per administration, or any dose therebetween.
Embodiment 2a is the method of embodiment 2, wherein the total dose is about 50mg to about 150mg per administration.
Embodiment 2b is the method of embodiment 2, wherein the total dose is about 100mg per administration.
Embodiment 3 is the method according to any one of embodiments 1 to 2b, wherein the subject has an inadequate response to standard therapy for PsA.
Embodiment 3a is the method of embodiment 3, wherein the standard therapy is at least one selected from the group consisting of: abiotic disease modifying antirheumatic drugs (DMARDs), oral corticosteroids, apremilast, non-steroidal anti-inflammatory drugs (NSAIDs).
Embodiment 3b is the method according to embodiment 3, wherein the standard therapy is a DMARD selected from the group consisting of: methotrexate (MTX) at 25 mg/week or less, sulfasalazine (SSZ) at 3 g/day or less, hydroxychloroquine (HCQ) at 400 mg/day or Leflunomide (LEF) at 20 mg/day or less is administered to the subject.
Embodiment 3c is the method according to embodiment 3, wherein the standard therapy is an oral corticosteroid administered to the subject in an amount equivalent to ∈10 mg/day prednisone.
Embodiment 3d is the method according to embodiment 3, wherein the standard therapy is an NSAID or other analgesic administered to the subject in a commercial dose approved by a regulatory agency.
Embodiment 3e is the method according to embodiment 3, wherein the standard therapy is apremilast administered to the subject at a commercially available dose approved by a regulatory agency.
Embodiment 3f is the method according to any one of embodiments 3 to 3e, wherein the subject is untreated with a biologic.
Embodiment 3g is the method of any one of embodiments 3 to 3e, wherein the subject has previously received at least one biological treatment for PsA.
Embodiment 3h is the method of embodiment 3g, wherein the subject has an inadequate response to the at least one biological treatment.
Embodiment 3i is the method of embodiment 3g or 3h, wherein the biologic therapy is selected from the group consisting of: the therapeutic agents may be selected from the group consisting of coumarone, you-tec-mab, secukinumab (AIN 457), anti-tumor necrosis factor alpha (tnfa) agents such as adalimumab, etanercept, infliximab, subcutaneous [ SC ] or intravenous [ IV ] golimumab, cetuzumab or their respective biological analogs, tiramer-mab (MK 3222), iszumumab (LY 2439821), budaruzumab (AMG 827), risperiduzumab (BI-655066), or other research biotherapy for PsA or psoriasis.
Embodiment 3j is the method according to embodiment 3i, wherein the subject is a non-responder to anti-tumor necrosis factor alpha (tnfa) treatment.
Embodiment 3k is the method according to any one of embodiments 1 to 3j, wherein the subject has plaque psoriasis of at least 3% Body Surface Area (BSA) prior to the treatment.
Embodiment 3l is the method according to any one of embodiments 1 to 3j, wherein the subject has at least one psoriatic plaque ≡2cm in diameter or a nail change conforming to psoriasis or a medical history of plaque psoriasis records prior to the treatment.
Embodiment 3m is the method according to any one of embodiments 1 to 3l, optionally further comprising administering to the subject a standard therapy for PsA.
Embodiment 3n is the method according to any one of embodiments 1 to 3l, optionally further comprising administering to the subject a biologic therapy for PsA.
Embodiment 4 is the method according to any one of embodiments 1 to 3n, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity, wherein disease activity is determined by one or more criteria selected from the group consisting of: 20% improvement in the american college core set disease index (ACR 20), 50% improvement in the american college core set disease index (ACR 50), 70% improvement in the american college core set disease index (ACR 70), health assessment questionnaire disability index (HAQ-DI), overall assessment by researchers (IGA), disease activity score 28 (DAS 28) C-reactive protein (CRP), resolution of tendinitis, resolution of dactylitis, litz tendinitis index (LEI), dactylitis assessment score, brief health investigation of psychological and physiological component summary (MCS and PCS) (SF-36), realization of Minimum Disease Activity (MDA), and realization of Very Low Disease Activity (VLDA).
Embodiment 4a is the method of embodiment 4, wherein the improvement is measured 16, 20, 24, 28, or 48 weeks after the initial treatment.
Embodiment 4b is the method of any one of embodiments 4 to 4a, wherein the improvement is measured 16 weeks after initial treatment.
Embodiment 4c is the method of any one of embodiments 4 to 4a, wherein the improvement is measured 24 weeks or 48 weeks after initial treatment.
Embodiment 5 is the method according to any one of embodiments 4 to 4c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity as determined by a 20% improvement in the american college of rheumatology core set disease index (ACR 20) at week 24 or week 48 of treatment with the antibody.
Embodiment 5a is the method according to any one of embodiments 4 to 4c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity as determined by a 20% improvement in the american college of rheumatology core set disease index (ACR 20) at week 16 of treatment with the antibody.
Embodiment 5b is the method according to any one of embodiments 4 to 4c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity as determined by a 50% improvement in the american college of rheumatology core set disease index (ACR 50) at week 24 or week 48 of treatment with the antibody.
Embodiment 5c is the method according to any one of embodiments 4 to 4c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity as determined by a 50% improvement in the american college of rheumatology core set disease index (ACR 50) at week 16 of treatment with the antibody.
Embodiment 5d is the method according to any one of embodiments 4 to 4c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity as determined by a 70% improvement in the american college of rheumatology core set disease index (ACR 70) at week 24 or week 48 of treatment with the antibody.
Embodiment 5e is the method according to any one of embodiments 4 to 4c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity, as determined by health assessment of questionnaire disability index (HAQ-DI) at week 24 or week 48 of treatment with the antibody.
Embodiment 5f is the method according to any one of embodiments 4 to 4C, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity as determined by disease activity score 28 (DAS 28) C-reactive protein (CRP) at week 24 or week 48 of treatment with the antibody.
Embodiment 5g is the method according to any one of embodiments 4 to 4c, wherein the subject is a responder to the treatment with the antibody and is identified as achieving an overall assessment (IGA) reduction of 0 (clearance) or 1 (min) and/or ≡2 IGA from baseline by the researcher at week 24 of treatment with the antibody, wherein the subject has a BSA score of > = 3% psoriasis involvement and > = 2 at baseline.
Embodiment 5h is the method according to any one of embodiments 4 to 4c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity, as determined by regression of Shi Jijian end-inflammatory at week 24 or week 48 of treatment with the antibody.
Embodiment 5i is the method according to any one of embodiments 4 to 4c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity, as determined by resolution of dactylitis at week 24 or week 48 of treatment with the antibody.
Embodiment 5j is the method according to any one of embodiments 4 to 4c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity, as determined by the tendinitis index (LEI) at week 24 or week 48 of treatment with the antibody Shi Lici.
Embodiment 5k is the method according to any one of embodiments 4 to 4c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity as determined by an dactylitis assessment score of 0-3 (0 = absent, 1 = mild, 2 = moderate, 3 = severe) at week 24 or week 48 of treatment with the antibody.
Embodiment 5l is the method according to any one of embodiments 4 to 4c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity, as determined by a Shi Jianming (SF-36) health survey at week 24 or week 48 of treatment with the antibody.
Embodiment 5m is the method according to any one of embodiments 4 to 4c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity, as determined by the mental and physiological component summary (MCS and PCS) scores at week 24 or week 48 of treatment with the antibody.
Embodiment 5n is the method according to any one of embodiments 4 to 4c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity, as determined by Minimum Disease Activity (MDA) criteria at week 24 or week 48 of treatment with the antibody.
Embodiment 5o is the method according to any one of embodiments 4 to 4c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity, as determined by the realization of Very Low Disease Activity (VLDA).
Embodiment 6 is the method of any one of embodiments 4 to 5o, wherein the improvement is maintained for at least 12 weeks, 24 weeks, 36 weeks, 48 weeks, 60 weeks, 72 weeks, or 84 weeks, or any time therebetween.
Embodiment 7 is the method of any one of embodiments 1 to 6, wherein the anti-IL-23 antibody is archaebankab.
Embodiment 8 is the method of any one of embodiments 1 to 7, further comprising administering to the subject one or more additional drugs for treating psoriatic arthritis.
Embodiment 8a is the method of embodiment 8, wherein the additional drug is selected from the group consisting of: immunosuppressants, non-steroidal anti-inflammatory drugs (NSAIDs), methotrexate (MTX), anti-B cell surface marker antibodies, anti-CD 20 antibodies, rituximab, TNF inhibitors, corticosteroids, and co-stimulatory modulators.
Embodiment 9 is a method of treating psoriatic arthritis (PsA) in a subject, the method comprising subcutaneously administering to the subject a pharmaceutical composition comprising a safe and effective amount of an anti-IL-23 antibody and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is administered at an initial dose, a dose 4 weeks later, and a dosing interval once every 8 weeks later (q 8 w), and wherein the subject has at least one psoriatic plaque of diameter ≡2cm or a recorded history of nail changes or plaque psoriasis consistent with psoriasis prior to the treatment.
Embodiment 9a is the method of embodiment 9, wherein the anti-IL-23 antibody comprises a heavy chain variable region comprising the complementarity determining region heavy chain 1 (CDRH 1) amino acid sequence of SEQ ID No. 1, CDRH2 of SEQ ID No. 2, and CDRH3 of SEQ ID No. 3; and the light chain variable region comprises the complementarity determining region light chain 1 (CDRL 1) amino acid sequence of SEQ ID NO. 4, CDRL2 of SEQ ID NO. 5 and CDRL3 of SEQ ID NO. 6.
Embodiment 9b is the method of embodiment 9, wherein the antibody comprises a heavy chain variable region of the amino acid sequence of SEQ ID NO. 7 and a light chain variable region of the amino acid sequence of SEQ ID NO. 8.
Embodiment 9c is the method of embodiment 9, wherein the anti-IL-23 antibody comprises the heavy chain amino acid sequence of SEQ ID NO. 9 and the light chain amino acid sequence of SEQ ID NO. 10.
Embodiment 10 is the method of any one of embodiments 9 to 9c, wherein the antibody is administered at a total dose of 25mg to 200mg per administration, such as 25mg, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg, and 200mg per administration, or any dose therebetween.
Embodiment 10a is the method of embodiment 10, wherein the total dose is about 50mg to about 150mg per administration.
Embodiment 10b is the method of embodiment 10, wherein the total dose is about 100mg per administration.
Embodiment 11 is the method according to any one of embodiments 9 to 10b, wherein the subject has an inadequate response to standard therapy for PsA.
Embodiment 11a is the method of embodiment 11, wherein the standard therapy is at least one selected from the group consisting of: abiotic disease modifying antirheumatic drugs (DMARDs), oral corticosteroids, apremilast, non-steroidal anti-inflammatory drugs (NSAIDs).
Embodiment 11b is the method of embodiment 11, wherein the standard therapy is a DMARD selected from the group consisting of: methotrexate (MTX) at 25 mg/week or less, sulfasalazine (SSZ) at 3 g/day or less, hydroxychloroquine (HCQ) at 400 mg/day or Leflunomide (LEF) at 20 mg/day or less is administered to the subject.
Embodiment 11c is the method of embodiment 11, wherein the standard therapy is an oral corticosteroid administered to the subject in an amount equivalent to ∈10 mg/day prednisone.
Embodiment 11d is the method of embodiment 11, wherein the standard therapy is an NSAID or other analgesic administered to the subject in a commercially available dose approved by a regulatory agency.
Embodiment 11e is the method of embodiment 11, wherein the standard therapy is apremilast administered to the subject at a commercially available dose approved by a regulatory agency.
Embodiment 11f is the method according to any one of embodiments 11 to 11e, wherein the subject is untreated with a biologic.
Embodiment 11g is the method of any one of embodiments 11 to 11e, wherein the subject has previously received at least one biological treatment for PsA.
Embodiment 11h is the method of embodiment 11g, wherein the subject has an inadequate response to the at least one biological treatment.
Embodiment 11i is the method of embodiment 11g or 11h, wherein the biologic therapy is selected from the group consisting of: the therapeutic agents may be selected from the group consisting of coumarone, you-tec-mab, secukinumab (AIN 457), anti-tumor necrosis factor alpha (tnfa) agents such as adalimumab, etanercept, infliximab, subcutaneous [ SC ] or intravenous [ IV ] golimumab, cetuzumab or their respective biological analogs, tiramer-mab (MK 3222), iszumumab (LY 2439821), budaruzumab (AMG 827), risperiduzumab (BI-655066), or other research biotherapy for PsA or psoriasis.
Embodiment 11j is the method according to embodiment 11i, wherein the subject is a non-responder to anti-tumor necrosis factor alpha (tnfa) treatment.
Embodiment 11k is the method according to any one of embodiments 9 to 11j, wherein the subject has plaque psoriasis of at least 3% Body Surface Area (BSA) prior to the treatment.
Embodiment 11l is the method according to any one of embodiments 9 to 11j, wherein the subject has at least one psoriatic plaque ≡2cm in diameter or a nail change conforming to psoriasis or a medical history of plaque psoriasis records prior to the treatment.
Embodiment 11m is the method according to any one of embodiments 9 to 11l, optionally further comprising administering to the subject a standard therapy for PsA.
Embodiment 11n is the method according to any one of embodiments 9 to 11l, optionally further comprising administering to the subject a biologic therapy for PsA.
Embodiment 12 is the method according to any one of embodiments 9 to 11n, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity, wherein disease activity is determined by one or more criteria selected from the group consisting of: 20% improvement in the american college core set disease index (ACR 20), 50% improvement in the american college core set disease index (ACR 50), 70% improvement in the american college core set disease index (ACR 70), health assessment questionnaire disability index (HAQ-DI), overall assessment by researchers (IGA), disease activity score 28 (DAS 28) C-reactive protein (CRP), resolution of tendinitis, resolution of dactylitis, litz tendinitis index (LEI), dactylitis assessment score, brief health investigation of psychological and physiological component summary (MCS and PCS) (SF-36), realization of Minimum Disease Activity (MDA), and realization of Very Low Disease Activity (VLDA).
Embodiment 12a is the method of embodiment 12, wherein the improvement is measured 16, 20, 24, or 28 weeks after the initial treatment.
Embodiment 12b is the method of any one of embodiments 12 to 12a, wherein the improvement is measured 16 weeks after initial treatment.
Embodiment 12c is the method of any one of embodiments 12 to 12a, wherein the improvement is measured 24 weeks after initial treatment.
Embodiment 13 is the method according to any one of embodiments 12 to 12c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity as determined by a 20% improvement in the american college of rheumatology core set disease index (ACR 20) at week 24 or week 48 of treatment with the antibody.
Embodiment 13a is the method according to any one of embodiments 12 to 12c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity as determined by a 20% improvement in the american college of rheumatology core set disease index (ACR 20) at week 16 of treatment with the antibody.
Embodiment 13b is the method according to any one of embodiments 12 to 12c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity as determined by american college of rheumatology 130% improvement criteria (ACR 130) at week 24 or week 48 of treatment with the antibody.
Embodiment 13c is the method according to any one of embodiments 12 to 12c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity as determined by the american college of rheumatology 130% improvement standard (ACR 130) at week 16 of treatment with the antibody.
Embodiment 13d is the method according to any one of embodiments 12 to 12c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity as determined by a 70% improvement in the american college of rheumatology core set disease index (ACR 70) at week 24 or week 48 of treatment with the antibody.
Embodiment 13e is the method according to any one of embodiments 12 to 12c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity, as determined by health assessment of questionnaire disability index (HAQ-DI) at week 24 or week 48 of treatment with the antibody.
Embodiment 13f is the method according to any one of embodiments 12 to 12C, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity as determined by disease activity score 28 (DAS 28) C-reactive protein (CRP) at week 24 or week 48 of treatment with the antibody.
Embodiment 13g is the method according to any one of embodiments 12 to 12c, wherein the subject is a responder to the treatment with the antibody and is identified as achieving a 0 (clearance) or 1 (minimal) and/or ≡2 reduction in overall assessment (IGA) of the researcher relative to baseline at week 24 of treatment with the antibody, wherein the subject has a BSA score of > = 3% psoriasis involvement and > = 2 at baseline.
Embodiment 13h is the method according to any one of embodiments 12 to 12c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity, as determined by regression of Shi Jijian end-inflammatory at week 24 or week 48 of treatment with the antibody.
Embodiment 13i is the method according to any one of embodiments 12 to 12c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity, as determined by resolution of dactylitis at week 24 or week 48 of treatment with the antibody.
Embodiment 13j is the method according to any one of embodiments 12 to 12c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity, as determined by the tendinitis index (LEI) at week 24 or week 48 Shi Lici of treatment with the antibody.
Embodiment 13k is the method according to any one of embodiments 12 to 12c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity as determined by an dactylitis assessment score of 0-3 (0 = absent, 1 = mild, 2 = moderate, 3 = severe) at week 24 of treatment with the antibody.
Embodiment 13l is the method according to any one of embodiments 12 to 12c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity, as determined by a Shi Jianming (SF-36) health survey at week 24 or week 48 of treatment with the antibody.
Embodiment 13m is the method according to any one of embodiments 12 to 12c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity, as determined by the mental and physiological component summary (MCS and PCS) scores at week 24 or week 48 of treatment with the antibody.
Embodiment 13n is the method according to any one of embodiments 12 to 12c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity, as determined by Minimum Disease Activity (MDA) criteria at week 24 or week 48 of treatment with the antibody.
Embodiment 13o is the method according to any one of embodiments 12 to 12c, wherein the subject is a responder to the treatment with the antibody and is identified as having a statistically significant improvement in disease activity, as determined by the realization of Very Low Disease Activity (VLDA).
Embodiment 14 is the method of any one of embodiments 12 to 13o, wherein the improvement is maintained for at least 12 weeks, 24 weeks, 36 weeks, 48 weeks, 60 weeks, 72 weeks, or 84 weeks, or any time therebetween.
Embodiment 15 is the method of any one of embodiments 9 to 14, wherein the anti-IL-23 antibody is archaebankab.
Embodiment 16 is the method of any one of embodiments 9 to 15, further comprising administering to the subject one or more additional drugs for treating psoriatic arthritis.
Embodiment 16a is the method of embodiment 16, wherein the additional drug is selected from the group consisting of: immunosuppressants, non-steroidal anti-inflammatory drugs (NSAIDs), methotrexate (MTX), anti-B cell surface marker antibodies, anti-CD 20 antibodies, rituximab, TNF inhibitors, corticosteroids, and co-stimulatory modulators.
Examples
List of terms abbreviations and definitions
ACR American college of rheumatology
AE adverse events
ALT alanine aminotransferase
AST aspartate aminotransferase
BSA body surface area
BMI body mass index
Classification criterion for CASPAR psoriatic arthritis
CMH Cochran-Mantel-Haenszel
CRF case report forms
CRP C reactive protein
CSR clinical study report
Disease activity of DAPSA psoriatic arthritis
DAS28 CRP disease Activity score 28-Joint count with C-reactive protein
Quality of life index for DLQI skin disease
Antirheumatic drugs for DMARDs to ameliorate disease
DRC data review Committee
eC-SSRS electronic Columbia suicide severity rating scale
eDC electronic data capture
Functional assessment of FACIT chronic therapies
Good clinical practice of GCP
HAQ-DI health assessment questionnaire disability index
HCQ hydroxychloroquine
HIV human immunodeficiency virus
ICF informed consent
IEC independent ethics committee
Overall evaluation of IGA researchers
IL-23 interleukin 23
IV intravenous (intravenous ground)
IWRS interactive network response system
JAK Janus kinase
LEF leflunomide
Lei litz tendinitis index
LS least squares (average)
MCS psychological component summary
MDA minimal disease activity
Meddra supervision active medical dictionary
MI multiple interpolation
MMRM repeated measurement hybrid model
MTX methotrexate
NSAID nonsteroidal anti-inflammatory drug
PsARC psoriasis arthritis response criteria
PASDAS psoriatic arthritis disease activity score
PASI psoriasis area and severity index
PCS physiological component summary
PFS-U with UltraSafe PLUS TM Prefilled syringe with passive needle protection sleeve
PRO patient reported results
PsA psoriatic arthritis
q8w every 8 weeks
SAE serious adverse events
SC subcutaneous (subcutaneous ground)
SF-36 concise health survey
SPARCC Canadian spinal arthritis research Association
SSZ sulfasalazine
Tuberculosis of TB
Adverse events triggered by TEAE treatment
Failure of TF treatment
TNF alpha tumor necrosis factor alpha
VAS vision analog scale
Very low disease activity of VLDA
WBC white blood cells
Example 1: evaluation of involvement in the treatment of active psoriatic arthritis and inadequate response to anti-tumor necrosis factor
Efficacy and safety of subcutaneously administered coumarone in patients phase 3b, multicenter, randomized, double-blind, placebo-controlled study
(COSMOS)
Target object:
The main objective of this study was to evaluate the efficacy of Gu Saiku mab relative to placebo in participants with active PsA and inadequate response to anti-tnfα therapy by assessing the reduction of signs and symptoms of joint disease. The primary endpoint was the proportion of participants who achieved the American College of Rheumatology (ACR) 20 response at week 24.
A secondary objective was to evaluate the efficacy of the archaebankab relative to placebo in improving body function, improving general and disease-specific health-related quality of life and patient reported health outcomes, and improving psoriasis skin lesions. The safety and tolerability of the archaebankab among the participants who received at least one dose of intervention was also a key secondary objective of the study.
Method:
This was a phase 3 randomized, double-blind, placebo-controlled, multicenter, 2-arm study to evaluate Gu Saiku mab in participants with insufficient or intolerant response to 1 or 2 anti-tnfa treatments with active PsA. The study included a placebo-controlled period from week 0 to week 24, a positive treatment period from week 24 to week 48 (the last study intervention at week 44), and a 12-week safety follow-up period from week 44 to week 56. At the time of the report, the study is ongoing; however, the placebo-controlled period from week 0 to week 24 has been completed and reported.
Number of participants (planning and analysis):
The planned total sample amount to achieve 90% of the ability to detect statistically significant treatment differences at the primary endpoint was about 245 participants (163 in the archaebankab group, 82 in the placebo group). At week 0, a total of 285 participants received study intervention at random; 96 subjects received placebo at random, and 189 subjects received Gu Saiku mab at a ratio of 2:1, randomized with the displacement block, which was stratified at the study level with baseline non-biological DMARD usage (yes/no) and prior exposure to 1 or 2 anti-tnfα drugs.
Group I: gu Saiku mab SC 100mg was administered at weeks 0 and 4 followed by placebo SC every 8 weeks (weeks 12, 20, 28, 36) to 44 and placebo SC at 24 to maintain blindness.
Group II: placebo SC were administered at weeks 0, 4, 12 and 20, crossing 100mg of Gu Saiku mab SC administered at weeks 24, 28, 36 and 44.
The duration of treatment planned in the study was 44 weeks, the double blind treatment period was 24 weeks, and the active treatment period was 20 weeks.
Diagnostic and primary inclusion criteria:
Qualified participants must have ≡3 tender joints and ≡3 swollen joints and have an inadequate or intolerance to anti-tnfα therapy, defined as the presence of active PsA (as assessed by the investigator) despite prior treatment with 1 or 2 anti-tnfα agents. Stable doses of selected non-biological DMARDs (MTX, SSZ, HCQ, LEF), oral corticosteroids (up to 10mg/d prednisone or equivalent) and NSAIDs/analgesics are allowed but not required.
Test product, dose and mode of administration:
All study interventions (archaebankizumab and placebo) were administered by SC injection. Participants in the placebo group received placebo at weeks 0 and 4, then every 8 weeks to 20, and 100mg of SC antikumamab at week 24, week 28, then every 8 weeks to 44. Participants in the group of coumarone received 100mg coumarone regimen at weeks 0 and 4 and then every 8 weeks.
Early disengagement:
At week 16, participants with <5% improvement over baseline in both tenderness and swollen joint numbers were eligible for early decubitus (EE). At any time after early disengagement, the participant may begin or increase the dose of one of the concomitant medications allowed up to the maximum allowable dose as specified in the regimen. Participants in the group of coumarone who met early disqualification received placebo at week 16 and Gu Saiku mab at week 20, followed by Gu Saiku mab every 8 weeks, with no change in the number and frequency of planned coumarone doses. Participants in the placebo group eligible for early disqualification will receive Gu Saiku mab at weeks 16 and 20 and then Gu Saiku mab every 8 weeks.
Duration of treatment:
The duration of treatment planned in the study was 44 weeks, the double blind treatment period was 24 weeks, and the active treatment period was 20 weeks. The study will remain blind to the initial treatment assignment until the final database is locked. Efficacy and safety of the coumarone mab up to week 24 is described in detail in this clinical study report.
Evaluation criterion:
The assessment of arthritis includes joint assessment (swelling and tendering joint counts), pain assessment of participants, overall assessment of disease activity (arthritis) by the patient, and overall assessment of disease activity by the physician on the Visual Analog Scale (VAS). Toe and tendinosis were also evaluated. Key efficacy measures for PsA response at week 24 included ACR response and HAQ-DI scores.
Given the diversity and highly individual nature of the domains involved in PsA (e.g., skin/nail disease, peripheral arthritis, dactylitis/tendinitis, axitic disease), a comprehensive index has been developed to more comprehensively assess disease activity and potentially identify agents with robust efficacy in all manifestations. The activity index includes a psoriatic arthritis disease activity score (PASDAS), a grepa composite score (GRACE), a Complex Psoriatic Disease Activity Index (CPDAI), a psoriatic arthritis response criterion (PsARC), and a psoriatic arthritis disease activity index (DAPSA). Disease states may be used to describe overall disease states such as DAPSA remission, minimal Disease Activity (MDA), or Very Low Disease Activity (VLDA).
Psoriasis response was assessed based on the overall assessment of psoriasis by the Investigator (IGA), the quality of life index of the skin Disease (DLQI), and the area and severity index of Psoriasis (PASI). The results reported by other patients were the SF-36 questionnaire and functional assessment of chronic disease therapy (facility) -fatigue, as well as the overall assessment of joint, skin and pain burden by the participants.
Safety assessments include Adverse Events (AE), serious Adverse Events (SAE), injection sites and allergic reactions, clinical laboratory parameters (hematology and chemistry; urine pregnancy test), electronic Columbia suicide severity rating scale (eC-SSRS), physical examination, vital signs, electrocardiogram (ECG; week 0 only), and early detection of Tuberculosis (TB).
Inclusion criteria
Participants must meet the following key inclusion criteria to be recruited into the study:
men or women at least 18 years old (or legal age in the jurisdiction in which the study is conducted).
PsA was diagnosed for at least 6 months prior to the first administration of study intervention and met the classification criteria for psoriatic arthritis (casar) at screening.
Have active PsA, defined by ≡3 tumescent joints and ≡3 tender joints at screening and baseline.
At least 1 PsA subgroup: distal interphalangeal joint involvement, polyarthritis without rheumatoid nodules, destructive arthritis, asymmetric peripheral arthritis or spondylitis with peripheral arthritis.
Has active plaque psoriasis, has at least one psoriasis plaque with a diameter of ≡2cm or a recorded history of nail changes or plaque psoriasis consistent with psoriasis.
Insufficient response to anti-tnfα therapy, defined as the presence of active PsA despite previous treatment with 1 or 2 anti-tnfα agents and any of the following:
lack of benefit of anti-tnfα therapy after at least 12 weeks of etanercept, adalimumab, golimumab or cetuximab therapy (or biosimilar) and/or at least 14 weeks of dose regimen of infliximab (or biosimilar).
Etanercept, adalimumab, golimumab, cetuximab, or infliximab (or biological analog) intolerance to anti-tnfα therapy.
If currently non-biological DMARDs (limited to MTX, SSZ, HCQ or LEFs) are used, the participants should receive treatment at least 3 months prior to the first administration of the study intervention; the dose must be stable for at least 4 weeks prior to the first administration study intervention and the abiotic DMARD should not produce serious toxic side effects. If MTX, SSZ or HCQ is not currently used, it is not acceptable for at least 4 weeks prior to the first administration study intervention. If no LEF is currently used, it is not accepted at least 12 weeks prior to the first administration of study intervention.
If MTX is used, the route of administration and the dose must be stable and the dose must be 25 mg/week or less; if SSZ is accepted, the dosage must be 3 g/day or less; if HCQ is accepted, the dosage must be less than or equal to 400 mg/day; if LEF is received, the dose must be 20 mg/day or less.
If the PsA is currently treated with NSAIDs or other analgesics, the participants must continue a steady dose for at least 2 weeks prior to the first administration of the study intervention. If no NSAID or other analgesic is currently used to treat PsA, then NSAID or other analgesic treatment cannot be received within 2 weeks prior to the first administration study intervention.
If the PsA is currently treated with an oral corticosteroid, the participants must last a steady dose equivalent of +.10 mg/day of prednisone at least 2 weeks before the first administration of the study intervention. If no oral corticosteroid is currently used, the participants must not receive an oral corticosteroid for at least 2 weeks prior to the first administration of the study intervention.
Exclusion criteria
Participants meeting any of the following key exclusion criteria were excluded from participation in the study:
other inflammatory diseases with which the evaluation of the efficacy of the archaebacteria therapy may be confounded, including but not limited to RA, axial spinal arthritis (which does not include primary diagnosis of PsA with spondylitis), systemic lupus erythematosus or lyme disease.
More than 2 different anti-tnfa agents have been accepted.
Receive an anti-tnfa agent in the following time frame prior to the first study intervention administration:
infliximab (or biological analogue), golimumab IV-within 8 weeks
Golimumab SC, adalimumab (or biosimilar), cetuximab-within 6 weeks
Etanercept (or biosimilar) -within 4 weeks
Previously treated with antikumab.
Any biological treatment (except for anti-tnfa agents) has previously been received.
Tofacitinib, barytinib, regoratinib, pefacitinib (ASP 015K), dectinib (VX-509), or any other JAK inhibitor has previously been accepted.
Any systemic immunosuppressant was previously received within 4 weeks of the first study intervention.
Receive abiotic DMARDs (except MTX, SSZ, HCQ, LEF) within 4 weeks prior to the first administration of study intervention.
Accept 2 or more (designated) abiotic DMARDs at baseline.
Apremilast was received 4 weeks prior to the first study intervention.
Phototherapy or any systemic drug/treatment that may affect psoriasis assessment was received within 4 weeks after the first study administration.
Topical drugs/treatments that may affect psoriasis assessment have been used within 2 weeks after the first administration of study dry matter.
Epidural, intra-articular, intramuscular or IV corticosteroids were received 4 weeks prior to the first administration study intervention.
Lithium was accepted within 4 weeks of the first administration of any study intervention.
Experimental antibodies or biological therapies (in addition to the anti-tnfa agents described in the inclusion criteria) or any other experimental therapies were received 90 days or 5 half-lives (whichever was longer) before the first administration of study intervention, or were currently recruited to another study using study agents or protocols.
Have a history or current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological, hematologic, rheumatic (other than PsA), psychotic, genitourinary or metabolic disorders.
Have unstable suicidal thoughts or suicidal behavior during the last 6 months and are confirmed by researchers to be at risk based on evaluation by mental health professionals.
Research intervention information
In the assembly with UltraSafe PLUS TM In a disposable prefilled syringe with passive needle protection sleeve (PFS-U), the archakuzumab was supplied for this study as a sterile liquid for SC injection; the product contains no preservative. Each disposable PFS-U contained 100mg of Gusaiku mab in 1mL of solution. In PFS-U, placebo is supplied as sterile liquid for SC injection. Each disposable PFS-U contains 1mL of solution. The sources of the archaebankab and placebo are stored under refrigerated conditions of 2 ℃ to 8 ℃ and protected from exposure to light.
Randomization and blind method
Randomization of
Center randomization was performed in this study. On week 0, based on a computer-generated randomization protocol, participants were randomized at a 2:1 ratio to receive both the coumarone and placebo, respectively. Randomization was balanced based on a displacement block randomization method and stratified by baseline abiotic DMARD use (yes or no) and by prior exposure to anti-tnfa agents (yes or no). An interactive network response system (IWRS) assigns a unique intervention code that specifies an intervention assignment and matching research intervention for that participant.
Blind
The participants were assigned a random number at baseline visit, which was used to instruct the venue to assign a pharmaceutical kit to each participant. The randomized code is maintained within an interactive network response system (IWRS). No randomization code was provided to the investigator. To maintain the study blind, study intervention containers have multipart labels that contain the appropriate regulatory requirements of the clinical supply, while not identifying the study intervention contained therein.
Blindness of treatment distribution can only be broken when a particular urgent treatment is affected by the participant's knowledge of treatment distribution.
Sponsor personnel blinded patient level data for data analysis and clinical study reporting at week 24 database lock were recorded prior to the database lock. All venue personnel and participants remain blind to the treatment distribution until the final database is locked.
Dosage and administration
All study interventions (archaebankizumab and placebo) were administered by Subcutaneous (SC) injection. Based on the evaluation of this dosing regimen in the phase 2 study of PsA (CNTO 1959PsA 2001) and the phase 3 study of psoriasis, a 100mg dose regimen of vasokumab at weeks 0 and 4 and then every 8 weeks (q 8 w) was selected for this study.
In the study of CNTO1959PSA2001, robust efficacy and clinically significant improvements were observed using this dosing regimen in all important areas of PsA, including joint signs and symptoms, body function, psoriasis, tendinitis, dactylitis and quality of life for psoriatic patients with active PsA and > 3% BSA. In addition, in phase 3 psoriasis studies, significant benefits of this dose regimen were also observed for plaque psoriasis in moderate to severe psoriasis patients. In the phase 3 PsA study, an additional dosing regimen (every 4 weeks; q4 w) was included. However, this dosage regimen is not expected to result in significantly higher levels of efficacy than achieved by q8w administration during maintenance.
The safety of this q8w dose regimen has been established in the large psoriasis development program. Furthermore, the safety profile in phase 2 studies in patients with PsA and RA was consistent with that observed in psoriasis procedures. The results of the PsA phase 3 procedure were not available when designing the current study.
Participants in the placebo group received placebo at weeks 0 and 4, then every 8 weeks to 20, and 100mg of SC antikumamab at week 24, week 28, then every 8 weeks to 44. At weeks 0 and 4, study interventions were administered by a Health Care Professional (HCP) at the study site. Beginning at week 12, at the discretion of the investigator and the participants, and after appropriate and recorded training, the participants have the option of self-administering the study agent at the study site under the supervision of the HCP or continuing study agent injection by the HCP. To limit the impact of the covd-19 pandemic, the protocol was modified to allow self-administration of subcutaneous injections of study interventions outside the study site after week 24, in cases where site visits were not possible in view of national, regional or local restrictions. Since this is relevant only after week 24, this cannot affect the results reported in this document. All visits up to the 24-week time point were conducted within the appropriate time frame as originally planned for the study (with exception reporting as major protocol bias).
The following key efficacy evaluations were performed to assess signs and symptoms of PsA associated with the primary and secondary endpoints of the study.
Joint evaluation: tenderness of each of the 68 joints was assessed by a designated independent joint evaluator (IJA) and swelling of each of the 66 joints (hip was excluded because of inability to assess swelling of the hip) which was not involved in any other study except joint assessment and tendinitis and dactylitis assessment. If it is physically impossible to evaluate a joint, the joint is designated as "non-evaluable" only by IJA.
Pain assessment of patient: participants were asked to evaluate their average pain on a 100mm Visual Analog Scale (VAS), with the left end indicating "no pain" and the right end indicating "worst possible pain".
Overall assessment of disease activity (arthritis and psoriasis) by patients: participants were asked to evaluate how they had felt their psoriasis and arthritis during the past week on a 100mm VAS, with the left end indicating "excellent" and the right end indicating "bad".
Overall evaluation of disease activity (arthritis) by patient: participants were asked to evaluate how they had felt their arthritis during the past week on a 100mmVAS, with the left end indicating "excellent" and the right end indicating "bad".
Physician overall assessment of disease activity: the physician is required to evaluate the patient for arthritis on a 100mm VAS, with the left end indicating "no arthritis activity" and the right end indicating "hyperactive arthritis".
American society of rheumatology (ACR) response: ACR 20 is defined as an ≡20% improvement over baseline in both the swollen joint count (66 joints) and the tender joint count (68 joints), and the ≡20% improvement over baseline in 3 of the following 5 assessments (pain assessment of patient on VAS, overall assessment of disease activity (arthritis, patient and physician VAS), overall assessment of disease activity by physician (VAS), HAQ-DI and CRP). ACR 50 and ACR 70 are similarly defined, except that the improvement threshold relative to baseline is 50% and 70%, respectively.
Health assessment questionnaire disability index (HAQ-DI): tools for 20 questions assess the difficulty of a person to complete a task in 8 functional areas (dressing, getting up, eating, walking, hygiene, stretching hands, grasping and activities of daily living). The response in each functional domain starts from 0, indicating no difficulty, to 3, indicating that no task can be performed in that domain (i.e., a lower score indicates better function). In PsA, a score decrease of 0.35 has been determined to be indicative of clinically significant improvement.
C-reactive protein (CRP): the serum concentration of CRP, a biomarker of total inflammatory burden, was measured by a high sensitivity method in a central laboratory.
Evaluation of skin disease activity by patient: participants were asked to evaluate how they had felt their psoriasis during the past week on a 100mm VAS, with the left end indicating "excellent" and the right end indicating "bad".
Body surface area of psoriasis (BSA): psoriasis BSA was measured using the palm method at week 0. The size of the body surface area with psoriasis lesions was estimated based on the number of palms of the participants, with each palm (from the root of the wrist to the proximal interphalangeal joint including the thumb) being equivalent to 1% BSA.
Overall evaluation of researchers (IGA): IGA records the assessment of participants for psoriasis at a given time point. The induration, erythema and scaling of the overall lesions were graded using 0 (no evidence), 1 (minimum), 2 (mild), 3 (moderate) and 4 (severe) scales. The IGA scores for psoriasis are based on the average of the induration, erythema and scale scores. Patients were assessed for psoriasis as clear (0), minimal (1), mild (2), moderate (3) or severe (4).
Psoriasis area and severity index or (PASI): a system for evaluating and grading the severity of psoriasis lesions and their response to therapy. In a PASI system, the body is divided into 4 regions: head, torso, upper limbs, and lower limbs. Each of these areas was evaluated for the percentage of the area involved, which translates into a numerical score ranging from 0 (no indication was involved) to 6 (90% to 100% involvement), and erythema, induration, and scaling, each rated on a scale of 0 to 4. PASI produces a numerical score that can range from 0 (no psoriasis) to 72. The PASI 50 response is defined as ≡50% improvement in PASI score over baseline; PASI 75, PASI 90, and PASI 100 are similarly defined.
Toe inflammation assessment: for each finger, the presence and severity of toe inflammation was assessed in both the hand and foot using a scoring system of 0 to 3 (0-no toe, 1-mild toe, 2-moderate toe, 3-severe toe). The results are summed to produce a final score ranging from 0 to 60.
Tendinosis evaluation: tendinitis is assessed using the litz tendinitis index (LEI) and the canadian institute of Spondyloarthritis (SPARCC) tendinitis index.
-LEI, tools specific for PsA patient verification, count the number of painful tendon ends in: left and right lateral humeral epicondyles, left and right medial femoral condyles, and left and right Achilles tendons. The LEI index ranges from 0 to 6.
The SPARCC tendinotefuran index was developed from the general population of spinal arthritis (i.e., not limited to PsA or AS), and the number of painful tendinoteurs in: left and right supraspinatus insertion, left and right medial humeral epicondylitis, left and right lateral humeral epicondylitis, left and right greater trochanter, left and right quadriceps to patella, left and right patella to tibia, left and right Achilles tendon insertion, and left and right plantar fascia. The SPARCC tendinitis index ranges from 0 to 16.
Minimal disease activity: the PsA MDA standard is a combination of 7 outcome measures used in PsA. If the participant satisfies 5 of the 7 outcome measures, it is classified as implementing MDA: the joint pressure pain count is less than or equal to 1; the count of swollen joints is less than or equal to 1; psoriasis activity and severity index is less than or equal to 1; the pain VAS score of the participants is less than or equal to 15; the overall disease activity VAS (arthritis and psoriasis) score of the participants is less than or equal to 20; HAQ-DI score was 0.5 or less; the endpoint of the tenderness tendon is less than or equal to 1.
Psoriasis arthritis disease activity score: the PASDAS (range 0-10) was calculated using the following variables: participant total VAS (arthritis and psoriasis, reaching 0-100), physician total VAS (range 0-100), swollen joint count (0-66), tenderness joint count (0-68), CRP level (mg/L), tendinitis (measured by LEI), dactylitis count (2 different counts are used: [1] score each finger from 0-3 and recode to 0-1, with any score >0 equal to 1, and [2] score each finger of tenderness 0-1), and finally, PCS scale of SF 36 health survey.
Group of studies and evaluations of psoriasis and psoriatic arthritis composite scores: grace is the composite score of the study and evaluation group of psoriasis and psoriatic arthritis (GRAPPA) derived as GRACE index= (1-amdF). Times.10, where amdF is the arithmetic mean of the desired function. AMDF is calculated by transforming the following variables using a predefined algorithm and expressing the total score as an average with a score range of 0-1, where 1 indicates a better state than 0: tended joint count (0-68), swollen joint count (0-66), HAQ-DI score (0-3), overall assessment of disease activity by participants (arthritis and psoriasis, 0 100 VAS), assessment of skin disease activity by participants (0-100 VAS), overall assessment of disease activity by participants (arthritis, 0-100 VAS), PASI score (0-72), and psoriatic arthritis quality of life index (PsAQOL) score.
Disease activity index score 28: DAS28 CRP is a statistically derived index combining tender joints (28 joints), swollen joints (28 joints), CRP, and overall assessment of disease activity (GH) by participants. The set of 28 joint counts is based on an assessment of shoulder, elbow, wrist, metacarpophalangeal joint (MCP) 1, MCP2, MCP3, MCP4, MCP5, proximal interphalangeal (PIP 1), PIP2, PIP3, PIP4, PIP5 joints and knee joints of both right and left lower limbs.
Disease activity index of psoriatic arthritis: the DAPSA score is calculated as the sum of the following components: tenderness joint count (0-68), tumescent joint count (0-66), CRP levels (mg/dL), pain assessment of participants (0-10 VAS), and overall assessment of disease activity by participants (arthritis, 0-10 VAS).
Modified psoriatic arthritis response criteria: a participant is considered a responder if it has an improvement in at least 2 of the following criteria (including at least 1 of the joint criteria), but no deterioration in the other criteria: the count of swollen joints (66 joints) is not less than 30 percent reduced; the joint count of tenderness (68 joints) is not less than 30 percent; an ≡20% improvement in overall assessment of disease (arthritis) by participants on VAS; and > 20% improvement in the overall assessment of disease by physicians on VAS.
Improved complex psoriasis disease activity index: the mCPDAI evaluates 4 domains (joint, skin, tendinous and digital inflammation). The mCPDAI score was calculated using the following evaluation: joints (66 swollen joint counts and 68 tender joint counts), HAQ-DI, PASI, dactylitis, and tendinitis. Within each domain, scores are assigned according to predefined cut-off values (ranges 0-3). The scores for each domain were then added together to give a final score range of 0 (none) to 12 (severe).
Papanic ankylosing spondylitis disease activity index: a participant self-evaluation questionnaire originally developed for ankylosing spondylitis consisted of 6 questions related to 5 major symptoms of the disease. Only the participants with spondylitis of peripheral arthritis (primary arthritic manifestations as their PsA (as assessed by the investigator)) had completed BASDAI, using 6 10-unit VAS measures to indicate the extent of their symptoms in the past week, based on the following criteria: fatigue, spinal pain, joint pain, tendinitis, qualitative morning stiffness, quantitative morning stiffness. A higher score indicates greater disease severity and a 50% or 2 score reduction is considered clinically significant.
36-concise health survey (SF-36): health status and quality of life were assessed using a multi-domain instrument with 36 items administered by study participants themselves. It includes 8 component tables covering the functional range: physical function, physical role function, physical pain, general mental well-being (psychological distress and happiness), emotional role function, social function, vitality (energy and fatigue), and general health perception. The scoring produces Physiological Component Summary (PCS), psychological component summary (MCS), and component table scores. A higher score represents better results, an increase of 5 points is considered clinically significant.
Functional assessment of chronic disease therapy (FACIT) -fatigue: the facility-fatigue questionnaire consisted of 13 questions that evaluate the participants' fatigue and tiredness levels over the past 7 days. Each question was rated in 5 minutes (0=no; 1=few; 2=slight; 3=quite many; 4=very many). Scores ranged from 0 to 52, with lower scores reflecting more severe fatigue. In rheumatology, a 4 point change is considered significant and has been used in the PsA population.
Biomarkers and methods for their use
Serum and stool samples were collected from all subjects for analysis of pharmacodynamic biomarkers. The samples will be used to better understand the biology of PsA, provide a biological assessment of patient response to treatment with coumarone, analyze differences between responders and non-responders, and determine whether markers can be used to classify patients as potential responders prior to treatment.
In addition, the samples will be used to analyze proteins associated with inflammation and spondyloarthropathies. Markers associated with PsA biology will be measured, including but not limited to Th17, IL-17A, IL-17F, IL-21, IL-22 and IL-23, metabolomics and bone homeostasis pathways. Ribonucleic acids from whole blood samples will be used in gene expression analysis to determine the molecular profile of PsA and to assess changes in gene expression following treatment with the archaebacterium.
Summary of demographics at baseline
A summary of demographic characteristics at baseline is given in table 1. The proportion of male participants in the placebo group (54.2%, n=52) was high in the Yu Gusai pool mab group (45.5%, n=86). Placebo group (91.7 kg [22.58 kg)]) The average (SD) body weight in the middle participants was also higher than that of the Gu Saiku mab group (83.6 kg [17.40 kg)]) This is consistent with a higher proportion of men in the group. Baseline characteristics of placebo and archaebankizumab groups were measured at age (mean SD]Respectively=49.1 [12.14 ]]Annual sum 49.1[12.31 ]]Years) and BMI (average [ SD ]]Respectively = 30.7[7.12 ]]kg/m 2 And 29.0[5.86 ]]kg/m 2 ) Balanced in aspect. The archaebankab group had a higher proportion of elderly participants (age ≡65 years) (10.6%, n=20 and 7.3%, n=7) than the placebo group. The participants in both study groups were most frequently obese, with BMI at baseline of > 30kg/m for placebo and archaebankin groups 2 The participant ratio of (a) was 45.3% (n=43) and 39.2% (n=74), respectively.
Keyword: iq=quartile range
Summary of psoriatic arthritis characteristics at baseline
The occurrence of different subtypes of psoriatic arthritis is balanced between the two groups. Polyarthritis without rheumatoid nodules (41.7%, [ n=40 ] and 39.4%, [ n=74 ]) and asymmetric peripheral arthritis (37.5% [ n=36 ] and 35.1% [ n=66 ]) were the most frequently reported subtypes in placebo and archaebankab groups, respectively. At baseline, participants in the placebo and the archaebankizumab groups were diagnosed with PsA for 8.7 (7.20) and 8.3 (7.77) years on average (SD), respectively. Except for 1 participant in the archaebankab group, all participants randomized in the study did not receive the combination procedure.
The PsA disease characteristics of the ACR component at baseline are summarized in table 2. The average (SD) numbers of swollen and tender joints (10.2 [6.75] and 21.0[13.21], respectively) were higher in the archaebacterium group than in the placebo group (9.0 [5.69] and 18.2[10.68], respectively). Within a scale of 0 to 10, the average (SD) VAS scores for pain assessments for patients in placebo and in the archaebankizumab group were 6.03 (1.813) and 6.46 (1.873), respectively. For disease activity rated on a scale of 1 to 10, the mean (SD) VAS scores for the overall assessment of the physician were 6.42 (1.743) and 6.87 (1.511) in the placebo and the archaebankab groups, respectively. The mean (SD) VAS scores for the overall evaluation of patients were 6.22 (1.739) and 6.52 (1.749) in the placebo and the archaebankizumab groups, respectively. The average (SD) HAQ-DI scores for the placebo and the archaebankizumab groups were 1.2227 (0.59747) and 1.3305 (0.60157), respectively.
The average (SD) CRP levels for the placebo and the archaebankizumab groups were 1.154mg/dL (2.5358 mg/dL) and 1.225mg/dL (1.9583 mg/dL), respectively.
/>
Keyword: acr=iq=quartile range, iq=quartile range
A summary of PsA disease characteristics at baseline for signs and symptoms other than ACR components is presented in table 3. Average (SD) DAS28 CRP levels observed in placebo and archaebankizumab groups were 4.57 (0.770) and 4.90 (1.002), respectively. The average (SD) numbers of swollen and tender joints (5.9 [4.05] and 10.6[6.46], respectively) were higher in the archaebacterium group than in the placebo group (4.7 [3.16] and 8.6[5.34], respectively) using 28 instead of 66/68 joint counts. Based on LEI, 66.7% (n=64) of the participants in the placebo group and 67.4% (n=126) of the participants in the archaebanking mab group had tendinitis, with average (SD) scores of 2.7 (1.45) and 2.9 (1.53) on the LEI tendinitis scale (ranging from 1 to 6), respectively. Based on the SPARCC tendinitis index, 76.0% (n=73) of the participants in the placebo group and 70.6% (n=132) of the participants in the archaebacterium group had tendinitis, and the average (SD) was scored as 5.1 (3.31) and 5.5 (3.80) on the SPARCC tendinitis index (ranging from 1 to 16), respectively. In the placebo and the archaebankizumab groups, dactylitis was reported by 37.5% (n=36) and 35.8% (n=67) participants, respectively. Within a scale of 1 to 60, the mean Scores (SD) for the participants of the placebo and the archaebankab groups were 7.4 (8.31) and 6.7 (6.47), respectively.
/>
Keyword: psA = psoriatic arthritis, IQ = quartile range, LEI = litz tendinitis index, DAS28 = disease activity index score 28 using CRP, CRP = C-reactive protein, SPARCC = canadian institute of spondyloarthritis, pasda = psoriatic arthritis disease a
Summary of psoriasis characteristics at baseline
A summary of the psoriatic disease characteristics at baseline is given in table 4. A total of 61 (63.5%) participants in the placebo group and 120 (63.4%) participants in the archaebankab group reported psoriasis skin disease at baseline. Among these participants, scalp psoriasis (78.7% [ n=48 ] and 82.5% [ n=99 ] in placebo and archaebacterium groups, respectively) and nail psoriasis (78.7% [ n=48 ] and 79.2% [ n=95 ] in placebo and archaebacterium groups, respectively) were the most commonly reported types of psoriasis at baseline. In the placebo and the archaebankizumab groups, hand and/or foot involvement was reported by 21.3% (n=13) and 23.3% (n=28) participants, respectively. At baseline, the extent of psoriasis (in terms of BSA) was most frequently <3% (34.4%, n=33) and > 3% and <10% (27.1%, n=26) in the placebo group, and > 20% (31.7%, n=60) and > 3% and <10% (29.1%, n=55) in the archaebankab group. PASI scores were most frequently <12 in placebo group (67.7%, n=65) and in the archaebankab group (63.3%, n=119); the average (SD) PASI score was 9.2 (9.41) in the placebo group and 11.7 (11.87) in the archaebankab group. The proportion of participants with IGA score > 2 was 69.8% (n=67) and 78.8% (n=149) in the placebo and the guluroumab groups, respectively. The overall patient assessment of arthritis and psoriasis based on the average (SD) VAS score was 6.4 (1.75) and 6.8 (1.80) in the placebo and the archaebankab groups, respectively. The average (SD) VAS scores from patient assessment of dermatological activity were 5.6 (2.40) and 6.3 (2.35) in the placebo and the archaebankab groups, respectively. Average (SD) baseline DLQI scores were 12.4 (7.34) and 13.5 (6.80) in placebo and archaebankizumab groups, respectively, and very large and extremely large effects of psoriasis on quality of life were reported in both groups of participants (58.3% [ n=56 ] and 63.6% [ n=119 ], respectively).
/>
/>
Keyword: iq=quartile range, dlqi=dermatological quality of life index, pasi=psoriasis area and severity index, vas=visual analog scale
Previous and concomitant medication/therapy
A summary of the previous medications received by the participants (recorded at baseline) is presented in table 5. The types of previous therapies and medications (recorded at baseline) received by the participants in both study groups were similar. Adalimumab (33.3% [ n=32 ] and 30.2% [ n=57 ]) and diclofenac (29.2% [ n=28 ] and 22.2% [ n=42 ]) are the most frequently used PsA-related drugs in the placebo and the guluroumab groups, respectively. Folic acid is the most frequently accepted prior drug (41.7% [ n=40 ] and 32.3% [ n=61 ] in placebo and archaebankizumab groups, respectively) that is not associated with PsA or psoriasis.
/>
/>
Keyword: psA = psoriatic arthritis
A summary of previous abiotic, DMARD, immunosuppressant, steroid, NSAID, or apremilast treatments received by the participants at baseline is presented in table 6.
Most of the participants in the placebo and the archaebankizumab groups had previously received abiotic DMARDs, immunosuppressives, or apremilast (94.8% [ n=91 ] and 93.7% [ n=177 ], respectively). All participants in both groups also reported the use of previous anti-tnfα drugs, most of which received 1 previous anti-TNF drug (88.5% [ n=85 ] and 88.4[ n=167 ] in the placebo and the coumarone groups, respectively). Methotrexate is the most frequently accepted DMARD, accepted by 91.7% (n=88) and 90.5% (n=171) participants in the placebo and the coumarone groups, respectively. Only a small fraction of the participants (< 6%) in both groups reported previous immunosuppressant or apremilast therapies.
Keyword: DMARD = disease modifying antirheumatic drug, NSAID = nonsteroidal anti-inflammatory drug, psA = psoriatic arthritis, TNF = tumor necrosis factor
A summary of concomitant medications after baseline frequently accepted by participants up to week 24 is presented in table 7. Up to week 24 of the study, concomitant drug use was balanced in the placebo group (77.1% [ n=74 ]) and the archaebankab group (70.4% [ n=133 ]). Participants in both groups received immunosuppressants such as methotrexate most frequently (53.1% [ n=51 ] and 55.6% [ n=105 ] in placebo and archaebankizumab groups, respectively). Concomitant use of acetaminophen (3.1% [ n=3 ] and 5.8% [ n=11 ]) and glucocorticoids (4.2% [ n=4 ] and 5.3% [ n=10 ]) was limited, but constituted the other most commonly accepted concomitant drugs in the placebo and the coumarone groups, respectively (table 7).
All participants randomized in the study had previously been treated with MTX, with > 3 years of exposure reported most frequently (51.1% [ n=45 ] in the placebo group and 45.0% [ n=77 ] in the archaebankab group). The maximum dose of MTX received over the last 3 months was similar for the participants in both groups (average [ SD ] in placebo and archaebankizumab groups = 10.7[8.12] and 10.5[8.09 ]). More than half of the participants in the two groups chose to continue with MTX during the study (58.0% [ n=51 ] and 61.4% [ n=105 ] in the placebo and the gulcomab groups, respectively).
Up to week 24, the combination protocol of 2 (2.1%) participants in the placebo group and 1 (0.5%) participant in the archaebankab group was reported. One (1.0%) of the participants in the placebo group and 4 (2.1%) of the participants in the archaebankab group received a combination injection until week 24 of the study.
A summary of the protocol bias up to week 24 is presented in table 8. Major regimen bias up to week 24 of the study was reported for 34 (35.4%) participants in the placebo group and 45 (23.8%) participants in the archaebankab group. The main cause of the deviation of the regimen is "receiving the wrong treatment or incorrect dose" (16.7% [ n=16 ] and 11.1% [ n=21 ] in placebo and archaebankizumab groups, respectively); however, most of these are related to study interventions administered outside the access window. A total of 8 (8.3%) participants in the placebo group and 12 (6.3%) participants in the gulf-mab group were incorrectly led to early break-away, although the early break-away criteria were not met. The "other" causes of the primary regimen bias were recorded for 14 (14.6%) and 27 (14.3%) participants in the placebo and the archaebankizumab groups, respectively.
The treatment compliance was high for both study groups until week 24, with an average (SD) rate of 99.8% (2.04%) in the placebo group and 99.6% (4.06%) in the archaebankizumab group. In the placebo group, the average (SD) compliance rate of placebo injection was 99.7% (3.40%). A total of 45 participants in the placebo group were assigned early break-away and received Gu Saiku mab injections prior to week 24. Among these participants, the compliance rate of the injection of the coumarone was 100.0%. In the group of the coumarone antibodies, the average (SD) compliance rate of the coumarone antibody injection was 99.6% (4.06%). A total of 39 participants in the archaebankab group were assigned early weaning and received placebo injections at week 16 with 100.0% compliance.
A summary of the participants meeting the criteria for treatment failure up to week 24 is presented in table 9. At week 24, 54.2% (n=52) and 27.0% (n=51) of the participants in the placebo and the archaebankizumab groups, respectively, met 1 or more treatment failure criteria. The largest proportion of the participants in the two study groups were classified as treatment failure due to early withdrawal at week 16 (46.9% [ n=45 ] and 20.6% [ n=39 ] in placebo and archaebankin groups, respectively). This also included 20 participants (8 and 12 in placebo and archaebankizumab groups, respectively) who were incorrectly guided to early break-off at week 16, but did not meet the early break-off criteria.
Keyword: DMARD = antirheumatic drug to ameliorate disease
A summary of the treatment exposures before week 24 is presented in table 10. Most (> 92%) of the participants in both groups had received ≡4 study interventions prior to week 24 visit. Of these 84 participants met early break-away criteria at week 16; early weaning participants (45 out of 96 participants) in the placebo group received Gu Saiku mab doses at weeks 16 and 20, while early weaning participants (39 out of 189 participants) in the archaebankab group received placebo at week 16. Participants in the placebo (early break away) and the coumarone mab groups received Gu Saiku mab up to week 24 received average (SD) 2.0 (0.15) and 3.9 (0.44) SC doses of coumarone mab, respectively. The total average (SD) dose of the coumarone mab was 197.8mg (14.91 mg) in the placebo early release group and 389.4mg (43.69 mg) in the coumarone mab group. The average (SD) duration of the follow-up for both groups was similar (23.8 weeks [2.14 weeks ] and 23.9 weeks [1.50 weeks ] for placebo and archaebankab groups, respectively).
Keyword: iq=quartile range
a Duration of study visit (week) =date of last visit or last contact or last evaluation (based on last time) until 24 th week visit-reference date +1)/7.
Statistical method:
Curative effect:
The primary analysis of efficacy included all randomized participants who received at least 1 dose (full or partial) of study agent. In efficacy analysis, participants were analyzed in their assigned randomized treatment groups, regardless of the treatment they received. For the binary response efficacy endpoint, a therapeutic comparison was made using the Cochran-Mantel-Haenszel (CMH) test, which was stratified by baseline use of the non-biological DMARD (yes, no) and prior exposure to 1 or 2 anti-tnfα. The magnitude of the treatment difference was estimated by the difference in response rate between the group of coumarone antibodies and the placebo group with 95% Confidence Interval (CI) and p-value calculated based on Wald statistics.
For continuous endpoints, treatment comparisons were made using a mixed effect model repeat measurement (MMRM) model. The model included all available data from 2 treatment groups to week 24. The difference in treatment between the archaebankab group and the placebo group was estimated by the difference in LSmeans. The 95% CI of the difference between the LSmeans and p values was calculated.
All treatment group comparisons will be performed at a bilateral alpha level of 0.05 unless otherwise indicated.
To control overall type 1 error rate, the primary endpoint and the secondary endpoint were tested in a fixed order. The first secondary endpoint (change in HAQ-DI score from baseline at week 24) was tested only if the primary endpoint (the proportion of participants who achieved ACR 20 response at week 24) was positive (p < 0.05). Similarly, the second secondary endpoint (the proportion of participants who achieved ACR 50 response at week 24), the third secondary endpoint (the change in SF-36PCS score from baseline at week 24) and the fourth secondary endpoint (the proportion of participants who achieved PASI 100 response at week 24) were tested only if the previous secondary endpoint was positive (p < 0.05). In the event that one of the primary or secondary endpoints is tested negatively and the formal test is stopped, then a 95% confidence interval and a nominal, unadjusted p-value are sequentially generated for the remaining endpoints.
Nominal p-values for exploratory analysis are reported.
Most efficacy analyses are based on comprehensive measures that evaluate treatment effects based on variable measures and concurrent events defined in terms of Treatment Failure (TF) criteria. The participant was considered TF from the earliest date he/she met any of the following TF criteria until week 24:
discontinuing study drug injection for any reason.
Termination of study participation for any reason.
Doses of either the non-biological DMARD (MTX, SSZ, HCQ, LEF) or oral corticosteroid were initiated or increased for PsA over baseline.
Disable drug/therapy for PsA onset regimen.
Meets early disengagement criteria.
This estimate acknowledges that meeting the TF criteria is a detrimental result. Thus, TF means no response for the responder type of endpoint, and no change from baseline for the continuous endpoint.
Safety of:
The safety analysis group included all participants who received at least 1 (full or partial) study dose. In safety analysis, participants were analyzed for treatment they received, regardless of which treatment group they were randomized to. Adverse events, laboratory analyte values and vital sign measurements triggered by treatment during the study are summarized. Adverse events caused by treatment were coded according to the regulatory active medical dictionary (MedDRA) version 23.0.
Results:
Study population:
Of the 285 participants randomized at week 0 (96 in placebo, 189 in the archaebankab group), 5 participants (2 [2.1% ], 3 [1.6% ] in the placebo group) discontinued the study by week 24. In the placebo group, 1 participant withdrawn consent, and 1 participant discontinued for "other" reasons. In the archaebankab group, 2 participants withdrawn consent, 1 loss of visit.
Demographic characteristics of participants in placebo and archaebankizumab groups were determined at age (mean SD]Respectively=49.1 [12.14 ]]Annual sum 49.1[12.31 ]]Years) and BMI (average [ SD ]]Respectively = 30.7[7.12 ]]kg/m2 and 29.0[5.86 ]]kg/m 2 ) Balanced in aspect. Participants in both study groups were most frequently obese and had BMI > 30kg/m at baseline 2 (45.3% [ n=43 in placebo and archaebankizumab groups, respectively]And 39.2% [ n=74 ]]). The archaebankab group had a higher proportion of elderly participants (age ≡65 years) (10.6%, n=20 and 7.3%, n=7) than the placebo group. The proportion of male participants in the placebo group (54.2%, n=52) was high in the Yu Gusai pool mab group (45.5%, n=86).
PsA characteristics at baseline:
Polyarthritis without rheumatoid nodules (41.7%, [ n=40 ] and 39.4%, [ n=74 ]) and asymmetric peripheral arthritis (37.5% [ n=36 ] and 35.1% [ n=66 ]) were the most frequently reported subtypes in placebo and archaebankab groups, respectively. For the ACR component, the average (SD) numbers of swollen and tender joints were 9.0 (5.69) and 18.2 (10.68), respectively, in the placebo group and 10.2 (6.75) and 21.0 (13.21), respectively, in the archaebankab group. The average (SD) HAQ-DI scores for the placebo and the archaebankizumab groups were 1.2227 (0.59747) and 1.3305 (0.60157), respectively. Similar average (SD) CRP levels (1.154 [2.5358] and 1.225[1.9583 ]) were observed in the placebo and the archaebankab groups.
Based on LEI, 66.7% (n=64) of the participants in the placebo group and 67.4% (n=126) of the participants in the archaebankab group had tendinitis. In the placebo and the archaebankizumab groups, dactylitis was reported by 37.5% (n=36) and 35.8% (n=67) participants, respectively.
Psoriasis characteristics at baseline:
A total of 61 (63.5%) participants in the placebo group and 120 (63.4%) participants in the archaebankab group reported psoriasis skin disease at baseline. In the case of BSA, the extent of psoriasis is most frequently <3% (34.4%, n=33) and > 3% and <10% (27.1%, n=26) in the placebo group, and > 20% (31.7%, n=60) and > 3% and <10% (29.1%, n=55) in the archaebankab group. Average (SD) PASI scores were 9.2 (9.41) and 11.7 (11.87) in placebo and archaebankizumab groups, respectively. The proportion of participants with IGA score > 2 was 69.8% and 78.8% in placebo and archaebankizumab groups, respectively. Scalp psoriasis (78.7% [ n=48 ] and 82.5% [ n=99 ] in placebo and archaebacterium groups, respectively) and nail psoriasis (78.7% [ n=48 ] and 79.2% [ n=95 ] in placebo and archaebacterium groups, respectively) are the most commonly reported types of psoriasis at baseline. In the placebo and the archaebankizumab groups, hand and/or foot involvement was reported by 21.3% (n=13) and 23.3% (n=28) participants, respectively. Baseline DLQI scores indicated a very large and extremely large impact of psoriasis on quality of life in both groups of participants (58.3% [ n=56 ] and 63.6% [ n=119 ] in placebo and archaebankizumab groups, respectively).
Treatment failure:
At week 24, 54.2% (n=52) and 27.0% (n=51) of the participants in the placebo and the archaebankizumab groups, respectively, met 1 or more treatment failure criteria. The largest proportion of the participants in the two study groups were classified as treatment failure due to early withdrawal at week 16 (46.9% [ n=45 ] and 20.6% [ n=39 ] in placebo and archaebankin groups, respectively). This also included 20 participants (8 and 12 in placebo and archaebankizumab groups, respectively) who were incorrectly guided to early break-off at week 16, but did not meet the early break-off criteria. Thus, the proportion of participants correctly guided EE was 38.5% (n=37) and 14.3% (n=27) for the placebo and the archaebankab groups, respectively.
Exposure degree:
Most (> 92%) of the participants in both groups had received ≡4 study interventions prior to week 24 visit. Participants in the placebo group (early break-off) and the group receiving SC and up to week 24 received average (SD) 2.0 (0.15) and 3.9 (0.44) doses of the archaeolizumab, respectively. This translates to a total average (SD) dose of 197.8mg (14.91 mg) of 2 times of the injection of the coumarone in the placebo (early break away) group and 389.4mg (43.69 mg) of the 4 times of the injection of the coumarone in the coumarone group.
Efficacy results:
The primary analysis of efficacy was performed using comprehensive measures in the total analysis set.
The main analysis is as follows: ACR20 response at week 24:
ACR20 response is defined as ≡20% improvement over baseline in both the tender joint count (68 joints) and the swollen joint count (66 joints), and ≡20% improvement over baseline in at least 3 of the 5 additional ACR-specified assessments. On week 24, based on the integrated measures, a significantly higher proportion of the participants in the archaebankizumab group achieved ACR20 responses (44.4% [ n=84 ] and 19.8% [ n=19 ]) than the placebo group; the percentage difference between the groups favoring the coumarone mab (95% CI) was 24.6 (14.1, 35.2; p < 0.001). See tables 11 and 12 below.
Keyword: acr=american college of rheumatology, ci=confidence interval, cmh=cochran-Mantel-Haenszel, crp=c-reactive protein, dmard=antirheumatic drug to ameliorate disease, HAQ-di=health assessment questionnaire disability index, tnf=tumor necrosis factor
a The participants have an observed ACR20 response status or meet TF criteria.
b Defined as observations that did not meet any TF criteria prior to this visitAnd (5) an arriving responder.
c Participants with data loss are assumed to be non-responders.
d The confidence interval is based on Wald statistics.
e The p-value was based on the CMH test, stratified by baseline using abiotic DMARDs (yes, no) and prior exposure to anti-tnfa agents (1 or 2).
h ACR 20 response is defined as an ≡20% improvement over baseline in both the tender joint count (68 joints) and the swollen joint count (66 joints), and the ≡20% improvement over baseline is in at least 3 of the following 5 assessments: pain assessment of the patient, overall assessment of disease activity by the physician, HAQ-DI and CRP.
Note that: under comprehensive strategies, treatment effects are evaluated not only based on variable measurements, but also based on concurrency events defined in TF standards. A participant is considered to be a non-responder if the participant meets any TF criteria.
Secondary analysis:
Changes in HAQ-DI from baseline to week 24:
HAQ-DI measures the functional status of participants, scoring on a scale of 0 to 3, with lower scores indicating higher function. At week 24, a significantly greater average decrease (LS mean (95% CI) =0.178 [ -0.269, -0.086] and-0.009 [ -0.120, -0.102 ]) was observed in the archaebacterium group compared to the placebo group. The average difference between the groups favoring the coumarone mab (95% CI) was-0.169 (-0.279, -0.059, p=0.003). See tables 13 and 14.
/>
Keyword: HAQ-di=health assessment questionnaire-disability index, ci=confidence interval, iq=quartile range, mmrm=mixed model of repeated measurements
a Defined as the change from baseline using observed data or 0 (no improvement) if participants met TF criteria before week 24.
b Participants observed a change from baseline at this visit or met TF criteria prior to this visit.
c LSmeans and p values are based on a mixed model of duplicate measurements (MMRM) under random deletion (MAR) assumption of missing data
d The HAQ score is the average of the calculated class scores (dressing, getting up, eating, walking, hygiene, grasping, and daily life). Lower scores indicate better functionality.
Note that: under comprehensive strategies, treatment effects are evaluated not only based on variable measurements, but also based on concurrency events defined in TF standards. If the participant meets any TF criteria, the participant is assigned a score that the continuous variable does not improve.
ACR50 response at week 24:
ACR50 response is defined as ≡50% improvement over baseline in ACR response criteria. At week 24, a significantly greater proportion of the participants in the archaebankizumab group (19.6%, n=37) achieved ACR50 response than the placebo group (5.2%, n=5). The percentage difference between the groups favoring the coumarone mab (95% CI) was 14.3 (7.2, 21.4; p=0.001). See tables 15 and 16.
Keyword: acr=american college of rheumatology, ci=confidence interval, cmh=cochran-Mantel-Haenszel, crp=c-reactive protein, dmard=antirheumatic drug to ameliorate disease, HAQ-di=health assessment questionnaire disability index, tnf=tumor necrosis factor
a The participants have an observed ACR 50 response status or meet TF criteria.
b Defined as the observed responders that did not meet any TF criteria prior to this visit.
c Participants with data loss are assumed to be non-responders.
d The confidence interval is based on Wald statistics.
e The p-value was based on the CMH test, stratified by baseline using abiotic DMARDs (yes, no) and prior exposure to anti-tnfa agents (1 or 2).
h ACR 50 response is defined as an ≡50% improvement over baseline in both the tender joint count (68 joints) and the swollen joint count (66 joints), and an ≡50% improvement over baseline in at least 3 of the 5 assessments (pain assessment of patient, overall assessment of disease activity by physician, HAQ-DI and CRP).
Note that: under comprehensive strategies, treatment effects are evaluated not only based on variable measurements, but also based on concurrency events defined in TF standards. A participant is considered to be a non-responder if the participant meets any TF criteria.
SF-36PCS change from baseline to week 24:
At week 24, a significantly greater improvement in SF-36PCS score over baseline was observed in the archaebankab group compared to placebo group (LS mean [95% CI ] respectively = 3.514[2.314,4.715] and-0.387 [ -1.841,1.067 ]). The difference in LS mean between the groups favoring the coumarone mab was 3.901 (95% ci=2.457, 5.346; p < 0.001). See tables 17 and 18.
PASI 100 response at week 24 among participants with BSA > 3% and IGA score > 2 at baseline:
At week 24, the proportion of those participants who achieved PASI 100 response in the Gu Saiku mab group was significantly higher than in the placebo group (30.8% [ n=41 ] and 3.8% [ n=2 ], respectively). The percentage difference between the groups favoring the coumarone mab (95% CI) was 27.4 (17.9, 36.8; p < 0.001). See tables 19 and 20.
Exploratory analysis
The change in the 24-week SF-36MCS score from baseline was calculated based on an 8-scale SF-36 instrument, with higher scores indicating better health. At week 24, the LS mean (95% CI) change in SF-36 scores was numerically higher in the Gusaikomab group (2.095 [0.540,3.650 ]) than in the placebo group (0.364 [ -1.525,2.252 ]). The average difference between the groups (95% CI) was 1.731 (-0.144,3.606). Although similar results were obtained from the analysis using all observed 24-week data, whether or not TF criteria were met, the average difference between groups (95% ci) (0.909 [ -1.222,3.040 ]) was lower than the results from the main analysis. For analysis to correct EE errors by ignoring the EE TF standard, the average difference (95% CI) (2.075 [0.178,3.972 ]) between groups favoring the archaemagglutinin is greater than that obtained in the main analysis.
At baseline, a total of 64 (66.7%) participants in the placebo group and 126 (67.4%) participants in the archaebankab group had tendinitis, LEI score >0. Changes in tendinitis from baseline were measured at week 24 with LEI. LEI was calculated based on 6 tendinitis sites, negative changes from baseline indicating improvement. At week 24, a greater improvement of tendinitis over baseline was observed in the archaebankizumab group compared to the placebo group (LS mean [95% CI ] respectively = -1.377[ -1.738, -1.015] and-0.680 [ -1.125, -0.235 ]). The average difference between the groups favoring the archaebankizumab (95% CI) was-0.697 (-1.145, -0.248). Similar results were obtained for analysis using all observed 24-week data, whether or not TF criteria were met (supplemental analysis 1); however, the average difference between groups (95% CI) (-0.269 [ -0.728,0.189 ]) was lower than the results of the primary analysis.
Changes from baseline in tendinitis at week 24 were measured in participants with a SPARCC score of >0 at baseline. The SPARCC measurement of tendinitis is based on applying pressure to the 16 tendinitis ends of interest and evaluating pain at that site, and a negative score indicates improvement. At week 24, a greater improvement of tendinitis relative to baseline was observed in the archaebankizumab group compared to the placebo group (LS mean [95% CI ] respectively = -2.049[ -2.719, -1.380] and-1.150 [ -1.978, -0.322 ]). An average difference of-0.899 (-1.735, -0.063) (95% CI) was observed between the groups favoring the archaebankizumab. Similar results were obtained for analysis using all observed 24-week data, whether or not TF criteria were met; however, the average difference between groups (95% CI) (-0.496 [ -1.403,0.412 ]) was lower than the primary analysis.
A total of 36 (37.5%) participants in the placebo group and 67 (35.8%) participants in the archaebankab group had dactylitis at baseline. Changes from baseline in dactylitis were measured in participants with dactylitis at baseline. The digital inflammation was scored on a scale of 0 to 60, with a maximum score of 3 for each finger, and a negative change from the baseline score indicating improvement. At week 24, participants in the archaebankizumab group recorded a greater average decrease in numerical value relative to baseline in the dactylitis score compared to the placebo group (LS mean [95% CI ] respectively = -2.488[ -3.704, -1.273] and-1.282 [ -2.695,0.131 ]). An average difference of-1.206 (-2.621,0.208) was observed between the groups (95% CI). Regardless of whether TF criteria were met, a comparison was observed in the analysis using all observed 24-week data, with the mean improvement in dactylitis in the archaebacterium group (95% CI) (0.323 [ -1.087,1.733 ]) being lower than in the placebo group.
The change from baseline in FACIT-F scores at week 24 was measured. The FACIT-F score is in the range of 0-52, with higher scores indicating less fatigue. At week 24, a greater average increase in FACIT-F score was observed in the Costuzumab group (4.607 [3.102,6.113 ]) compared to the placebo group (1.050 [ -0.780,2.881 ]). The average difference between the groups favoring the archaebankizumab (95% CI) was 3.557 (1.741,5.373). The analysis using all observed 24-week data was similar to the primary analysis, regardless of whether TF criteria were met. However, the average difference (95% CI) between the groups favoring the archaebankab (2.979 [0.859,5.098 ]) was less than the average difference of the primary analysis.
Changes from baseline in swelling and tenderness joint counts caused by visit up to week 24 were measured. Tenderness and swelling joints were counted from a total of 68 and 66 rated joints, respectively. The change at each time point was measured from baseline 0 (no improvement), with positive values indicating an increase in the swollen or tender joint and negative values indicating a decrease in the swollen or tender joint. Improvement of the tended and swollen joints after treatment with the coumarone mab was evident from week 8, where average (95% CI) differences between groups of-3.308 (-5.487, -1.129) and-1.847 (-3.074, -0.620), respectively, were observed, favoring coumarone mab. The divergence between interventions at week 8 increased over time, and average differences (95% CI) in the nociception and swelling joint counts at week 24 were observed for-3.965 (-6.046, -1.884) and-2.433 (-3.638, -1.228) favoring the coumarone, respectively.
Changes from baseline in DAS28 CRP at week 24 were measured. DAS28 combines the total assessment of tenderness joint count (28 joints), tumescent joint count (28 joints), CRP, and patient activity with higher scores indicating greater PsA severity. At week 4, a greater decrease in average DAS28 score was observed in the group of palace mab compared to the placebo group of palace mab. The average difference between the groups favoring the archaebankizumab (95% CI) was-0.272 (-0.449, -0.095). The differences between groups were maintained over time, increasing from week 4 to week 24; at week 24, the average difference (95% CI) between the groups favoring the archaebankab was-0.655 (-0.898, -0.412). Similar results were obtained for analysis using all observed 24-week data, whether or not TF criteria were met; at week 4, the average difference between groups (95% CI) was-0.259 (-0.439, -0.079). The difference between the subsequent time point groups increased, and the average difference between the 24 th week group (95% CI) was-0.474 (-0.728, -0.221).
The change in DAPSA score from baseline was measured. The DAPSA score is a combination of the tenderness and swollen joint count, CRP, pain assessment of the patient, and overall assessment of the patient's activity on the arthritic disease, and a higher DAPSA score indicates greater disease severity. At week 24, a greater average (95% CI) decrease in DAPSA score relative to baseline was observed in the Costuzumab group (-14.541 [ -17.639, -11.443 ]) compared to the placebo group (-5.754 [ -9.517, -1.991 ]). The average difference between the groups favoring the archaebankizumab (95% CI) was-8.787 (-12.538, -5.036). The observed 24-week data analysis results were consistent with the results of the primary analysis, however the difference between the groups (95% CI) (-5.764 [ -9.595, -1.933 ]) was of lower magnitude.
The proportion of participants who achieved an improvement in BASDAI score of ≡20%,. Gtoreq.50%,. Gtoreq.70% and ≡90% over baseline by visit up to week 24 was measured. BASDAI is based on 6 problems associated with 5 major symptoms of ankylosing spondylitis by self-assessment of patients. A higher score indicates greater disease severity and a 50% or 2 score reduction is considered clinically significant. Of the placebo group (26 [27.1% ]) and the archaebankizumab group (47 [25.0% ]), of the subgroups of participants with spondylitis and peripheral joint involvement (as their primary arthritic manifestations), a similar proportion of participants in the placebo group and the archaebankizumab group achieved. Score improvement of > 70% and > 90% (2.8% [ n=6 ] and 2.1% [ n=1 ], respectively) was observed only in the archaebankizumab group.
Changes from baseline through visit up to week 24 were measured. The mCPDAI score was calculated from a combination of tenderness and swollen joint counts, HAQ-DI, PASI, DLQI, digital inflammation and tendinitis. The final score ranged from 0 to 12, with higher scores indicating more severe disease. At weeks 16 and 24, a greater average (95% CI) decrease in the mCPDAI score relative to baseline was observed in the group of Costuzumab (1.913 [ -2.334, -1.493] and-1.853 [ -2.318, -1.388], respectively) compared to the placebo group (-0.560 [ -1.061, -0.058] and-0.426 [ -0.981, -0.130], respectively). The average differences (95% CI) between the groups favoring the archaebankab at weeks 16 and 24 were-1.354 (-1.850, -0.858) and-1.428 (-1.974, -0.881), respectively. Similar results were obtained from analysis using all observed 24-week data, regardless of whether TF criteria were met, however, at week 24 (-0.864 [ -1.389, -0.339 ]), the magnitude of the difference between the groups of antikumab (95% CI) was lower compared to the primary analysis.
The measurement is based on a comprehensive measure of change in the Grace score at week 24 from baseline. The GRACE index score is calculated from the arithmetic mean of the expectation function (AMDF). AMDF is a function of the tenderness and swelling joint count, HAQ-D score, overall patient assessment of disease activity (arthritis and psoriasis), patient assessment of skin disease activity, overall patient assessment of disease activity (arthritis), PASI score, and quality of life index score for psoriatic arthritis. A higher GRACE score indicates greater disease severity. At weeks 16 and 24, a larger average decrease in GRACE score (95% CI) relative to baseline was observed in the group of Costuzumab (-1.451, -1.749, -1.153, and-1.538, -1.850), respectively, compared to the placebo group (-0.363, -0.720, -0.005, and-0.287, -0.663,0.088, respectively). This indicated a decrease in disease activity from baseline to week 24 in the Gu Saiku mab group. The average differences (95% CI) between the groups favoring the archaebankab at weeks 16 and 24 were-1.089 (-1.446, -0.731) and-1.251 (-1.626, -0.876), respectively. Similar results were obtained from analysis using all observed 24-week data, regardless of whether TF criteria were met, however, the size of the difference (95% CI) (-0.815 [ -1.181, -0.450 ]) between the groups favoring the coumarone at week 24 was lower compared to the main analysis.
Results were measured for participants who achieved low disease activity (.ltoreq.2.3) based on GRACE up to week 24. At weeks 16 and 24, lower disease activity was observed in a greater proportion of the participants in the group of coumarone antibodies (15.3% [ n=29 ] and 17.5% [ n=33 ]) than in the placebo group (5.2% [ n=5 ] and 3.1% [ n=3 ], respectively). The percentage difference (95% CI) between the 16 th and 24 th week groups favoring the archaebankab was 10.1 (3.4, 16.8) and 14.3 (7.9, 20.6), respectively. At baseline, a total of 64 (66.7%) participants in the placebo group and 126 (67.4%) participants in the archaebankab group had tendinitis, LEI score >0.
At week 24, tendinitis regression was defined as the absence of tendinitis in participants with at least 1 (6 total) tendinitis sites at baseline. At week 24, a higher proportion of the participants in the archaebankizumab group (39.7% [ n=50 ]) reported resolution of tendinitis than the placebo group (18.8% [ n=12 ]). At week 24, the percentage difference (95% CI) between the groups favoring the coumarone mab was 21.6 (8.8, 34.4). Similar results were obtained from analysis using all observed 24-week data, whether or not TF criteria were met; however, the percentage difference (95% CI) (11.0 [ -3.7, 25.7 ]) between the groups favoring the archaebankab was lower than the percentage difference obtained from the primary analysis.
The proportion of participants who had tendinitis (LEI) resolved by visit up to week 24 based on a comprehensive measure and analysis using all observed data at week 24, whether or not TF standard analysis 1 was met, among those who had tendinitis (LEI) at baseline, was presented in accessory TEFENL05 and accessory TEFENL06, respectively.
A total of 36 (37.5%) participants in the placebo group and 67 (35.8%) participants in the archaebankab group had dactylitis at baseline. The proportion of participants who achieved resolution of the digital inflammation at week 24 was measured. The digital inflammation was scored on a scale of 0 to 60 with a maximum score of 3 for each finger (hand and foot). Resolution of dactylitis is defined as the 0 score of participants scoring above zero at baseline. At week 24, a greater proportion of the participants in the archaebankizumab group (44.8%, n=30) achieved resolution of dactylitis than the placebo group (25.0%, n=9). A percentage difference of 19.9 (2.7, 37.1) (95% CI) was observed between the groups favoring the archaebankab. Analysis results using all observed 24-week data, whether or not TF criteria were met, were compared to the primary analysis; a numerically greater proportion of the participants in the placebo group (63.9%, n=23) achieved resolution of the dactylitis than the archaebacterium group (59.7%, n=40). The percent difference between the groups (95% CI) was-3.0 (-21.8, 15.8).
The proportion of participants who achieved MDA and VLDA at week 24 was measured. Minimum Disease Activity (MDA) is defined as achieving 5 of the following 7 criteria: the pain joint count is less than or equal to 1, the swelling joint count is less than or equal to 1, the psoriasis activity and severity index is less than or equal to 1, the pain assessment of a patient is less than or equal to 15, the overall assessment of the disease activity of the patient is less than or equal to 20, the HAQ-DI score is less than or equal to 0.5, and the endpoint of the pain tendon is less than or equal to 1. Very Low Disease Activity (VLDA) is obtained if all 7 criteria below are met. At week 24, a greater proportion of the participants in the archaebankizumab group (14.8%, n=28) achieved MDA responses than the placebo group (3.1%, n=3). The percentage difference (95% CI) between the groups favoring the archaebankab was 11.7 (5.6, 17.7). The results of the analysis using all observed 24 th week data were consistent with the primary analysis, whether or not TF criteria were met; the percentage difference between the groups favoring the archaebankizumab (95% CI) was 11.6 (4.7, 18.5). At week 24, 7 (3.7%) participants in the Gu Saiku mab group achieved VLDA response, while none of the participants in the placebo group achieved VLDA response. Regardless of whether TF criteria are met, the results obtained from the analysis using all observed 24-week data are consistent with the primary analysis.
At weeks 16 and 24, a greater proportion of the participants in the archaebankab group (10.6% [ n=20 ] and 14.8% [ n=28 ], respectively) achieved MDA responses than the placebo group (3.1%, n=3 at both time points). The percentage difference (95% CI) between the groups favoring the coumarone mab at week 16 and week 24 was 7.5 (1.9, 13.0) and 11.7 (5.6, 17.7), respectively. The results of the analysis using all observed 24 th week data were consistent with the primary analysis, whether or not TF criteria were met; the percentage difference (95% ci) between the groups favoring the coumarone mab at week 16 and week 24 was 7.5 (1.5, 13.5) and 11.6 (4.7, 18.5), respectively. At week 16, 3 (1.6%) and 1 (1.0%) participants in the Gu Saiku mab group had achieved VLDA responses. By week 24, 7 (3.7%) participants in the Gu Saiku mab group achieved VLDA responses; by week 24, no participants in the placebo group achieved VLDA responses.
Security results:
the data set for safety analysis up to week 24 was:
Take placebo: this included 96 participants randomly assigned to the placebo group at week 0. Of these, 51 participants received placebo only at week 24 and 45 received placebo until conversion to coumarone at week 16. For this group, only the safety when placebo is taken is described.
Conversion from placebo to archaebankizumab before week 24: this included 45 participants, who were randomly assigned to the placebo group, but who met early break-away criteria and converted to coumarone at week 16. For this group, only the safety events when the coumarone mab was taken are described.
Random distribution to the archaebankizumab: this included 189 participants, who were randomly assigned to the group of coumarone antibodies at week 0 and received only coumarone antibodies until week 24. Participants in the group who were assigned early on week 16 who left the placebo injection to maintain blindness were also considered part of the group.
Combined antique-saikomab: this included 234 participants that received at least 1 dose of the archaebankzumab up to week 24, and included those that received Gu Saiku mab at week 0 Zhou Suiji (189 participants), plus those from the placebo group that converted to archaebankzumab prior to week 24 after early break-off (45 participants).
Summary of AEs up to week 24:
Up to week 24, 86 (36.8%) participants in the 46 (47.9%) participants and the combined group of coumarone administration of placebo reported at least one TEAE, of which 3 (3.1%) and 8 (3.4%) reported at least one Serious Adverse Event (SAE), respectively, and 2 (2.1%) and 5 (2.1%) discontinued study intervention due to AE, respectively. Of the participants who converted to coumarone after early break-off, 6 (13.3%) reported at least one TEAE,1 (2.2%) reported at least one SAE, and no one discontinued the study intervention due to AE. The vast majority (> 95%) of the participants in each group reported only mild or moderate intensity AEs. Death was not reported until week 24.
Related TEAE up to week 24:
In the placebo group, infection and infestation (n= 8,8.3%) were the most frequently reported treatment-induced AEs considered to be relevant to study intervention. In the combination group of the coumarone antibodies, TEAE considered reasonably relevant to the study intervention was reported by 27 (11.5%) participants, 2 of which had been converted to the coumarone antibody after early detachment. The most frequently reported TEAEs with reasonable causal relationship to the archaebankizumab are infection and infestation (n= 10,4.3%), general disorder and administration site status (n= 6,2.6%) and abnormalities in laboratory studies (n= 6,2.6%).
Serious adverse events up to week 24:
Up to week 24, 3 (3.1%) placebo-administered participants and 8 (3.4%) participants in the combined group of coumarone experienced at least one SAE, of which 1 had been converted to coumarone after early break-off.
Other significant adverse events:
Up to week 24, 2 (2.1%) participants taking placebo and 5 (2.1%) participants in the combined group of coumarone discontinued study intervention after one or more TEAEs.
Conclusion at week 24:
In this study, 100mg of coumarone was treated at weeks 0 and 4 and then every 8 weeks, indicating superiority of coumarone over placebo for the primary endpoint of ACR 20 response at week 24. Based on a predefined grading test protocol, the superiority of the archaebankab over placebo was determined at week 24 relative to all 4 key secondary endpoints: HAQ-DI, ACR 50 response, SF-36PCS, and PASI 100.
In general, the archaebankenomab exhibits strong efficacy against signs and symptoms of joint and skin psoriasis, improves physical function, and improves physiological components of health-related quality of life.
In this study, the archaebankab dosing regimen was safe and well tolerated up to week 24. The safety profile of Gu Saiku mab in psoriatic arthritis patients of this population refractory to anti-TNF therapy is generally consistent with that demonstrated in psoriatic or untreated psoriatic arthritis indications.
Week 48 efficacy results
Before week 48, 11.6% and 13.5% of subjects in the GUS and PBO groups, respectively, discontinued study medication. The most common causes of discontinuation of study agents were adverse events (31.8% and 23.1, respectively), lack/loss of efficacy (22.7% and 23.1, respectively), and subject withdrawal (22.7% and 23.1, respectively). Of the subjects continuing to study the agent after week 24 (174 and 87, respectively, included in FAS 2) in the GUS and PBO groups, 4.0% and 4.6% of the subjects discontinued study the agent after week 24 and before week 48, respectively. Before week 48, 45.0% and 45.8% of subjects with one or more major regimen deviations were reported in the GUS and PBO groups, respectively, of which 24.7% and 20.5% were attributed to covd-19, respectively. Based on the medical examination of the data, a total of 11 subjects were excluded from each regimen analysis at week 56, as the primary regimen deviation affected the 48 week efficacy analysis.
ACR response
The proportion of subjects who achieved ACR20/50/70 response over the period of weeks 4 to 48 is summarized below. As shown in tables 21 and 22 below, the overall observed proportion of subjects who achieved ACR20 responses in GUS randomized subjects was 54.9% at week 24, and further up to 72.3% at week 48. Of the subjects directed to week 16 EE, 36.8% achieved ACR20 response at week 24, and 58.3% achieved ACR20 response at week 48. Among those subjects without week 16 EE, 59.6% observed ACR20 response at week 24, and 76.2% observed ACR20 response at week 48. ACR20 was achieved at week 24 and study continued until week 48 of GUS randomized subjects 91.2% maintained ACR20 at week 48, regardless of EE route.
/>
Keyword: acr=american college of rheumatology, crp=c reactive protein, dmard=antirheumatic drug to ameliorate disease,
HAQ-DI = health assessment questionnaire disability index, TNF = tumor necrosis factor
a ACR20 response is defined as an improvement of ≡20% over baseline in both the tender joint count (68 joints) and the swollen joint count (66 joints), and an improvement of ≡20% over baseline in 5 assessments (pain assessment of patient, patient versus disease Overall assessment of activity, overall assessment of disease activity by a physician, HAQ-DI and CRP).
Keyword: acr=american college of rheumatology, crp=c-reactive protein, dmard=antirheumatic drug to ameliorate disease, HAQ-di=health assessment questionnaire disability index, tnf=tumor necrosis factor
a ACR 20 response is defined as an ≡20% improvement over baseline in both the tender joint count (68 joints) and the swollen joint count (66 joints), and an ≡20% improvement over baseline in at least 3 of the 5 assessments (pain assessment of patient, overall assessment of disease activity by physician, HAQ-DI and CRP).
Full analysis set 2 included all randomized subjects still on study treatment at week 24.
As shown in tables 23 and 24 below, 13.2% and 26.7% ACR50 responses were observed at week 24 for subjects who were guided to week 16 EE and subjects who were not guided to week 16 EE, respectively, in GUS randomized subjects. At week 48, this increased to 41.7% and 50.4%, respectively. Overall, 48.5% achieved ACR50 response at week 48. ACR50 was achieved at week 24 and the study continued until week 48 of GUS randomized subjects, 94.6% maintained ACR50 at week 48, regardless of EE route.
/>
Keyword: acr=american college of rheumatology, crp=c-reactive protein, dmard=antirheumatic drug to ameliorate disease, HAQ-di=health assessment questionnaire disability index, tnf=tumor necrosis factor
a ACR 50 response is defined as an ≡50% improvement over baseline in both the tender joint count (68 joints) and the swollen joint count (66 joints), and an ≡50% improvement over baseline in at least 3 of the 5 assessments (pain assessment of patient, overall assessment of disease activity by physician, HAQ-DI and CRP).
Keyword: acr=american college of rheumatology, crp=c-reactive protein, dmard=antirheumatic drug to ameliorate disease, HAQ-di=health assessment questionnaire disability index, tnf=tumor necrosis factor
a ACR 50 response is defined as an ≡50% improvement over baseline in both the tender joint count (68 joints) and the swollen joint count (66 joints), and an ≡50% improvement over baseline in at least 3 of the 5 assessments (pain assessment of patient, overall assessment of disease activity by physician, HAQ-DI and CRP).
Full analysis set 2 included all randomized subjects still on study treatment at week 24.
As shown in tables 25 and 26 below, 2.6% and 10.3% ACR70 responses were observed at week 24, respectively, in GUS randomized subjects, for subjects who were lead to week 16 EE and those who were free of EE. At week 48, ACR70 response rates increased to 22.2% and 30.1%, respectively. Overall, 28.4% achieved ACR70 response at week 48. ACR70 was achieved at week 24 and study continued until week 48 of GUS randomized subjects 81.3% achieved ACR70 at week 48.
Keyword: acr=american college of rheumatology, crp=c reactive protein, dmard=antirheumatic drug to ameliorate disease,
HAQ-DI = health assessment questionnaire disability index, TNF = tumor necrosis factor
a ACR70 response is defined as an improvement of > 70% over baseline in both the tender joint count (68 joints) and the swollen joint count (66 joints), and an improvement of > 70% over baseline in at least 3 of the 5 assessments (pain assessment of patient, overall assessment of disease activity by physician, HAQ-DI and CRP).
Keyword: acr=american college of rheumatology, crp=c-reactive protein, dmard=antirheumatic drug to ameliorate disease, HAQ-di=health assessment questionnaire disability index, tnf=tumor necrosis factor
a ACR 70 response is defined as an improvement of > 70% over baseline in both the tender joint count (68 joints) and the swollen joint count (66 joints), and an improvement of > 70% over baseline in at least 3 of the 5 assessments (pain assessment of patient, overall assessment of disease activity by physician, HAQ-DI and CRP).
Full analysis set 2 included all randomized subjects still on study treatment at week 24.
HAQ-DI
As shown in Table 27 below, GUS randomized subjects improved on average by 0.29 score at week 24 and 0.47 score at week 48 starting with an average HAQ-DI of 1.33 at baseline. Subjects who were led to week 16 EE had a slightly higher baseline than 1.31 compared to those without EE: 1.42. although the improvement was smaller in GUS randomized subjects who were guided to EE at week 24 compared to GUS subjects without EE, which was-0.18 compared to-0.32, the improvement between these groups was similar at week 48, respectively: compared to-0.48, is-0.43.
/>
/>
/>
/>
Keyword: HAQ-DI = health assessment questionnaire disability index, IQ = quartile range.
a The HAQ score is the average of the calculated class scores (dressing, getting up, eating, walking, hygiene, grasping, and daily life). Lower scores indicate better functionality.
SF36-PCS
As shown in Table 28 below, GUS randomization was initiated with an average SF36-PCS score of 33.0 from baseline
Subjects were on average improved by 5.83 points at week 24 and 8.44 points at week 48. Compared to those without EE, subjects directed to EE had a slightly lower baseline than 33.3: 31.8. average improvements were 5.11 and 6.02 at week 24 and 7.83 and 8.60 at week 48, respectively.
/>
/>
Keyword: iq=quartile range, pcs=physiological component summary, SF-36=conciseness-36 (term).
a PCS was calculated based on 8 scales of SF-36 health related quality of life instruments with 36 questions. The higher the score, the better the health condition.
PASI response
PASI100, PASI90, and PASI75 responses were evaluated in subjects with an overall evaluation (IGA) score of ≡3% Body Surface Area (BSA) psoriasis involvement and ≡2 (mild) at baseline (recruitment) (55% and 70% of the overall PBO and GUS population, respectively).
As shown in table 29 below, the overall observed proportion of subjects who achieved PASI100 response in GUS randomized subjects was 41.1% at week 24 and increased to 66.1% at week 48. In GUS subjects who had been led to week 16 EE, 53.6% achieved a PASI100 response at week 48, while in those without EE, 69.9% achieved a PASI100 response at week 48. The overall response at week 48 was 84.3% for PASI90 and 93.4% for PASI 75.
/>
Keyword: bsa=body surface area, crp=c-reactive protein, iga=overall assessment by the investigator, dmard=anti-rheumatic drug to improve disease, pasi=psoriasis area and severity index, tnf=tumor necrosis factor a PASI scores are a combination of areas of involvement of erythema, induration, and scaling states on the body. PASI scores in the range of 0 to 72, with higher scores indicating more severe disease. PASI 100 response is defined as 100% improvement in PASI score over baseline.
Joint tenderness count
As shown in table 30 below, for GUS randomized subjects, the average number of tender joints at baseline was 21.0, the average improvement was-10.1 at week 24 and-12.9 at week 48. Subjects who were led to week 16 EE had on average more joints with tenderness at baseline than those without EE than those with 20.5: 22.9. for patients with or without EE, the average improvement was-6.3 and-11.1 at week 24 and-12.0 and-13.2 at week 48, respectively.
/>
/>
/>
/>
Keyword: iq=quartile range.
a The tenderness joint count is the total number of tenderness joints in 68 joints evaluated for tenderness.
Swollen joint count
As shown in table 31 below, for GUS randomized subjects, the average number of swollen joints at baseline was 10.2, the average improvement was-6.7 at week 24 and-8.5 at week 48. Subjects who were led to week 16 EE had on average more swollen joints at baseline than those without EE than 9.7: 12.4. average improvements were-6.0 and-6.9 at week 24 and-9.8 and-8.2 at week 48, respectively.
/>
/>
/>
/>
Keyword: iq=quartile range.
a The swollen joint count is the total number of swollen joints in the 66 joints evaluated for swelling.
MDA state
As shown in table 32 below, the overall observed proportion of subjects who achieved MDA in GUS randomized subjects was 17.4% at week 24 and 32.5% at week 48. In subjects who were led to EE at week 16, 5.3% achieved MDA at week 24 and 22.2% achieved MDA at week 48, and in those without EE, this was 20.5% at week 24 and 35.3% at week 48.
/>
Keyword: crp=c-reactive protein, dmard=antirheumatic drug to ameliorate disease, mda=minimal disease activity, tnf=tumor necrosis factor
a If 5 of the following 7 criteria are met (tender joint count. Ltoreq.1, swollen joint count. Ltoreq.1, psoriasis activity and severity index. Ltoreq.1, pain assessment of the patient. Ltoreq.15, overall assessment of patient to disease activity. Ltoreq.20, HAQ-DI score)
MDA is realized when the end point of the tenderness tendon is less than or equal to 0.5 and less than or equal to 1).
Resolution of tendinitis
Resolution of tendinitis was assessed in 67% of subjects with tendinitis in baseline (LEI > 0), GUS and PBO populations. As shown in table 33 below, the overall observed proportion of subjects achieving resolution of tendinitis in GUS randomized subjects was 52.0% at week 24 and 67.50% at week 48. In subjects who led to EE at week 16, 61.5% achieved resolution of tendinitis at week 48, and in those without EE, this was 69.3%.
/>
Keyword: crp=c reactive protein, dmard=antirheumatic drug to ameliorate disease, lei=litz tendinitis index, tnf=tumor necrosis factor
a Tendinitis score is a total score of 6 evaluation sites (left and right: lateral humeral epicondylitis, medial femoral condyle, achilles tendon insertion), ranging from 0 to 6. Negative changes from baseline indicate improvement. When the subject having at least one tenderness tendinous at baseline had no tenderness tendinous in the 6 sites included in LEI, tendinous inflammation was determined to resolve.
FACIT-fatigue improvement
As shown in Table 34, the total observed proportion of subjects with an improvement of ≡4 over baseline in the FACIT-fatigue score was 58.5% at week 24 and 69.0% at week 48 in GUS randomized subjects. Of GUS subjects directed to week 16 EE, 60.0% achieved a.gtoreq.4 score improvement in FACIT-fatigue at week 48, as compared to 71.3% in EE-free subjects.
Keyword: crp=c-reactive protein, dmard=antirheumatic drug to improve disease, ffacit=functional assessment of chronic disease therapy, tnf=tumor necrosis factor
a The FACIT-fatigue score was calculated based on a FACIT-fatigue questionnaire that included 13 questions, each of which was ranked on a 5-score scale (0-4). The FACIT-fatigue score may be in the range of 0 to 52, with a higher score indicating less fatigue.
Safety up to week 56:
Week 56 safety was assessed in all randomized and treated participants receiving at least 1 dose of archakurimab (partial or complete) based on actual treatment received during the study, irrespective of the randomized allocated treatment. This is also referred to as a security analysis set. The key security events are summarized in table 35 below.
Up to week 56, a total of 49.8% of the subjects reported at least one adverse event. For patients crossing GUS at week 16 or week 24, this was 46.7% and 44.4%, respectively. For patients randomly assigned to GUS, there were more patients reporting adverse events during the first 24 weeks (42.3%) than patients reporting adverse events during the follow-up period after week 24 (30.5%). In GUS randomized subjects, 3.7% had Severe Adverse Events (SAE) up to week 24 and 2.9% had SAE during the follow-up period after week 24. SAE were reported at 4.4% in PBO randomized patients crossing GUS at week 16 and those who hybridized at week 24. Overall, 2.5% of subjects reported adverse events leading to discontinuation of the administration of the coumarone, mainly 24 weeks (2.1% versus 1.7%) prior to the study.
Up to week 56, 21.9% of GUS treated subjects had at least one infection identified by the investigator. For GUS randomized subjects, infection was reported more frequently during the first 24 weeks (21.2%) than during the follow-up period (9.2%) after weeks 24 to 56. Of the subjects randomly assigned to PBO, 15.6% reported infection after the 16 th week crossover and 13.3% reported infection after the 24 th week crossover. Two subjects (0.7%) reported one or more severe infections, one GUS randomized subject and one PBO randomized subject reported pneumonia.
Up to week 56, overall, 1.8% (n=5) GUS treated subjects had at least one injection site response.
Malignancy was reported in 1 (0.5%) subjects up to week 56. This malignancy reported in the GUS group at study week 19 was prostate cancer. Considering the subject's history of chronic prostatitis, and the relatively short interval between study treatment initiation and cancer diagnosis, causal relationships were assessed as independent of study treatment.
Death, opportunistic infections, tuberculosis, suicidal ideation or behavior, and allergic or serological reactions were not reported until week 56.
By week 56, the most common treatment-induced adverse event System Organ Categories (SOCs) observed were infection and infestation (20.8%), with the most common AEs reported being nasopharyngitis (5.7%) and upper ventilator infection (3.6%).
By week 56, an increase in alanine Aminotransferase (ALT) serum levels was reported as AE in 11 subjects (3.9%), one of which reached SAE designation. Elevated aspartate Aminotransferase (AST) serum levels were reported as AE in 6 subjects (2.2%). For one subject (0.4%), elevated liver enzymes were reported as SAE. Further details of these SAEs will be provided in CSR.
By week 56, a decrease in neutrophil and white blood cell counts (reported as adverse events) of 1.1% and 1.1%, respectively, was observed. None of these events reached the SAE threshold.
As shown in table 36 below, the results of the additional secondary endpoints evaluated at week 24 also show the numerical benefits of the coumarone relative to placebo for achieving ACR70, MDA and VLDA and for achieving PASI75 and PASI90 in patients with psoriasis ≡3% BSA and IGA ≡2 at baseline. These analyses were performed using non-responder interpolation. Of the participants with tendinitis or dactylitis at baseline, a numerically higher proportion of the archaebankrimab had tendinitis or dactylitis resolved at week 24, respectively, than placebo patients. The proportion of patients achieving a score of > 4 improvement (reflecting clinically significant improvement) in FACIT-F was higher in the archaebankizumab group than in the placebo group. In the archaebankab group, the mean variation of LS from baseline in SF-36MCS score was also numerically greater.
After 24 weeks, responses and mean improvement of secondary endpoints in patients randomly assigned to the archaebacterium at baseline continued or improved numerically until week 48. In patients crossing from placebo to coumarone at week 24, the response rate and mean change of the secondary endpoint increased at week 48.
Evaluation Gu Saiku mab randomization patients achieved maintenance of response of ACR20, ACR50, or ACR70 response at week 24; in these patients, responses were maintained at week 48 at 83.3% (70/84), 81.1% (30/37) and 86.7% (13/15), respectively.
Unless otherwise indicated, the data shown are N (%) or N/N (%)
a Up to week 24, patients interrupting study agent/study participation, starting or increasing the allowable csDMARD/oral corticosteroid dose beyond the baseline of PsA, starting regimen-prohibited PsA drugs/therapies, or meeting EE criteria (including those incorrectly assigned to EE) were considered non-responders or did not improve over baseline at a later time point for any reason. After week 24, patients who met the EE criteria (excluding those that were incorrectly assigned to EE) and who discontinued study medication/study participation for any reason were considered non-responders or did not improve over baseline at a later time point; missing data is estimated as unresponsive or multiple interpolations (assuming random missing).
b CI based on Wald statistics c Based on the unadjusted (nominal) p-value of the Cochran-Mantel-Haenszel test, layering by baseline use (Yes/No) of csDMARD and previous exposure to TNFi (1/2)
d In patients with LEI score of 1 or more at baseline
e In patients with DSS scores of > 1 at baseline
f In patients with > 3% BSA psoriasis involvement and IGA > 2 at baseline
g LSmeans and unadjusted (nominal) p values of the hybrid model based on repeated measurements under the random missing assumption of missing data. LS averages were determined only up to week 24.
h After week 24, multiple interpolations of the 0 change and missing data (assuming random missing) were used to determine the average change from baseline for patients who discontinued or met the EE criteria prior to week 24 (excluding patients who were incorrectly assigned to EE).
ACR, american college of rheumatology; BSA, body surface area; CI, confidence interval; csDMARD, a conventionally synthesized antirheumatic drug for improving diseases; DSS, digital inflammatory severity score; EE, early detachment; FACIT-F, functional assessment of chronic disease therapy-fatigue; IGA, overall assessment of psoriasis by researchers; LEI, litz tendinitis index; MDA, minimal disease activity; PASI, psoriasis area and severity index;
PsA, psoriatic arthritis; Q8W, once every 8 weeks; SF-36MCS, summary of psychological components of 36 brief health survey profiles; SD: standard deviation; TNFi, tumor necrosis factor-inhibitor; VLDA, very low disease activity
Discussion and week 48/56 conclusions
Overall, COSMOS test evaluates efficacy and safety of Gu Saiku mab (GUS) 100mg at weeks 0, 4 and then q8w up to week 44, and demonstrates in efficacy: (i) Superiority of GUS relative to PBO for its primary endpoint of ACR20 response at week 24, (ii) superiority of GUS relative to PBO for all 4 key secondary endpoints at week 24 (based on predefined grading test protocol): HAQ-DI, ACR50 responses, SF36-PCS and PASI100, (iii) benefits of GUS relative to PBO on exploratory endpoints such as resolution of tendinitis and dactylitis, SF-36, facility-fatigue, etc., (iv) high maintenance of response in combined results (ACR 20:91.2%; ACR50:94.6%; ACR70: 81.3%) up to week 48 of GUS treatment, and (v) high patient retention observed in study (up to week 48 above 85%).
In general, up to 48 weeks of therapy, GUS showed strong efficacy against signs and symptoms of joint and skin psoriasis, improving physical functions and physiological components of health-related quality of life. In this study, GUS dosing regimen was safe and well tolerated up to week 56. The safety profile of the poorest mab up to 56 Zhou Gusai in psoriatic arthritis patients of this population refractory to anti-TNF therapy is generally consistent with that demonstrated in psoriatic or psoriatic arthritis indications that have not received biological treatment. For all results evaluated after week 24, a trend was observed to increase the benefit over time. Considering that these trends are based on "observed" data, appropriate non-respondents and multiple interpolation techniques will be applied to these observations to confirm the findings. These and other exploratory analyses will be reported in clinical study reports, including the effect of converting PBO patients to GUS.
Overall theoretical basis of research
The study of the archaebankizumab in this phase 3b PsA clinical study was supported by: robust efficacy results and favorable safety profiles for phase 3 studies in psoriasis (including subgroups of patients with PsA) and for phase 2a studies and two phase 3 studies using archaebacterium in PsA.
Phase 3 studies of archakuzumab in psoriasis included 2 larger placebo and activity comparator control studies (CNTO 1959PSO3001[ VOYAGE-1] and CNTO1959PSO3002[ VOYAGE-2 ]), including participants with active PsA at baseline (18.6% and 18.0%, respectively). These studies consistently demonstrate that the archaebankab is highly effective and that the treatment results in rapid, substantial and clinically significant improvement of psoriasis in this population. The archatock mab is equally effective in all sub-populations compared to the overall population, as defined by gender, baseline age, baseline body weight, race, geographic region, presence or absence of PsA at baseline, and history of psoriasis treatment. In both studies, the gulcomab was statistically superior to placebo or adalimumab (p < 0.001) for the common primary and all primary secondary endpoints.
Phase 2a studies of archaebankab in PsA, CNTO1959, 2001 demonstrated significant improvement of symptoms, including joint symptoms, body function, psoriasis, tendinitis, dactylitis, and quality of life of participants with active PsA and > 3% of psoriatic Body Surface Area (BSA). Primary and all secondary endpoints were met in this study, with efficacy maintained during about 1 year of exposure in the participants of the archaebankab group. These data were confirmed in 2 registered phase 3 studies (CNTO 1959PSA3001[ DISCOVER-1] and CNTO1959PSA3002[ DISCOVER-2 ]), validating Gu Saiku mab as a potent therapeutic intervention in PsA.
Phase 3 studies (DISCOVER program) included primarily patients who did not receive biological therapy. The purpose of this study (CNTO 1959PSA3003[ COSMOS ") was to further define clinical efficacy (signs and reduction of symptoms of joint and psoriasis skin diseases) and to evaluate the safety of Gu Saiku mab in treating patients with active PSA who had previously failed (i.e., refractory) or intolerant anti-tnfα therapy.
The invention also includes pharmaceutical compositions and packages of anti-IL-23 antibodies for treating psoriatic arthritis in a subject having inadequate response to anti-TNF therapy, wherein the antibodies comprise: (i) A heavy chain variable region and a light chain variable region, the heavy chain variable region comprising: the complementarity determining region heavy chain 1 (CDRH 1) amino acid sequence of SEQ ID NO. 1, the CDRH2 amino acid sequence of SEQ ID NO. 2, and the CDRH3 amino acid sequence of SEQ ID NO. 3; and the light chain variable region comprises: the complementarity determining region light chain 1 (CDRL 1) amino acid sequence of SEQ ID NO. 4, the CDRL2 amino acid sequence of SEQ ID NO. 5, and the CDRL3 amino acid sequence of SEQ ID NO. 6; (ii) A heavy chain variable region of the amino acid sequence of SEQ ID NO. 7 and a light chain variable region of the amino acid sequence of SEQ ID NO. 8; or (iii) the heavy chain of the amino acid sequence of SEQ ID NO. 9 and the light chain of the amino acid sequence of SEQ ID NO. 10.
The invention may be described in connection with the following numbered embodiments:
1. use of an anti-IL-23 antibody for treating psoriatic arthritis in a subject in need thereof, wherein the subject exhibits an insufficient response to treatment with anti-TNF therapy, wherein about 50mg to about 150mg of the antibody is administered subcutaneously to the subject once every 4 weeks (q 4 w), and wherein the antibody comprises a heavy chain variable region comprising the complementarity determining region heavy chain 1 (CDRH 1) amino acid sequence of SEQ ID NO:1, CDRH2 of SEQ ID NO:2, and CDRH3 of SEQ ID NO:3, and a light chain variable region comprising the complementarity determining region light chain 1 (CDRL 1) amino acid sequence of SEQ ID NO:4, CDRL2 of SEQ ID NO:5, and CDRL3 of SEQ ID NO:6, and wherein the subject achieves at least a 20% improvement in the american college of rheumatology core set disease index (ACR 20) after the treatment.
2. The use according to embodiment 1, wherein the antibody comprises a heavy chain variable region of the amino acid sequence of SEQ ID NO. 7 and a light chain variable region of the amino acid sequence of SEQ ID NO. 8.
3. The use according to embodiment 1, wherein the antibody comprises the heavy chain amino acid sequence of SEQ ID NO. 9 and the light chain amino acid sequence of SEQ ID NO. 10.
4. The use according to embodiment 1, wherein the antibody is administered at a dose of about 100mg per administration.
5. The use according to embodiment 1, wherein the ACR20 is effected after a treatment period of about 24 weeks.
6. The use according to embodiment 5, wherein the ACR20 is achieved or maintained after a treatment period of about 48 weeks.
7. The use according to embodiment 1, wherein the anti-TNF therapy is an anti-tnfα antibody or a tnfα non-antibody antagonist.
8. The use according to embodiment 7, wherein the anti-tnfα is adalimumab, golimumab, cetuximab therapy, infliximab and/or a biological analogue thereof, and the tnfα non-antibody antagonist is etanercept and/or a biological analogue thereof.
9. The use according to embodiment 1, wherein after the treatment the subject further achieves an improvement in disease activity determined by at least one criterion selected from the group consisting of: the U.S. rheumatology society core set disease index 50% improvement (ACR 50), the U.S. rheumatology society core set disease index 70% improvement (ACR 70), the health assessment questionnaire disability index (HAQ-DI), the overall assessment of researchers (IGA), the disease activity score 28 (DAS 28) C-reactive protein (CRP), resolution of tendinitis, resolution of dactylosin, litz tendinitis index (LEI), dactylitis assessment score, conciseness health investigation (SF-36) of psychological and physiological component summary (MCS and PCS), realization of Minimum Disease Activity (MDA), very Low Disease Activity (VLDA), ankylosing spondylitis disease activity index (BASDAI), graace comprehensive score (GRACE), psoriatic arthritis disease activity score (pasda), modified complex psoriatic disease activity index (cpmdai), psoriasis Area and Severity Index (PASI), dermatological quality of life index (DLQI), functional assessment of chronic therapy (FACIT) and patient reported outcome measurement information system-29 (proc-29).
10. The use according to embodiment 1, wherein the subject further achieves at least a 50% improvement in the american college of rheumatology core set disease index (ACR 50) after the treatment.
11. The use according to embodiment 1, wherein the subject further achieves an improvement in health assessment questionnaire disability index (HAQ-DI) after a treatment period of at least about 24 weeks or about 48 weeks.
12. The use according to embodiment 1, wherein the subject further achieves an improvement in disease activity score 28 (DAS 28) C-reactive protein (CRP) after a treatment period of at least about 24 weeks or about 48 weeks.
13. The use according to embodiment 1, wherein the subject further achieves a 0 (clearance) or 1 (minimum) or 2 or higher IGA reduction in the overall assessment (IGA) of the researcher after a treatment period of at least about 24 weeks or at least about 48 weeks, wherein the subject has a Body Surface Area (BSA) psoriasis involvement of 3% or greater and an IGA score of 2 or greater at baseline prior to treatment.
14. The use according to embodiment 1, wherein the subject is not responsive to standard therapy for PsA, optionally the standard therapy is also administered to the subject during treatment.
15. Use of an anti-IL-23 antibody in a subject in need thereof, wherein the subject shows an insufficient response to treatment with an anti-TNF therapy, wherein about 50mg to about 150mg of the anti-IL-23 antibody is administered subcutaneously to the subject at 0 Zhou Yici, once every 4 weeks and once every 8 weeks thereafter (q 8 w), wherein the antibody comprises a heavy chain variable region comprising the complementarity determining region heavy chain 1 (CDRH 1) amino acid sequence of SEQ ID NO:1, the CDRH2 of SEQ ID NO:2 and the CDRH3 of SEQ ID NO:3, and a light chain variable region comprising the complementarity determining region light chain 1 (CDRL 1) amino acid sequence of SEQ ID NO:4, the CDRL2 of SEQ ID NO:5 and the CDRL3 of SEQ ID NO:6, and wherein the subject has at least one psoriasis plaque or nail change consistent with psoriasis or a sign of psoriasis prior to the treatment, and the subject achieves an improvement in the index of at least 20% of the heart rate of the disease.
16. The use according to embodiment 15, wherein the antibody comprises a heavy chain variable region of the amino acid sequence of SEQ ID NO. 7 and a light chain variable region of the amino acid sequence of SEQ ID NO. 8.
17. The use according to embodiment 16, wherein the antibody comprises the heavy chain amino acid sequence of SEQ ID NO. 9 and the light chain amino acid sequence of SEQ ID NO. 10.
18. The use according to embodiment 15, wherein the antibody is administered at a dose of about 100mg per administration.
19. The use according to embodiment 1 or 15, wherein the ACR20 is effected after a treatment period of about 24 weeks or about 48 weeks.
20. The use according to embodiment 15, wherein the anti-TNF therapy is an anti-tnfα antibody or a tnfα non-antibody antagonist.
21. The use according to embodiment 20, wherein the anti-tnfα is adalimumab, golimumab, cetuximab therapy, infliximab and/or a biological analogue thereof, and the tnfα non-antibody antagonist is etanercept and/or a biological analogue thereof.
22. The use according to embodiment 15, wherein after the treatment the subject further achieves an improvement in disease activity determined by at least one criterion selected from the group consisting of: the U.S. rheumatology society core set disease index 50% improvement (ACR 50), the U.S. rheumatology society core set disease index 70% improvement (ACR 70), the health assessment questionnaire disability index (HAQ-DI), the overall assessment of researchers (IGA), the disease activity score 28 (DAS 28) C-reactive protein (CRP), resolution of tendinitis, resolution of dactylosin, litz tendinitis index (LEI), dactylitis assessment score, conciseness health investigation (SF-36) of psychological and physiological component summary (MCS and PCS), realization of Minimum Disease Activity (MDA), very Low Disease Activity (VLDA), ankylosing spondylitis disease activity index (BASDAI), graace comprehensive score (GRACE), psoriatic arthritis disease activity score (pasda), modified complex psoriatic disease activity index (cpmdai), psoriasis Area and Severity Index (PASI), dermatological quality of life index (DLQI), functional assessment of chronic therapy (FACIT) and patient reported outcome measurement information system-29 (proc-29).
23. The use according to embodiment 15, wherein the subject further achieves at least a 50% improvement in the american college of rheumatology core set disease index (ACR 50) after the treatment.
24. The use according to embodiment 15, wherein the subject further achieves an improvement in health assessment questionnaire disability index (HAQ-DI) after a treatment period of at least about 24 weeks or about 48 weeks.
25. The use according to embodiment 15, wherein the subject further achieves improvement in disease activity score 28 (DAS 28) C-reactive protein (CRP) after a treatment period of at least about 24 weeks or at least about 48 weeks.
26. The use according to embodiment 15, wherein the subject further achieves a 0 (clearance) or 1 (minimum) or 2 or higher IGA reduction in the overall assessment (IGA) of the researcher after a treatment period of at least about 24 weeks, wherein the subject has a Body Surface Area (BSA) psoriasis involvement of 3% or greater and an IGA score of 2 or greater at baseline prior to treatment.
27. The use according to embodiment 1, wherein the subject has an inadequate response to standard therapy for PsA.
28. The use according to embodiment 27, wherein the subject is also administered the standard therapy during the treatment.
29. A pharmaceutical composition of anti-IL-23 antibodies for use in treating psoriatic arthritis in a subject in need of treatment with anti-TNF therapy, the pharmaceutical composition comprising
The composition comprises:
a. an antibody comprising: (i) A heavy chain variable region and a light chain variable region, the heavy chain variable region comprising: the complementarity determining region heavy chain 1 (CDRH 1) amino acid sequence of SEQ ID NO. 1, the CDRH2 amino acid sequence of SEQ ID NO. 2, and the CDRH3 amino acid sequence of SEQ ID NO. 3; and the light chain variable region comprises: the complementarity determining region light chain 1 (CDRL 1) amino acid sequence of SEQ ID NO. 4, the CDRL2 amino acid sequence of SEQ ID NO. 5, and the CDRL3 amino acid sequence of SEQ ID NO. 6; (ii) A heavy chain variable region of the amino acid sequence of SEQ ID NO. 7 and a light chain variable region of the amino acid sequence of SEQ ID NO. 8; or (iii) a heavy chain of the amino acid sequence of SEQ ID NO. 9 and a light chain of the amino acid sequence of SEQ ID NO. 10; and
b. a package comprising one or more pharmaceutical product tag elements comprising data from a randomized, double-blind, placebo-controlled clinical study of adult males and females with moderate to severe active psoriatic arthritis who have an inadequate response to anti-TNF therapy.
30. A method of marketing a pharmaceutical product comprising a archakurimab, the method comprising: manufacturing the archaebanking monoclonal antibody; promoting that the therapy comprising the archaebankab is safe and effective for treating a subject suffering from active psoriatic arthritis who exhibits an insufficient response to treatment with an anti-TNF therapy, wherein performing the steps a) and b) results in the purchase of the pharmaceutical product by a healthcare professional (HCP); thereby selling the pharmaceutical product.
Sequence listing:
/>
Sequence listing
<110> Janssen Biotech, Inc.
Hsia, Elizabeth
Karyekar, Chetan
Kollmeier, Alexa
Noel, Wim
Vigueras, Jaime Oliver
Schubert-Wlodarczyk, Agata
Shawi, May
Taliadouros, Virginia
Theander, Elke
Xu, Xie
<120> treatment of inadequate response to TNF therapy with anti-IL 23 specific antibodies
Is a method for treating psoriatic arthritis patients
<130> JBI6473WOPCT1
<140> to be transferred
<141> 2022-03-09
<150> 63/160078
<151> 2021-03-12
<151> 63/188707
<151> 2021-05-14
<160> 10
<170> patent in version 3.5
<210> 1
<211> 5
<212> PRT
<213> Chile person
<400> 1
Asn Tyr Trp Ile Gly
1 5
<210> 2
<211> 17
<212> PRT
<213> Chile person
<400> 2
Ile Ile Asp Pro Ser Asn Ser Tyr Thr Arg Tyr Ser Pro Ser Phe Gln
1 5 10 15
Gly
<210> 3
<211> 8
<212> PRT
<213> Chile person
<400> 3
Trp Tyr Tyr Lys Pro Phe Asp Val
1 5
<210> 4
<211> 14
<212> PRT
<213> Chile person
<400> 4
Thr Gly Ser Ser Ser Asn Ile Gly Ser Gly Tyr Asp Val His
1 5 10
<210> 5
<211> 7
<212> PRT
<213> Chile person
<400> 5
Gly Asn Ser Lys Arg Pro Ser
1 5
<210> 6
<211> 11
<212> PRT
<213> Chile person
<400> 6
Ala Ser Trp Thr Asp Gly Leu Ser Leu Val Val
1 5 10
<210> 7
<211> 117
<212> PRT
<213> Chile person
<400> 7
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ser Asn Tyr
20 25 30
Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Ile Ile Asp Pro Ser Asn Ser Tyr Thr Arg Tyr Ser Pro Ser Phe
50 55 60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
65 70 75 80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Arg Trp Tyr Tyr Lys Pro Phe Asp Val Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser
115
<210> 8
<211> 111
<212> PRT
<213> Chile person
<400> 8
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ser Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Trp Thr Asp Gly
85 90 95
Leu Ser Leu Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu
100 105 110
<210> 9
<211> 447
<212> PRT
<213> Chile person
<400> 9
Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Glu
1 5 10 15
Ser Leu Lys Ile Ser Cys Lys Gly Ser Gly Tyr Ser Phe Ser Asn Tyr
20 25 30
Trp Ile Gly Trp Val Arg Gln Met Pro Gly Lys Gly Leu Glu Trp Met
35 40 45
Gly Ile Ile Asp Pro Ser Asn Ser Tyr Thr Arg Tyr Ser Pro Ser Phe
50 55 60
Gln Gly Gln Val Thr Ile Ser Ala Asp Lys Ser Ile Ser Thr Ala Tyr
65 70 75 80
Leu Gln Trp Ser Ser Leu Lys Ala Ser Asp Thr Ala Met Tyr Tyr Cys
85 90 95
Ala Arg Trp Tyr Tyr Lys Pro Phe Asp Val Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu
115 120 125
Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys
130 135 140
Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
145 150 155 160
Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser
165 170 175
Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
180 185 190
Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn
195 200 205
Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His
210 215 220
Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440 445
<210> 10
<211> 217
<212> PRT
<213> Chile person
<400> 10
Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15
Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Ile Gly Ser Gly
20 25 30
Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu
35 40 45
Leu Ile Tyr Gly Asn Ser Lys Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60
Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80
Gln Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ser Trp Thr Asp Gly
85 90 95
Leu Ser Leu Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
115 120 125
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
130 135 140
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145 150 155 160
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
165 170 175
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
180 185 190
His Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
195 200 205
Lys Thr Val Ala Pro Thr Glu Cys Ser
210 215
Claims (30)
1. A method of treating psoriatic arthritis in a subject in need thereof, wherein the subject exhibits an insufficient response to treatment with anti-TNF therapy, the method comprising subcutaneously administering to the subject about 50mg to about 150mg of an anti-IL-23 antibody once every 4 weeks (q 4 w), wherein the antibody comprises a heavy chain variable region comprising the complementarity determining region heavy chain 1 (CDRH 1) amino acid sequence of SEQ ID NO:1, CDRH2 of SEQ ID NO:2, and CDRH3 of SEQ ID NO:3, and a light chain variable region comprising the complementarity determining region light chain 1 (CDRL 1) amino acid sequence of SEQ ID NO:4, CDRL2 of SEQ ID NO:5, and CDRL3 of SEQ ID NO:6, and wherein the subject achieves at least a 20% improvement in the american collectile disease index (ACR 20) after the treatment.
2. The method of claim 1, wherein the antibody comprises a heavy chain variable region of the amino acid sequence of SEQ ID No. 7 and a light chain variable region of the amino acid sequence of SEQ ID No. 8.
3. The method of claim 1, wherein the antibody comprises the heavy chain amino acid sequence of SEQ ID No. 9 and the light chain amino acid sequence of SEQ ID No. 10.
4. The method of any one of claims 1 to 3, wherein the antibody is administered at a dose of about 100mg per administration.
5. The method of any one of claims 1-4, wherein the ACR20 is achieved after a treatment period of about 24 weeks.
6. The method of claim 5, wherein the ACR20 is achieved or maintained after a treatment period of about 48 weeks.
7. The method of any one of claims 1-6, wherein the anti-TNF therapy is an anti-tnfa antibody or tnfa non-antibody antagonist.
8. The method of claim 7, wherein the anti-tnfa is adalimumab, golimumab, cetuximab therapy, infliximab and/or a biological analog thereof, and the tnfa non-antibody antagonist is etanercept and/or a biological analog thereof.
9. The method of any one of claims 1 to 8, wherein following the treatment, the subject further achieves an improvement in disease activity determined by at least one criterion selected from the group consisting of: the U.S. rheumatology society core set disease index 50% improvement (ACR 50), the U.S. rheumatology society core set disease index 70% improvement (ACR 70), the health assessment questionnaire disability index (HAQ-DI), the overall assessment of researchers (IGA), the disease activity score 28 (DAS 28) C-reactive protein (CRP), resolution of tendinitis, resolution of dactylosin, litz tendinitis index (LEI), dactylitis assessment score, conciseness health investigation (SF-36) of psychological and physiological component summary (MCS and PCS), realization of Minimum Disease Activity (MDA), very Low Disease Activity (VLDA), ankylosing spondylitis disease activity index (BASDAI), graace comprehensive score (GRACE), psoriatic arthritis disease activity score (pasda), modified complex psoriatic disease activity index (cpmdai), psoriasis Area and Severity Index (PASI), dermatological quality of life index (DLQI), functional assessment of chronic therapy (FACIT) and patient reported outcome measurement information system-29 (proc-29).
10. The method of any one of claims 1-9, wherein the subject further achieves at least a 50% improvement in american college of rheumatology core set disease index (ACR 50) following the treatment.
11. The method of any one of claims 1-10, wherein the subject further achieves an improvement in health assessment questionnaire disability index (HAQ-DI) after a treatment period of at least about 24 weeks or about 48 weeks.
12. The method of any one of claims 1-11, wherein the subject further achieves improvement in disease activity score 28 (DAS 28) C-reactive protein (CRP) after a treatment period of at least about 24 weeks or about 48 weeks.
13. The method of any one of claims 1 to 12, wherein the subject further achieves a reduction in overall assessment (IGA) of a researcher of 0 (clearance) or 1 (minimum) or 2 or higher IGA after a treatment period of at least about 24 weeks or at least about 48 weeks, wherein the subject has a Body Surface Area (BSA) psoriasis involvement of 3% or greater and an IGA score of 2 or higher at baseline prior to the treatment.
14. The method of any one of claims 1 to 13, wherein the subject is not responsive to standard therapy for PsA, optionally the standard therapy is also administered to the subject during the treatment.
15. A method for treating psoriatic arthritis in a subject in need of treatment exhibiting inadequate response to anti-TNF therapy, the method comprising subcutaneously administering to the subject about 50mg to about 150mg of an anti-IL-23 antibody at Zhou Yici, once every 4 weeks and once every 8 weeks thereafter (q 8 w), wherein the antibody comprises a heavy chain variable region comprising the complementarity determining region heavy chain 1 (CDRH 1) amino acid sequence of SEQ ID NO:1, the CDRH2 of SEQ ID NO:2 and the CDRH3 of SEQ ID NO:3, and a light chain variable region comprising the complementarity determining region light chain 1 (CDRL 1) amino acid sequence of SEQ ID NO:4, the l2 of SEQ ID NO:5 and the CDRL3 of SEQ ID NO:6, and wherein the subject has at least one psoriasis of diameter ≡2cm or nail change or type consistent with psoriasis prior to the treatment, and the subject has an index of improvement in the history of rheumatism of at least 20% of the heart disease (ACR is achieved).
16. The method of claim 15, wherein the antibody comprises a heavy chain variable region of the amino acid sequence of SEQ ID No. 7 and a light chain variable region of the amino acid sequence of SEQ ID No. 8.
17. The method of claim 16, wherein the antibody comprises the heavy chain amino acid sequence of SEQ ID No. 9 and the light chain amino acid sequence of SEQ ID No. 10.
18. The method of any one of claims 15 to 17, wherein the antibody is administered at a dose of about 100mg per administration.
19. The method of any one of claims 1-18, wherein the ACR20 is achieved after a treatment period of about 24 weeks or about 48 weeks.
20. The method of any one of claims 15-19, wherein the anti-TNF therapy is an anti-tnfa antibody or tnfa non-antibody antagonist.
21. The method of claim 20, wherein the anti-tnfa is adalimumab, golimumab, cetuximab therapy, infliximab and/or a biological analog thereof, and the tnfa non-antibody antagonist is etanercept and/or a biological analog thereof.
22. The method of any one of claims 15 to 21, wherein following the treatment, the subject further achieves an improvement in disease activity determined by at least one criterion selected from the group consisting of: the U.S. rheumatology society core set disease index 50% improvement (ACR 50), the U.S. rheumatology society core set disease index 70% improvement (ACR 70), the health assessment questionnaire disability index (HAQ-DI), the overall assessment of researchers (IGA), the disease activity score 28 (DAS 28) C-reactive protein (CRP), resolution of tendinitis, resolution of dactylosin, litz tendinitis index (LEI), dactylitis assessment score, conciseness health investigation (SF-36) of psychological and physiological component summary (MCS and PCS), realization of Minimum Disease Activity (MDA), very Low Disease Activity (VLDA), ankylosing spondylitis disease activity index (BASDAI), graace comprehensive score (GRACE), psoriatic arthritis disease activity score (pasda), modified complex psoriatic disease activity index (cpmdai), psoriasis Area and Severity Index (PASI), dermatological quality of life index (DLQI), functional assessment of chronic therapy (FACIT) and patient reported outcome measurement information system-29 (proc-29).
23. The method of any one of claims 15-22, wherein the subject further achieves at least a 50% improvement in american college of rheumatology core set disease index (ACR 50) following the treatment.
24. The method of any one of claims 15-23, wherein the subject further achieves an improvement in health assessment questionnaire disability index (HAQ-DI) after a treatment period of at least about 24 weeks or about 48 weeks.
25. The method of any one of claims 15-24, wherein the subject further achieves improvement in disease activity score 28 (DAS 28) C-reactive protein (CRP) after a treatment period of at least about 24 weeks or at least about 48 weeks.
26. The method of any one of claims 15 to 25, wherein the subject further achieves a reduction in overall assessment (IGA) of a researcher of 0 (clearance) or 1 (minimum) or 2 or higher IGA after a treatment period of at least about 24 weeks, wherein the subject has a Body Surface Area (BSA) psoriasis involvement of 3% or greater and an IGA score of 2 or higher at baseline prior to the treatment.
27. The method of any one of claims 1 to 26, wherein the subject has an inadequate response to standard therapy for PsA.
28. The method of claim 27, wherein the subject is also administered the standard therapy during the treatment.
29. A pharmaceutical composition of an anti-IL-23 antibody for treating psoriatic arthritis in a subject in need of treatment with anti-TNF therapy that exhibits inadequate response, the pharmaceutical composition comprising:
a. an antibody comprising: (i) A heavy chain variable region and a light chain variable region, the heavy chain variable region comprising: the complementarity determining region heavy chain 1 (CDRH 1) amino acid sequence of SEQ ID NO. 1, the CDRH2 amino acid sequence of SEQ ID NO. 2, and the CDRH3 amino acid sequence of SEQ ID NO. 3; and the light chain variable region comprises: the complementarity determining region light chain 1 (CDRL 1) amino acid sequence of SEQ ID NO. 4, the CDRL2 amino acid sequence of SEQ ID NO. 5, and the CDRL3 amino acid sequence of SEQ ID NO. 6; (ii) A heavy chain variable region of the amino acid sequence of SEQ ID NO. 7 and a light chain variable region of the amino acid sequence of SEQ ID NO. 8; or (iii) a heavy chain of the amino acid sequence of SEQ ID NO. 9 and a light chain of the amino acid sequence of SEQ ID NO. 10; and
b. a package comprising one or more pharmaceutical product tag elements comprising data from a randomized, double-blind, placebo-controlled clinical study of adult males and females with moderate to severe active psoriatic arthritis who have an inadequate response to anti-TNF therapy.
30. A method of selling a pharmaceutical product comprising a archaebankizumab, the method comprising: manufacturing the archaebanking monoclonal antibody; promoting that a therapy comprising archaebankizumab is safe and effective for treating a subject suffering from active psoriatic arthritis who exhibits an insufficient response to treatment with anti-TNF therapy, wherein performing said steps a) and b) results in the purchase of said pharmaceutical product by a Health Care Professional (HCP); thereby selling the pharmaceutical product.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63/160078 | 2021-03-12 | ||
US202163188707P | 2021-05-14 | 2021-05-14 | |
US63/188707 | 2021-05-14 | ||
PCT/IB2022/052163 WO2022190034A1 (en) | 2021-03-12 | 2022-03-10 | Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117337302A true CN117337302A (en) | 2024-01-02 |
Family
ID=89279689
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202280034037.9A Pending CN117337302A (en) | 2021-03-12 | 2022-03-10 | Methods of treating psoriatic arthritis patients with inadequate response to TNF therapy with anti-IL 23 specific antibodies |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117337302A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114025796A (en) * | 2019-06-04 | 2022-02-08 | 詹森生物科技公司 | Safe and effective method for treating psoriatic arthritis with anti-IL 23 specific antibodies |
-
2022
- 2022-03-10 CN CN202280034037.9A patent/CN117337302A/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114025796A (en) * | 2019-06-04 | 2022-02-08 | 詹森生物科技公司 | Safe and effective method for treating psoriatic arthritis with anti-IL 23 specific antibodies |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2023025173A (en) | Methods for treating psoriasis with anti-il23 specific antibodies | |
US20230340103A1 (en) | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody | |
JP2024088688A (en) | Safe and effective method for treating psoriasis with anti-IL23 specific antibodies | |
JP2023182641A (en) | Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody | |
JP2024038223A (en) | Sustained response predictors after treatment with anti-il23 specific antibody | |
CN117337302A (en) | Methods of treating psoriatic arthritis patients with inadequate response to TNF therapy with anti-IL 23 specific antibodies | |
US20220289834A1 (en) | Method of Treating Psoriatic Arthritis Patients with Inadequate Response to TNF Therapy with Anti-IL23 Specific Antibody | |
US20220025035A1 (en) | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody | |
CN116348491A (en) | Methods of treating Crohn's disease with anti-IL 12/IL23 antibodies | |
CN113395979A (en) | Safe and effective methods for treating psoriasis with anti-IL-23 specific antibodies | |
US20220298236A1 (en) | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody | |
CN118475608A (en) | Methods of treating Crohn's disease with anti-IL 23 specific antibodies | |
CN118401550A (en) | Methods of treating ulcerative colitis with anti-IL 23 specific antibodies | |
CN118251413A (en) | Methods of treating Crohn's disease with anti-IL 23 specific antibodies | |
JPWO2020104943A5 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |